0000313216-23-000012.txt : 20230424 0000313216-23-000012.hdr.sgml : 20230424 20230424074403 ACCESSION NUMBER: 0000313216-23-000012 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20230424 FILED AS OF DATE: 20230424 DATE AS OF CHANGE: 20230424 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KONINKLIJKE PHILIPS NV CENTRAL INDEX KEY: 0000313216 STANDARD INDUSTRIAL CLASSIFICATION: X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844] IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-05146-01 FILM NUMBER: 23837953 BUSINESS ADDRESS: STREET 1: BREITNER CENTER STREET 2: AMSTELPLEIN 2 CITY: AMSTERDAM STATE: P7 ZIP: 1096 BC BUSINESS PHONE: 31 20 59 77777 MAIL ADDRESS: STREET 1: BREITNER CENTER STREET 2: AMSTELPLEIN 2 CITY: AMSTERDAM STATE: P7 ZIP: 1096 BC FORMER COMPANY: FORMER CONFORMED NAME: KONINKLIJKE PHILIPS ELECTRONICS NV DATE OF NAME CHANGE: 19981217 FORMER COMPANY: FORMER CONFORMED NAME: PHILIPS ELECTRONICS N V DATE OF NAME CHANGE: 19930727 FORMER COMPANY: FORMER CONFORMED NAME: PHILIPS NV DATE OF NAME CHANGE: 19910903 6-K 1 phg-20230331.htm Royal Philips - 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

April 24, 2023

KONINKLIJKE PHILIPS N.V.

(Exact name of registrant as specified in its charter)

Royal Philips

(Translation of registrant’s name into English)

The Netherlands

(Jurisdiction of incorporation or organization)

Breitner Center, Amstelplein 2, 1096 BC Amsterdam, The Netherlands

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

Name and address of person authorized to receive notices and communications from the Securities and Exchange Commission:

M.J. van Ginneken
Koninklijke Philips N.V.
Amstelplein 2
1096 BC Amsterdam – The Netherlands

This report comprises a copy of the following report:

“Philips’ First Quarter Results 2023”, dated April 24, 2023.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf, by the undersigned, thereunto duly authorized at Amsterdam, on the 24th day of April 2023.

KONINKLIJKE PHILIPS N.V.

/s/ M.J. van Ginneken
(Chief Legal Officer)

Philips shape

Philips delivers solid operational performance as supply chain improves and actions to enhance execution start to take effect

Amsterdam, April 24, 2023

First-quarter highlights

  • Group sales increased to EUR 4.2 billion, with 6% comparable sales growth
  • Comparable order intake growth was flat, with double-digit growth in the Diagnosis & Treatment businesses, offset by a decline in the Connected Care businesses
  • Income from operations amounted to a loss of EUR 583 million, mainly due to provisions for accelerated restructuring and an important step in litigation
  • EUR 575 million litigation provision is related to the anticipated resolution of the Respironics recall-related economic loss class action in the US 
  • Adjusted EBITA increased to EUR 359 million, or 8.6% of sales, compared to EUR 243 million, or 6.2% of sales, in Q1 2022
  • Operating cash flow improved to EUR 202 million, compared to an outflow of EUR 227 million in Q1 2022
  • Simplification of operating model and restructuring plans on track

Roy Jakobs, CEO of Royal Philips:

“I am encouraged that we delivered a solid start to the year, with sales, profitability and operating cash flow improvements in the quarter, a first step to drive progressive value creation. We are executing on our three priorities to enhance patient safety and quality, strengthen our supply chain reliability, and establish a simplified, more agile operating model.

Resolving the Philips Respironics recall for patients remains our highest priority. In the first quarter, we have recorded a provision in anticipation of a resolution of the economic loss class action in the US. This is an important step in addressing the litigation related to the recall.

Our supply chain improvements enabled good growth across the Diagnosis & Treatment businesses and in Hospital Patient Monitoring. Supported by significant change management efforts, we have reduced the workforce by approximately 5,400 roles out of the planned reduction of 10,000 roles globally.

I realize that we are asking a lot from our employees to work through the necessary changes and deeply appreciate their tremendous efforts and ongoing commitment to deliver on our company purpose. I would also like to thank our customers and partners for their continued trust and support. I have met many of them in the last few months, and it is clear that Philips remains a preferred innovation partner.

Looking ahead, based on our solid performance in the quarter, our order book, and the ongoing actions to further improve execution, we are confident in our plan for the year 2023, acknowledging that uncertainties remain.”

Group and business segment performance

Sales for the Group increased to EUR 4.2 billion, with 6% comparable sales growth, mainly driven by the Diagnosis & Treatment businesses. Additionally, sales in the quarter were supported by the good momentum for the Diagnosis & Treatment and Connected Care businesses in China. Adjusted EBITA for the Group increased to EUR 359 million, or 8.6% of sales, mainly due to increased sales and productivity measures, partly offset by cost inflation. Philips’ order book remains strong and is 10% higher than one year ago despite flat order intake growth.

The Diagnosis & Treatment businesses’ comparable sales increased by a strong 15% in the quarter, with double-digit growth in Ultrasound and Image-Guided Therapy, and mid-single-digit growth in Diagnostic Imaging, driven by continued supply chain improvements. Comparable order intake grew double-digit, with double-digit growth in Image-Guided Therapy and Enterprise Diagnostic Informatics and mid-single-digit growth in Diagnostic Imaging. The Adjusted EBITA margin increased to 11.3%, which was mainly due to increased sales and productivity measures, partly offset by cost inflation.

The Connected Care businesses’ comparable sales increased 3% in the quarter, driven by double-digit growth in Hospital Patient Monitoring, largely offset by a decline in Sleep & Respiratory Care. Comparable order intake declined double-digit after strong growth in the period between 2020 and 2022. The Adjusted EBITA margin increased to 2.4%, driven by the improved Adjusted EBITA margin of the Connected Care businesses excluding Sleep & Respiratory Care.

The Personal Health businesses’ comparable sales decreased by 6% in the quarter due to the anticipated lower consumer demand, on the back of 8% growth in Q1 2022. The Adjusted EBITA margin amounted to 13.2%. Sales and Adjusted EBITA were both significantly impacted by portfolio decisions related to Russia in 2022.

Productivity

In the first quarter, operating model productivity savings amounted to EUR 94 million, procurement savings amounted to EUR 32 million, and other productivity programs delivered savings of EUR 64 million, resulting in total savings of EUR 190 million.

Customer and innovation highlights

  • In the quarter, the company announced multiple new partnerships, demonstrating the confidence hospital leaders have in Philips’ innovative portfolio. These include an agreement with Grupo Angeles, the largest private hospital group in Mexico, to provide informatics, diagnostic imaging and image-guided therapy solutions to advance patient care in cardiology, oncology and radiology.
  • Highlighting the strength of its comprehensive patient monitoring offering, Philips announced a multi-year partnership with Northwell Health to standardize and centralize patient monitoring across the hospital, allowing caregivers to see what is happening at each bedside.
  • Leveraging its leading expertise in sustainable healthcare operations, Philips announced a multi-year agreement with Champalimaud Foundation in Portugal aimed at halving its diagnostic imaging carbon footprint by 2028. The partnership will help drive quality and efficiency, while reducing environmental impact.
  • Philips further expanded its industry-leading ultrasound portfolio with the launch of Ultrasound Compact 5500 CV, which enables first- time-right ultrasound exams for cardiology and vascular patients at the bedside.
  • To improve oral care habits among children, Philips introduced Sonicare for Kids 'Design a Pet Edition' with an entry price point designed to give more parents access to an electric toothbrush for their children.
  • Philips took a top ranking in medical technology patent filings at the European Patent Office and was included on the Clarivate Top 100 Global Innovator list for the 10th year in a row.

Philips Respironics field action for specific sleep therapy and ventilator devices

To date, more than 95% of the new replacement devices and repair kits required for the remediation of the registered devices have been produced. The vast majority of the produced sleep therapy devices have been sent to patients and home care providers. The remaining 5% of the registered devices are primarily ventilators, for which Philips Respironics is fully focused on working towards a solution.

In Q2 2023, Philips Respironics expects to report on the VOC testing of ozone-induced foam degradation in the first-generation DreamStation devices, and on the complete set of testing results for the SystemOne and DreamStation Go sleep therapy devices.

As previously disclosed, Philips is a defendant in several class-action lawsuits and individual personal injury claims. In the US, an economic loss class action, a medical monitoring class action and personal injury claims have been filed. This quarter, Philips Respironics recorded a EUR 575 million provision in connection with the anticipated resolution of the economic loss class action, an important step in addressing the litigation related to the recall.

Philips Respironics is subject to an investigation by the US Department of Justice and remains in ongoing discussions with the FDA regarding a proposed consent decree. Given the uncertain nature of the relevant events, and of their potential financial and operational impact and associated obligations, if any, the company has not made any provisions in the accounts for these matters.

Conference call and audio webcast

Roy Jakobs, CEO, and Abhijit Bhattacharya, CFO, will host a conference call for investors and analysts at 10:00 am CET today to discuss the results and Philips’ plan to create value with sustainable impact. A live webcast of the conference call will be available on the Philips Investor Relations website and can be accessed here.

Philips performance

Key data

in millions of EUR unless otherwise stated

  Q1 2022 Q1 2023
Sales 3,918 4,167
Nominal sales growth 2% 6%
Comparable sales growth1) (4)% 6%
Comparable order intake2) 5% 0%
Income from operations (181) (583)
as a % of sales (4.6)% (14.0)%
Financial expenses, net (27) (79)
Investments in associates, net of income taxes (11) (16)
Income tax (expense) benefit 67 15
Income from continuing operations (152) (663)
Discontinued operations, net of income taxes - (3)
Net income (151) (665)
Earnings per common share (EPS)    
Income from continuing operations attributable to shareholders3) (in EUR) - diluted (0.17) (0.75)
Adjusted income from continuing operations attributable to shareholders3) (in EUR) - diluted1) 0.15 0.22
Net income attributable to shareholders3) (in EUR) - diluted (0.17) (0.75)
EBITA1) (107) (510)
as a % of sales (2.7)% (12.2)%
Adjusted EBITA1) 243 359
as a % of sales 6.2% 8.6%
Adjusted EBITDA1) 488 575
as a % of sales 12.5% 13.8%
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information. 2) Comparable order intake is presented when discussing the Philips Group's performance. For the definition of this measure, refer to chapter 12.4, Other Key Performance Indicators, of the Annual Report 2022. 3) Shareholders refers to shareholders of Koninklijke Philips N.V.
  • Comparable sales increased by 6%, driven by continued supply chain improvements. The Diagnosis & Treatment businesses recorded double-digit growth and the Connected Care businesses low-single-digit growth, while the Personal Health businesses posted a mid-single-digit decline.
  • Comparable order intake was flat, with double-digit growth in the Diagnosis & Treatment businesses, which was offset by a decline in the Connected Care businesses in the quarter on the back of the expansion and renewal of the patient monitoring installed base during the period 2020 through 2022.
  • Adjusted EBITA improved to EUR 359 million and the margin increased to 8.6%, mainly due to increased sales and productivity measures, partly offset by cost inflation.
  • Restructuring, acquisition-related and other charges amounted to EUR 868 million, compared to EUR 350 million in Q1 2022. Q1 2023 includes a EUR 575 million provision in connection with an anticipated resolution of the economic loss class action in the US related to the Respironics recall, EUR 150 million restructuring charges related workforce reduction, and EUR 54 million Respironics field-action running remediation costs.
  • Financial income and expenses resulted in a net expense of EUR 79 million, compared to a net expense of EUR 27 million in Q1 2022. Q1 2023 includes higher interest expense, primarily due to bonds issued in April 2022 and a term loan entered into in October 2022, as well as fair value losses on the value of Philips' minority participations.
  • The income tax benefit of EUR 15 million in Q1 2023 is due to negative income. 
  • Net income in Q1 2023 decreased compared to Q1 2022, due to the factors outlined above. 

Sales per geographic cluster

in millions of EUR unless otherwise stated

      % change
  Q1 2022 Q1 2023 nominal comparable1)
Western Europe 785 801 2% 4%
North America 1,650 1,779 8% 3%
Other mature geographies 410 416 1% 9%
Total mature geographies 2,846 2,996 5% 4%
Growth geographies 1,072 1,171 9% 10%
Philips Group 3,918 4,167 6% 6%
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.
  • Comparable sales in mature geographies increased by 4%, with low-single-digit growth in North America and mid-single-digit growth in Western Europe. In growth geographies, sales increased by 10% on a comparable basis, with strong contributions from China, Middle East & Turkey, Latin America and Central & Eastern Europe. 

Cash and cash equivalents balance

in millions of EUR

  Q1 2022 Q1 2023
Beginning cash balance 2,303 1,172
Free cash flow1) (402) 117
Net cash flows from operating activities (227) 202
Net capital expenditures (175) (85)
Other cash flows from investing activities (347) (104)
Treasury shares transactions (39)
Changes in debt (40) (22)
Other cash flow items 14 (31)
Net cash flows from discontinued operations (44) (4)
Ending cash balance 1,445 1,128
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.
  • Net cash flows from operating activities increased, mainly as a result of higher customer receipts, higher cash earnings and lower income tax payments.
  • Other cash flows from investing activities mainly includes a cash payment with respect to foreign exchange derivative contracts, whereas Q1 2022 mainly included the acquisitions of Vesper Medical and Cardiologs.
  • Net capital expenditures includes cash proceeds from the sale of real estate.

Composition of net debt to group equity1)

in millions of EUR unless otherwise stated

  December 31, 2022 March 31, 2023
Long-term debt 7,270 7,141
Short-term debt 931 1,034
Total debt 8,201 8,175
Cash and cash equivalents 1,172 1,128
Net debt 7,028 7,048
Shareholders' equity 13,249 12,332
Non-controlling interests 34 33
Group equity 13,283 12,366
Net debt : group equity ratio1) 35:65 36:64
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.

Amounts may not add up due to rounding.

Performance per segment

Diagnosis & Treatment businesses

Key data

in millions of EUR unless otherwise stated

  Q1 2022 Q1 2023
Sales 1,911 2,204
Sales growth    
Nominal sales growth 3% 15%
Comparable sales growth1) (2)% 15%
Income from operations 88 157
as a % of sales 4.6% 7.1%
EBITA1) 114 181
as a % of sales 6.0% 8.2%
Adjusted EBITA1) 113 250
as a % of sales 5.9% 11.3%
Adjusted EBITDA1) 181 308
as a % of sales 9.5% 14.0%
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.
  • Comparable sales increased by 15%, driven by double-digit growth in Ultrasound and Image-Guided Therapy and mid-single-digit growth in Diagnostic Imaging, due to continued supply chain improvements.
  • Comparable sales in mature and growth geographies showed double-digit growth, with strong contributions from North America, Western Europe and China. 
  • Adjusted EBITA improved to EUR 250 million and the margin increased to 11.3%, mainly due to increased sales and productivity measures, partly offset by cost inflation.
  • Restructuring, acquisition-related and other charges amounted to EUR 68 million, compared to a net gain of EUR 1 million in Q1 2022. Q1 2023 includes EUR 31 million restructuring costs related to workforce reduction. In Q2 2023, restructuring, acquisition-related and other charges are expected to total approximately EUR 35 million.

Connected Care businesses

Key data

in millions of EUR unless otherwise stated

  Q1 2022 Q1 2023
Sales 993 1,033
Sales growth    
Nominal sales growth (14)% 4%
Comparable sales growth1) (21)% 3%
Income from operations (378) (710)
as a % of sales (38.1)% (68.7)%
EBITA1) (334) (667)
as a % of sales (33.6)% (64.6)%
Adjusted EBITA1) 4 25
as a % of sales 0.4% 2.4%
Adjusted EBITDA1) 60 72
as a % of sales 6.0% 7.0%
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.
  • Comparable sales increased by 3%, driven by double-digit growth in Hospital Patient Monitoring, largely offset by a decline in Sleep & Respiratory Care.
  • Comparable sales in growth geographies showed double-digit growth, driven by double-digit growth in China. Mature geographies recorded a low-single-digit decline, mainly due to flat sales in North America and a decline in Western Europe.   
  • Adjusted EBITA improved to EUR 25 million and the Adjusted EBITA margin increased to 2.4%, driven by the improved Adjusted EBITA margin of the Connected Care businesses excluding Sleep & Respiratory Care.
  • Restructuring, acquisition-related and other charges were EUR 691 million, compared to EUR 339 million in Q1 2022. Q1 2023 includes a EUR 575 million provision in connection with an anticipated resolution of the economic loss class action in the US related to the Respironics recall, EUR 54 million Respironics field-action running remediation costs, and EUR 30 million restructuring costs related to workforce reduction. In Q2 2023, restructuring, acquisition-related and other charges are expected to total approximately EUR 75 million. This excludes the impact of the ongoing discussion on the proposed consent decree, as well as ongoing litigation and the investigation by the US Department of Justice related to the Respironics field action.

Personal Health businesses

Key data

in millions of EUR unless otherwise stated

  Q1 2022 Q1 2023
Sales 838 798
Sales growth    
Nominal sales growth 13% (5)%
Comparable sales growth1) 8% (6)%
Income from operations 124 96
as a % of sales 14.8% 12.0%
EBITA1) 128 101
as a % of sales 15.3% 12.7%
Adjusted EBITA1) 128 105
as a % of sales 15.3% 13.2%
Adjusted EBITDA1) 159 128
as a % of sales 19.0% 16.0%
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.
  • Comparable sales declined by 6%, including a 4 percentage-point impact from the Russia-Ukraine war, and due to the anticipated lower consumer demand.
  • Comparable sales in mature geographies showed a mid-single-digit decline, mainly due to North America. Growth geographies recorded a high-single-digit decline, mainly due to a double-digit decline in Russia.
  • Adjusted EBITA was EUR 105 million and the margin amounted to 13.2%, significantly impacted by portfolio decisions related to Russia in 2022.
  • Restructuring charges amounted to EUR 5 million and related to workforce reduction.  

Other

Key data

in millions of EUR

  Q1 2022 Q1 2023
Sales 176 132
Income from operations (16) (126)
EBITA1) (15) (124)
Adjusted EBITA1) of: (2) (20)
IP Royalties 100 59
Innovation (30) (32)
Central costs (63) (45)
Other (9) (2)
Adjusted EBITDA1) 87 66
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.
  • Sales decreased by EUR 44 million, mainly due to lower royalty income and a decrease in supplies to the divested Domestic Appliances business.
  • Adjusted EBITA decreased by EUR 18 million, mainly due to lower royalty income.
  • Restructuring, acquisition-related and other charges amounted to EUR 104 million, mainly related to workforce reduction, compared to EUR 12 million in Q1 2022. In Q2 2023, restructuring, acquisition-related and other charges are expected to total approximately EUR 40 million.

Forward-looking statements and other important information

Forward-looking statements

This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about our strategy, estimates of sales growth, future Adjusted EBITA*), future restructuring and acquisition-related charges and other costs, future developments in Philips’ organic business and the completion of acquisitions and divestments. Forward-looking statements can be identified generally as those containing words such as “anticipates”, “assumes”, “believes”, “estimates”, “expects”, “should”, “will”, “will likely result”, “forecast”, “outlook”, “projects”, “may” or similar expressions. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

These factors include but are not limited to: Philips’ ability to gain leadership in health informatics in response to developments in the health technology industry; Philips’ ability to transform its business model to health technology solutions and services; macroeconomic and geopolitical changes; integration of acquisitions and their delivery on business plans and value creation expectations; securing and maintaining Philips’ intellectual property rights, and unauthorized use of third-party intellectual property rights; Philips’ ability to meet expectations with respect to ESG-related matters; failure of products and services to meet quality or security standards, adversely affecting patient safety and customer operations; breaches of cybersecurity; challenges in connection with Philips’ strategy to improve execution and other business performance initiatives; the resilience of our supply chain; attracting and retaining personnel; COVID-19 and other pandemics; challenges to drive operational excellence and speed in bringing innovations to market; compliance with regulations and standards including quality, product safety and (cyber) security; compliance with business conduct rules and regulations including privacy and upcoming ESG disclosure and due diligence requirements; treasury and financing risks; tax risks; reliability of internal controls, financial reporting and management process; global inflation. For a discussion of factors that could cause future results to differ from such forward-looking statements, see also the Risk management chapter included in the Annual Report 2022.

Philips has recognized a provision related to the voluntary recall notification in the US/field safety notice outside the US for certain sleep and respiratory care products, based on Philips’ best estimate for the expected field actions. Future developments are subject to significant uncertainties, which require management to make estimates and assumptions, about items such as quantities and the portion to be replaced or repaired. Actual outcomes in future periods may differ from these estimates and affect the company’s results of operations, financial position and cash flows. Furthermore, Philips is a defendant in several class-action lawsuits and individual personal injury claims, and is in ongoing discussions with the FDA regarding a proposed consent decree. Given the uncertain nature of the relevant events, and of their potential financial and operational impact and associated obligations, if any, the company has not made any provisions in the accounts for these matters, except for the following. In the first quarter of 2023, Philips Respironics recorded a provision in connection with an anticipated resolution of the economic loss class action pending in the US. The provision is subject to final resolution and court approval of the negotiated settlement agreement and is based on Philips’ best estimate for the expected settlement amounts, which is, in part, based on the expected number of claims ultimately filed pursuant the settlement once it is approved. Actual outcomes in future periods of the above matters may differ from these estimates and affect the company’s results of operations, financial positions and cash flows.

Third-party market share data

Statements regarding market share, contained in this document, including those regarding Philips’ competitive position, are based on outside sources such as specialized research institutes, industry and dealer panels in combination with management estimates. Where information is not yet available to Philips, market share statements may also be based on estimates and projections prepared by management and/or based on outside sources of information. Management’s estimates of rankings are based on order intake or sales, depending on the business.

Market Abuse Regulation

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Use of non-IFRS information

In presenting and discussing the Philips Group’s financial position, operating results and cash flows, management uses certain non-IFRS financial measures. These non-IFRS financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measure and should be used in conjunction with the most directly comparable IFRS measures. Non-IFRS financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-IFRS measures to the most directly comparable IFRS measures is contained in this document. Further information on non-IFRS measures can be found in the Annual Report 2022.

Use of Fair value information

In presenting the Philips Group’s financial position, fair values are used for the measurement of various items in accordance with the applicable accounting standards. These fair values are based on market prices, where available, and are obtained from sources that are deemed to be reliable. Readers are cautioned that these values are subject to changes over time and are only valid at the balance sheet date. When quoted prices or observable market data are not readily available, fair values are estimated using appropriate valuation models and unobservable inputs. Such fair value estimates require management to make significant assumptions with respect to future developments, which are inherently uncertain and may therefore deviate from actual developments. Critical assumptions used are disclosed in the Annual Report 2022. In certain cases, independent valuations are obtained to support management’s determination of fair values.

Presentation

All amounts are in millions of euros unless otherwise stated. Due to rounding, amounts may not add up precisely to totals provided. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2022 except for the adoption of new standards and amendments to standards which are also expected to be reflected in the company's consolidated IFRS financial statements as at and for the year ending December 31, 2023.

*) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.

Condensed consolidated statements of income

in millions of EUR unless otherwise stated

  Q1
  2022 2023
Sales 3,918 4,167
Cost of sales (2,407) (2,411)
Gross margin 1,511 1,755
Selling expenses (1,064) (1,079)
General and administrative expenses (155) (158)
Research and development expenses (495) (528)
Other business income 32 14
Other business expenses (11) (588)
Income from operations (181) (583)
Financial income 17 14
Financial expenses (44) (93)
Investment in associates, net of income taxes (11) (16)
Income before taxes (219) (678)
Income tax (expense) benefit 67 15
Income from continuing operations (152) (663)
Discontinued operations, net of income taxes - (3)
Net income (151) (665)
     
Attribution of net income    
Net income attributable to shareholders1) (151) (665)
Net income attributable to non-controlling interests - -
Income from continuing operations attributable to shareholders1) (152) (663)
     
Earnings per common share    
Weighted average number of common shares outstanding (after deduction of treasury shares) during the period (in thousands):    
- basic 869,370 881,519
- diluted 869,370 881,519
Income from continuing operations attributable to shareholders1) (in EUR)    
- basic (0.17) (0.75)
- diluted (0.17) (0.75)
Net income attributable to shareholders1) (in EUR)    
- basic (0.17) (0.75)
- diluted (0.17) (0.75)
1) Shareholders refers to shareholders of Koninklijke Philips N.V.

Amounts may not add up due to rounding.

Reconciliation of non-IFRS information

Certain non-IFRS financial measures are presented when discussing the Philips Group’s performance:

  • Comparable sales growth
  • Adjusted income from continuing operations attributable to shareholders
  • Adjusted income from continuing operations attributable to shareholders per common share (in EUR) - diluted (Adjusted EPS)
  • EBITA
  • Adjusted EBITA
  • Adjusted EBITDA
  • Free cash flow
  • Net debt : group equity ratio

For the definitions of the non-IFRS financial measures listed above, refer to chapter 12.3, Reconciliation of non-IFRS information, of the Annual Report 2022 and to the Forward-looking statements and other important information.

Comparable order intake is presented when discussing the Philips Group’s performance. For the definition of this measure, refer to chapter 12.4, Other Key Performance Indicators, of the Annual Report 2022.

Sales growth composition

in %

  Q1 2023
  nominal growth consolidation changes currency effects comparable growth
2023 versus 2022        
Diagnosis & Treatment 15.3% 1.0% (1.1)% 15.2%
Connected Care 4.0% 0.1% (1.5)% 2.6%
Personal Health (4.7)% 0.0% (1.2)% (5.9)%
Philips Group 6.3% 0.5% (1.1)% 5.7%

Adjusted income from continuing operations attributable to shareholders 1)

in millions of EUR unless otherwise stated

  Q1
  2022 2023
Net income (151) (665)
Discontinued operations, net of income taxes - 3
Income from continuing operations (152) (663)
Income from continuing operations attributable to non-controlling interests - -
Income from continuing operations attributable to shareholders 1 ) (152) (663)
Adjustments for:    
Amortization and impairment of acquired intangible assets 74 74
Restructuring and acquisition-related charges 25 224
Other items: 325 644
Respironics litigation provision   575
Respironics field-action provision 165  
Respironics field-action running remediation costs 50 54
Portfolio realignment charges 87  
Remaining items 23 15
Net finance expenses (1) 4
Tax impact of adjusted items and tax only adjusting items (136) (91)
Adjusted income from continuing operations attributable to shareholders 1 ) 135 192
Earnings per common share:    
Income from continuing operations attributable to shareholders1) per common share (in EUR) - diluted (0.17) (0.75)
Adjusted income from continuing operations attributable to shareholders1) per common share (in EUR) - diluted 0.15 0.22
1) Shareholders refers to shareholders of Koninklijke Philips N.V.

Amounts may not add up due to rounding.

Reconciliation of Net income to Adjusted EBITA

in millions of EUR

  Philips Group Diagnosis & Treatment Connected Care Personal Health Other
Q1 2023          
Net income (665)        
Discontinued operations, net of income taxes 3        
Income tax benefit (15)        
Investments in associates, net of income taxes 16        
Financial expenses 93        
Financial income (14)        
Income from operations (583) 157 (710) 96 (126)
Amortization and impairment of acquired intangible assets 74 24 43 4 2
EBITA (510) 181 (667) 101 (124)
Restructuring and acquisition-related charges 224 67 47 5 104
Other items: 644 1 644 (1) -
Respironics litigation provision 575   575    
Respironics field-action running remediation costs 54   54    
Remaining items 15 1 15 (1) -
Adjusted EBITA 359 250 25 105 (20)
           
Q1 2022          
Net income (151)        
Discontinued operations, net of income taxes -        
Income tax benefit (67)        
Investments in associates, net of income taxes 11        
Financial expenses 44        
Financial income (17)        
Income from operations (181) 88 (378) 124 (16)
Amortization and impairment of acquired intangible assets 74 25 44 4 1
EBITA (107) 114 (334) 128 (15)
Restructuring and acquisition-related charges 25 (1) 20 - 6
Other items: 325 319 6
Respironics field-action provision 165   165    
Respironics field-action running remediation costs 50   50    
Portfolio realignment charges 87   87    
Remaining items 23   17   6
Adjusted EBITA 243 113 4 128 (2)

Reconciliation of Net income to Adjusted EBITDA

in millions of EUR

  Philips Group Diagnosis & Treatment Connected Care Personal Health Other
Q1 2023          
Net income (665)        
Discontinued operations, net of income taxes 3        
Income tax benefit (15)        
Investments in associates, net of income taxes 16        
Financial expenses 93        
Financial income (14)        
Income from operations (583) 157 (710) 96 (126)
Depreciation, amortization and impairments of fixed assets and acquired intangible assets 311 85 91 28 107
Restructuring and acquisition-related charges 224 67 47 5 104
Other items: 644 1 644 (1) -
Respironics litigation provision 575   575    
Respironics field-action running remediation costs 54   54    
Remaining items 15 1 15 (1) -
Adding back impairment of fixed assets included in Restructuring and acquisition-related charges and Other items (21) (3) - (19)
Adjusted EBITDA 575 308 72 128 66
           
Q1 2022          
Net income (151)        
Discontinued operations, net of income taxes -        
Income tax benefit (67)        
Investments in associates, net of income taxes 11        
Financial expenses 44        
Financial income (17)        
Income from operations (181) 88 (378) 124 (16)
Depreciation, amortization and impairments of fixed assets and acquired intangible assets 355 95 133 35 92
Restructuring and acquisition-related charges 25 (1) 20 - 6
Other items: 325 319 6
Respironics field-action provision 165   165    
Respironics field-action running remediation costs 50   50    
Portfolio realignment charges 87   87    
Remaining items 23   17   6
Adding back impairment of fixed assets included in Restructuring and acquisition-related charges and Other items (35) (1) (33) (1)
Adjusted EBITDA 488 181 60 159 87

Composition of free cash flow

in millions of EUR

  January to March
  2022 2023
Net cash flows from operating activities (227) 202
Net capital expenditures (175) (85)
Purchase of intangible assets (28) (43)
Expenditures on development assets (61) (47)
Capital expenditures on property, plant and equipment (92) (72)
Proceeds from disposals of property, plant and equipment 7 77
Free cash flow (402) 117

Philips statistics

in millions of EUR unless otherwise stated

  2022 2023
  Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Sales 3,918 4,177 4,310 5,422 4,167      
Comparable sales growth1) (4)% (7)% (5)% 3% 6%      
Comparable order intake2) 5% 1% (6)% (8)% 0%      
Gross margin 1,511 1,731 1,730 2,221 1,755      
as a % of sales 38.6% 41.4% 40.1% 41.0% 42.1%      
Selling expenses (1,064) (1,111) (1,154) (1,280) (1,079)      
as a % of sales (27.2)% (26.6)% (26.8)% (23.6)% (25.9)%      
G&A expenses (155) (146) (175) (195) (158)      
as a % of sales (4.0)% (3.5)% (4.1)% (3.6)% (3.8)%      
R&D expenses (495) (490) (615) (504) (528)      
as a % of sales (12.6)% (11.7)% (14.3)% (9.3)% (12.7)%      
Income from operations (181) 11 (1,529) 171 (583)      
as a % of sales (4.6)% 0.3% (35.5)% 3.2% (14.0)%      
Net income (151) (20) (1,329) (105) (665)      
Income from continuing operations attributable to shareholders3) per common share (in EUR) - diluted (0.17) (0.03) (1.50) (0.13) (0.75)      
Adjusted income from continuing operations attributable to shareholders3) per common share (in EUR) - diluted1) 0.15 0.14 0.25 0.41 0.22      
EBITA1) (107) 92 (94) 301 (510)      
as a % of sales (2.7)% 2.2% (2.2)% 5.5% (12.2)%      
Adjusted EBITA1) 243 216 209 651 359      
as a % of sales 6.2% 5.2% 4.8% 12.0% 8.6%      
Adjusted EBITDA1) 488 461 466 891 575      
as a % of sales 12.5% 11.0% 10.8% 16.4% 13.8%      
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information, of this document. 2) Comparable order intake is presented when discussing the Philips Group's performance. For the definition of this measure, refer to chapter 12.4, Other Key Performance Indicators, of the Annual Report 2022. 3) Shareholders refers to shareholders of Koninklijke Philips N.V.

Philips statistics

in millions of EUR unless otherwise stated

  2022 2023
  January-March January-June January-September January-December January-March January-June January-September January-December
Sales 3,918 8,095 12,405 17,827 4,167      
Comparable sales growth1) (4)% (5)% (5)% (3)% 6%      
Comparable order intake2) 5% 3% (1)% (3)% 0%      
Gross margin 1,511 3,243 4,973 7,194 1,755      
as a % of sales 38.6% 40.1% 40.1% 40.4% 42.1%      
Selling expenses (1,064) (2,175) (3,329) (4,609) (1,079)      
as a % of sales (27.2)% (26.9)% (26.8)% (25.9)% (25.9)%      
G&A expenses (155) (301) (476) (671) (158)      
as a % of sales (4.0)% (3.7)% (3.8)% (3.8)% (3.8)%      
R&D expenses (495) (985) (1,600) (2,103) (528)      
as a % of sales (12.6)% (12.2)% (12.9)% (11.8)% (12.7)%      
Income from operations (181) (170) (1,700) (1,529) (583)      
as a % of sales (4.6)% (2.1)% (13.7)% (8.6)% (14.0)%      
Net income (151) (171) (1,500) (1,605) (665)      
Income from continuing operations attributable to shareholders3) per common share (in EUR) - diluted (0.17) (0.20) (1.72) (1.84) (0.75)      
Adjusted income from continuing operations attributable to shareholders3) per common share (in EUR) - diluted1) 0.15 0.30 0.55 0.96 0.22      
EBITA1) (107) (15) (109) 192 (510)      
as a % of sales (2.7)% (0.2)% (0.9)% 1.1% (12.2)%      
Adjusted EBITA1) 243 459 667 1,318 359      
as a % of sales 6.2% 5.7% 5.4% 7.4% 8.6%      
Adjusted EBITDA1) 488 948 1,414 2,305 575      
as a % of sales 12.5% 11.7% 11.4% 12.9% 13.8%      
Number of common shares outstanding (after deduction of treasury shares) at the end of period (in thousands) 869,298 885,316 885,348 881,481 881,539      
Shareholders' equity per common share (in EUR) 16.64 16.63 16.31 15.03 13.99      
Net debt : group equity ratio1) 28:72 31:69 34:66 35:65 36:64      
Total employees 78,548 78,831 79,097 77,233 73,712      
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information, of this document. 2) Comparable order intake is presented when discussing the Philips Group's performance. For the definition of this measure, refer to chapter 12.4, Other Key Performance Indicators, of the Annual Report 2022. 3) Shareholders refers to shareholders of Koninklijke Philips N.V.

© 2023 Koninklijke Philips N.V.

All rights reserved.

https://www.philips.com/investorrelations
Philips shield
GRAPHIC 2 visual0001.jpg begin 644 visual0001.jpg M_]C_X 02D9)1@ ! 0 0 ! #_VP!# 4#! 0$ P4$! 0%!04&!PP(!P<' M!P\+"PD,$0\2$A$/$1$3%AP7$Q0:%1$1&"$8&AT='Q\?$Q)!P>'Q[_ MVP!# 04%!0<&!PX(" X>%!$4'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX> M'AX>'AX>'AX>'AX>'AX>'AX>'AX>'A[_P 1" 6V! # 2( A$! Q$!_\0 M'0 ! (" P$! $$ P8"!P@%"?_$ %H0 0 ! @(%!0<-#0,, M @(# ! @,$!081$C%!!P@389,6559QL<+2%Q@A-#=14W."E+*SX105(C(V M(C0S.5)"9D_\0 &P$! (# 0$ M $&! 4' @/_Q Y$0$ 0$$!@@% @8# 0 0(#! 6Q$14T M4H&A!A,4(3%1<=$207*1P3)A%C,U0E/A(O#Q(__: P# 0 "$0,1 #\ ]E@ M 3N02 XRXRY<'"0<98ZI M3JZ'Y7_A1MU+6D,ZN@^5_P"%"U4"Y14ST2J6Y9Z)!9HEDI8:)9: 9:7*'"ES MC<#DF'&-R8!( (E'!/%$@B=SA+E+A(,=3%7+)4PUR#%7*O<#[0 M M /C:2SJG#_*_\/G6JE_2F=4X;Y7_A\NU(+UJ5BW*G:E:M M2"U;EEH8++A(,53#6S M5,%8,%R56[.]8N*MV=X*UV=[ZFBD^SBOD><^1=G>^KHCOQ?R/.!]X M M 'PM+)U3A?E_^'RK,OIZ7;\+\OS7R M;,@O696K4J5F5NT"U;9Z%>VL4 RT,D,=+)&X'.$N,;W($P$;@ $(E*) M!PGBQRR3Q8Y!BJ8+C/7Q5ZP5[O%4N\5JXJ7>(*EZ=[ZVB&_%_(\Y\B].]];0 M_P#&Q?R/.!L M -?TPWX3Y? MFOD69?6TRWX3Y?FOCV07K,K=E3LK=H%JVL6U>VL6P9:66G MOBKW 5KO%3N\5R[Q4[O$%._Q?7T-_&QGR/.?(O<7U]#=^,^1YP-A M M !KNF>_"?+\U\>R^QIGOPGR_-?'L@N MV5NSO5+*W9W@M6]RQ;5[>Y8M@S4,E&Z6.ADHW2#G#DXPY F-P1N 0B M4HD'"=TL=3).Z6.H&&OBKUK%?%7K!6N\5.[Q7+O%3N\04[W%]?0W?C/D><^1 M>XOKZ&[\9\CS@;" M #7=,]^ M$^7YKX]E]C3/?A/E^:^/9!=LK=G>J65NSO!:M[EBVKV]RQ;!FH9*-TL=#)1N MD'.')QAR!,;@C< A$I1(.$[I8ZF2=TL=0,-?%7K6*^*O6"M=XJ=WBN M7>*G=X@IWN+Z^AN_&?(\Y\B]Q?7T-WXSY'G V$ :1RRZ<8C0/1O#9 MIAL!:QM=_%QA]BY3<5R\Z?WM?1XC+\/\ %X2)^E,O MG7.6?E)KF?\ ^QS3'O4X.Q'F,ZGHU>Y\9ICC/LU]72NY1X15/"/=[#'C6OE= MY1:]^D^(_99M1Y*6&OE4Y0:M^E.._9LQY(>XZ,WGYU4\_9\YZ6W7Y45,S:JHJ_QIJU?P;OHWSBHCKF/P:HCQ1+$M<"OMG&GX=/I/\ V6;8=(KA:SH^/1ZQ M_P!AW:/CZ+Z4:/Z386<3D6:X;'41^-315JKH_.HG553^V'V&IKHJHGX:HT2W M5%=-I3\5$Z8_8 >7H!T9IGR\XO(-*\SR2C1NQB*<%B*K,79QSZ#=>1WE:Q&GFDF)RF]D MEK 4V,'5B(N4XB:YF8KHIU:IIC_7_@^5M@][L:)M*Z=$1^\>[ZV&.W&WM(L[ M.O3,^'=/L[5 :QMP =+\I'+=BM$M-MZ/6<73A)MZKU6*FB:MJW37NV9 MU?C:OV-=][36N/W"RKFBJOOB=$]T_+ M@]%#SKZY'&^"F'^>SZ!ZY'&^"F'^>SZ#WJ&_;G./=X_B/#M_E/L]%#J#DJY9 M,3III=;R*[D-G!4UV:[G2TXF:YC9C7JU;,.WVOO-UM;K7\%K&B6RNE\L;Y9] M98SICP_[I <+]?1V+ES5KV:9JU>_JACLIS'G7UR.-\%,/\]GT#UR.-\%,/\ M/9]!N-0W[BAYU];*SJM:XHI\9[GJUM:;&B;2N>Z(TRV<>=?7(XWP4P_SV?0/7(X MWP4P_P ]GT&UU#?MSG'NT_\ $>';_*?9Z*'G7UR.-\%,/\]GT#UR.-\%,/\ M/9] U#?MSG'N?Q'AV_RGV>BA\G0S.*L_T4RS.J[$8>K&X:B]-J*MJ*-<:]6O MB^LU-=$T533/C#=45Q73%5/A( \O0 //6+YQF-L8J]9C17#U1;KJHU_=D^S MJF8_U.IB]=?7(XWP4P_ MSV?0/7(XWP4P_P ]GT$ZAOVYSCW/XCP[?Y3[/10Z]Y%^4:]R@6LTKO95;R_[ MAJM1$47IN;>WM>_$:M6S_%V$UMO85W>TFSM(T3#:W:\V=YLHM;*=-,_^ /A: M?Y]7HSH=F6?6L-3B:\';BN+556S%6NJ(W_M>+.B;2J**?&>Y]+2TILZ)KJ\( M[WW1YFQ7.,TFJU__9A[,>2A]HZ,WKYU4\_9\)Z6W/Y4U?:/=[('C"OE6Y0J]^E&,_931'DA% MOE5Y0;?XNE.-G\Z*:O+#U_#-XWXY^SS_ !;==RKE[O: \K1T)H]SC<)75%O/]'KMF.-W!W8K_Z*M7TI=H:(\HNAVE%RBQE.=6:L M55NPUZ)M79GWHIJU;7[-;6WC#+U=^^THG1Y^,8TT4=WG/2,?RZ)JF;.8X3!Q/"S@Z)U?\\5/DWN5GE$NS,U:48J-?^I;MT^2 MF&RIZ-7J?&JF/O[-55TLN<>%-4\(]WLT>,+7*MRA6I_!THQL_G4T5>6%RSRS M\I%OV.Z+;CWJ\'8GS-:9Z,WGY54\_9$=+;I\Z*N7N]ACRIE?+]IUA9B,53E> M/CCTN'FF?^BJF/X-JROG(;J&Q?FU4_P#EC6G1^^T>%,3Z3[Z&59=) M;A7XU3'K$_C2] BKE&.M9GE.#S*Q%46L78HOT15OBFNF*HU_LE:::8F)T2WT M3%4:8 $) :[IGOPGR_-?'LOL:9[\)\OS7Q[(+EEWN6+8,U#)1NECH9*-T@YPY.,.0)C<$;@ $(E*)!PG=+'4R3NECJ!A MKXJ]:Q7Q5ZP5KO%3N\5R[Q4[O$%.]Q?7T-WXSY'G/D7N+Z^AN_&?(\X&P@ M Z:YW'Y 99^M*/JKKS"]/<[C\@,L_6E'U5UYA7[H]L4>LN;=)]OGT@ ; MQ7@%^G)J?X/,U1'C+U33-7A"@+&+P.-PD1.*P>(L: M]W2VII\JNF)B?!$Q,=T@"4,^!QF+P&*HQ6!Q5["XBW.NB[9N3173/5,>S#OC MDFY=;G36C]L;Y= ##OEQL;W1\-I''YPSKC MB-O@7/+]4 M^0\3\L'NHZ1_K"[Y7MAXGY8/=1TC_6%WRMUT8_GU^GY:#I=L]'K^&J +JH([ MCYH_NAYE^J;GUUITX[CYH_NAYE^J;GUUIK<7V*T]&UP3;[+U>H '-W50 'CO MG$>[)GWCL?\ ;VV@-_YQ'NR9]X['_;VV@.GW#9;+Z8R^B]9O)G-?]U?#_HE[Z+UFHG2/:X](_+HO1789^J?P,6-]IW_ M (NKR2RL6-]IW_BZO)+0T^*R3X/ (#K+BP #TIS0OR7SO]-H^A#N]TAS0OR7 MSO\ 3:/H0[O _P!/LO3\R.MNY%F7 MQUCZVE\<.VNR^J,V1BFQ6OTSD\B@.FN2 /;/(_[EVCGZOM>1M35>1_W+M'/ MU?:\C:G++U_/K]9S=AN>SV?I&0 ^#) >!AN9W[5TF_/PWDNN_707,[]JZ3?GX;R77?KG>.;=:<,H M=1Z/?TZSXYR-)Y=?,@'47( 7,/E6:8FS3>P^6XR]:J_%KMV*JJ9X>Q,0C$Y9F6&HZ3$Y? MB[-$?Y5RS53'\8>?CITZ-+W\%6C3H5 'IX$TS--454S,3$ZXF." ';/)ERVY M]H_=LX'2"N[G&51,4S57.O$6H]^FJ?QHCWJOV3#TYD.;Y=GF48?- M(IVK=RGC[\3&^)C=,3[,2\%.R^0+3^[HCI+1E^.O3]Y]5U>*%;Q?!:+6B;6PC15'R\_]K5@F/VEC7%C>)TTSX3/R_P!9/7 "DN@, M.-Q6&P6#O8S&7[=C#V:)KNW;E6JFBF/9F9GWGF;E6Y;LTSJ[>RO16Y=RW+8J MFF<53,TW\1'OQ.^BF>KV??F/9A]KG4Z:W.GM:%8"[--N*:;^833/XTS[-%N> MJ/8JGQT^\Z!7# \(HZN+Q;1IF?"/RHW2'&[3K)NUA.B(\9\Y\DU3-4S55,S, M^S,SQ0"U*< ]LUJF/X50[%M8KXJ]8*UWBIW> M*Y=XJ=WB"G>XOKZ&[\9\CSGR+W%]?0W?C/D><#80 =-<[C\@,L_6E' MU5UYA>GN=Q^0&6?K2CZJZ\PK]T>V*/67-ND^WSZ0 -XKP]Z:.?D]EWZ):^A# MP6]Z:.?D]EWZ):^A"J=*/T6?'\+ET/\ UVOI'Y7;E%%RBJWF?)'H7I'8N3&66LLQE43LXG!4Q;F)]^:8_!JZ]<:^N&_"K6-O:V%7Q6=4 MQ/[+C;W:RO%/PVM,3'[O$7*-H5FVA&?3EF91%RW7&WAL31$Q1?H]^/>F.,<. MN-4SK+V1R[Z,VM)>3C,:>CB<7@*)QF&JU>S%5$3-5/RJ=J-7OZO>>-U_PB_S M?;#XJOU1W3[N:XWAL7"\?#3^F>^/;@ -JTRQEF-Q.6YEALPP=R;>)PUVF]:K MC_)JIG7$_P",/=6C&:V<\T=R_.;$:K>,PU%Z*=?XNU&N8_9/L?L>#7K;FR9A M5C>2C"V:JIJG!8F]A]<^]M;NQ^4QI MXQ_Z[->)^6#W4=(_UA=\KVP\3\L'NHZ1_K"[Y6!T8_GU^GY;+I=L]'K^&J + MJH([CYH_NAYE^J;GUUITX[CYH_NAYE^J;GUUIK<7V*T]&UP3;[+U>H '-W50 M 'COG$>[)GWCL?\ ;VV@-_YQ'NR9]X['_;VV@.GW#9;+Z8R^B]9O)G-?]U?#_HE[Z+UFHG2/:X](_+HO1789^J?P,6- M]IW_ (NKR2RL6-]IW_BZO)+0T^*R3X/ (#K+BP #TIS0OR7SO]-H^A#N]TAS M0OR7SO\ 3:/H0[O _P!/LO3\R.MN MY%F7QUCZVE\<.VNR^J,V1BFQ6OTSD\B@.FN2 /;/(_[EVCGZOM>1M35>1_W M+M'/U?:\C:G++U_/K]9S=AN>SV?I&0 ^#) >!AN9W[5TF_/PWDNN_707,[]JZ3?GX;R77?KG>.;= M:<,H=1Z/?TZSXYR-)Y=?,@'47( 'L7F\>XYD/YM_Z^XWYH/-X]QS(?S;_U]QOSF%_VJU^J M M#Q8S/!W\OS+%9?B:=F_AKU=FY'O54S,3_&%=T.)B8TPYA,3$Z) $H>Q^0/2* MO2/DSR^]?KFO$X+7@K]4SKF9HB-F9ZYHFB9ZYEOCS_S/LPJFC2'*ZJ_P8FSB M+=/7.U35/\*'?6.FJ,#?FC\:+=6SX]4N;8I818WRNB/#3GWNK8/>9M[C9VD^ M.C1]N[\/#6FV:UYYIAFV;U5;7W5B[ERGV=U&U.S'[(U0^.#H]%$44Q3'A#EE M=RZS-.K5.7J\3>JK.J9BF/"/DZ/T=N=VBYTV MM-,35/C/S\?#]E:K+\!5&JK X:8Z[5/]%/&Z-:.XVW-O&9#E6(IGA=PENJ/X MP^J-)%I7'A*P39T5=TQ#0LXY'N3W,J9VL@MX6N=U>%NUVIC]D3L_P:%I-S<\ M)5;JN:-Y]>MW.%G'4153/RZ(B8_Y9=]#-L<5O=C^FTGCWYM?;X-/^5G'# MNR=?<@FC6=Z)Z'XK)L]L6[=ZC'UUV:K=R*Z:[M8KXJ]8*UWBIW>*Y=XJ=WB"G>XOKZ&[\9\CSG MR+W%]?0W?C/D><#80 =-<[C\@,L_6E'U5UYA>GN=Q^0&6?K2CZJZ\P MK]T>V*/67-ND^WSZ0 -XKP]Z:.?D]EWZ):^A#P6]Z:.?D]EWZ):^A"J=*/T6 M?'\+ET/_ %VOI'Y7P%07APO6Z+UFNS_$^Q+P!73LUU4Z]>J=3W MMGF-HRW)<=F-R8BC"X>Y?JF>$4TS5/D>")]F5NZ+1.BUGY=WY4GIA,:;*/G_ M ,OP +8I8].\T:J9T!S2CA&:53'[;5O^CS$]4-,,2_V%5XN]=E3XS#-PZ\4W:]46M?A M$O^V'^9VOZ*A_#5[\Z?O/LN_\5W+RJ^T>[UT M/(OJX_.G[S['\5W+RJ^T>ZKSB/=DS M[QV/^WMM ?2TFSS,=(\\Q&IO8W$[/2UTT13$[-,4Q[$>Q'L4P^:N=ULI MLK"BSJ\8B(^T*)>[6FVO%=I3X53,_>0!]V,[0YK_ +J^'_1+WT7K-Y,YK_NK MX?\ 1+WT7K-1.D>UQZ1^71>BNPS]4_@8L;[3O_%U>265BQOM._\ %U>26AI\ M5DGP> 0'67%@ 'I3FA?DOG?Z;1]"'=[I#FA?DOG?Z;1]"'=[G&,[=:>OX=3P M'^GV7I^9'6W.6]R+,OCK'UM+LEUMSEO10'37) 'MGD?\ OY]?K.;L-SV>S] M(R 'P9( #P+FO]J8OXZOZ4JRSFO]J8OXZOZ4JSK%/Z8<7J_5( ]/+T-S._:N MDWY^&\EUWZZ"YG?M72;\_#>2Z[]<[QS;K3AE#J/1[^G6?'.1I/+K[DFD'Z/3 M]92W9I/+K[DFD'Z/3]92PKEM-G]49LZ_[+:_3.4O&0#J+D #V+S>/<4S2'%6YVJ)QURBF??BB=B)_Z6KNI72) MBPHB?'1&3CU\F)O%I,>&F=>9]A:JLSTBQNK\&W9L6O'-554^:]%.?8_.F_5<,G3.C5,QA]&GSG. M7@W2C+:\GTDS+*;E,TU8/%7+.J?>IJF(G_"'SG=G.GT.N8#/[6EN#M3.$Q\1 M;Q6S'XEZF-43/553$?MIGWW2:[7&\Q>;"FTCYQW^OS4#$+I5=+S793\I[O3Y M #+83/E^,Q>7XVSC<#B+N&Q-FJ*[=VW5--5,QQB8=[Z"Y M]&-+M&M);,7,CSG"8RJ8US:IKU7:8ZZ)U51^V'W'Y_V;MRS=INV;E=NY1.NF MNB=4TS[\3#L#1'EDTXT?FFW7F7WUPT;[./UW)U=5>O;C_'5U*U>>C-<=]A7I M_:??_P 6NZ=+:*NZ\4:/WCV_]>P!U)H3R\Z+YS71AMWK-RG:HN6ZHJIJCWXF/8F%>O%TMKM5\-K3H6 M>ZWVPO=/Q6-43_WR\60!CLH !KNF>_"?+\U\>R^QIGOPGR_-?'L@N6 M5RSO4[*Y9W@M6]RQ;5[>Y8M@S4,E&Z6.ADHW2#G#DXPY F-P1N 0B4 MHD'"=TL=3).Z6.H&&OBKUK%?%7K!6N\5.[Q7+O%3N\04[W%]?0W?C/D><^1> MXOKZ&[\9\CS@;" #IKG'O31S\GLN_1+7T(>"WNW1W&X*-'\NB<7AXF,+:UQT MD?ZD=:J])XF:;/1^_P"%QZ(3$5VNG]OR^L/DYGI-H[EE,U9CGN682-6O_P"; M%44S/BB9]EUKIYR\Z.97AKF'T:B+Q.BSHF['WPS:-FJF)]FW8B? MPJI_.U;,>_KJ]YY7?0TASG,L_P WOYKF^*KQ6+OU:ZZZOX1$;HB.$1N?/= P MRXQ)^6#W4=(_UA=\KVP\3 M\L'NHZ1_K"[Y7QZ,?SZ_3\OOTNV>CU_#5 %U4$ !VAS7_=7P_P"B M7OHO6;R9S7_=7P_Z)>^B]9J)TCVN/2/RZ+T5V&?JG\#%C?:=_P"+J\DLK%C? M:=_XNKR2T-/BLD^#P" ZRXL ]*Y%F7QUCZVEV2ZVYRWN19E\=8^MI?'#MK MLOJC-D8IL5K],Y/(H#IKD@ #VSR/^Y=HY^K[7D;4U7D?]R[1S]7VO(VIRR]? MSZ_67H;F=^U=)OS\-Y+KOUT%S._:NDWY^&\EUWZYWCFW6G#*'4>CW].L^.< MC2>77W)-(/T>GZRENS2>77W)-(/T>GZREA7+:;/ZHS9U_P!EM?IG*7C(!U%R M ![%YO'N.9#^;?^ON-^==\WS%X6WR/Y%1]'XT]42U[2_EKT*R.Q73@L;.= M8R(_ LX3V:)GAKN3^#$>+7/4\U\H6FN=:;9S]\,VNQ%NC73A\-;_ /QV*9X1 M'&9]C7,^S/BB(C889@MM;VD56M.BB//YM9BV/6%VLYHL:OBKGR^7[_Z:Y_'O3$^S$\)B'D M;E7Y,LXT(QU=^**\9DMRO58QE,:]G7NIN:OQ:OX3PXQ'L9CQ-BSB*X198A1_R[JH\)]_V M> !Z7Y0.0'*LQJN8W13%4Y7B*M*=4KM=,4NUZC_A5W^4]T_P#?1S^^X/>[G,_' M3ICSCOC_ %Q:R V+5@ #<>3CE&TBT)Q=/W!B)Q&7S5KO8&]5,VZ_?FG_ %*N MN/VZ]S3A\K6QHMJ)HM(TQ+ZV-O:6%<5V2=TMA>)N2W3+&:%:5V,TL357A:YBWC+$3[%VU,^S^V-\3[\>] M,Z_:N$Q%G%86UBL/_"?+\U\>R^QIGOPGR_-?'L@N65RSO4[*Y9 MW@M6]RQ;5[>Y8M@S4,E&Z6.ADHW2#G#DXPY F-P1N 0B4HD'"=TL=3 M).Z6.H&&OBKUK%?%7K!6N\5.[Q7+O%3N\04[W%]?0W?C/D><^1>XOKZ&[\9\ MCS@;" #IKG 'T=&\ES+2'.FN3K0+(=",MG#Y79FYB;D1] MT8R[$3=NSX^%/O4Q['CGV6EQ'&K&ZQ--$_%7Y>7K[-_A> 6]\JBJN/AH\_/T M]_!QY*]"<%H-HQ1EEBJF]B[L])C,1$:NEN=7^[&Z(_;OF6V H=K:UVMZCI'^L+OE>V'B?E@]U'2/]87?*L/1C^?7Z?E6. MEVST>OX:H NJ@CL3D!T1R?3+2[&9;G=%ZO#VL!5?IBUY%F7QUCZVE\<.VNR^J,V1BFQ6OTSD\B@.FN2 /;/(_P"Y=HY^K[7D M;4U7D?\ GEZ&YG?M72;\_#>2Z[]=!#F=56,Q&NBS M'BG?5XJ8E\[6UHLJ?BKG1#ZV-C:6U?P6=,S/[-6PF&Q&+Q5K"X6S55YEFE--6>8RC5=B)B8P]O7KZ.)XS[$35/ MOQ$1NUS?Y*^2S)-![?W5K^^.;U1JJQERC5L1QIMT^SLQU[Y]_5[#?U+Q?&NT MQ-C8_I^<^?\ I?<#P#LD]?;_ *_E'E_L 5U: F(F-4[@!HNEW)+H1I'-=V M_E-.!Q5>_$8*>BJU^_,1&S,](TST%<1:OQ'5K M_!J_QCQ/3@V=UQ>]W;NIJTQY3WM3>\$N=ZTS51HGSCNGV^[P%CL)BL#C+N#Q MN'NX;$6:IIN6KM$TU43[TQ.YA>MN<#H-E^D6AV-SBW8MV\VRVQ5?MWZ:=55R MW1$U56ZO?C5$ZO>G5[\Z_)*[8;B%-^LOCB-$QXPY_BN&5X?;?!,Z8GOB0!L6 MK'KWFXYO%,ZZ8_9353'['D)Z?YH^UZGV9:_Q?OK M7J\?16M?_AH>D=$57/3/RF%DZ+6DTW[X8^<3[NY %#=& :[IGOPGR_- M?'LOL:9[\)\OS7Q[(+EEWN6+8,U#)1NECH9*-T@YPY M.,.0)C<$;@ $(E*)!PG=+'4R3NECJ!AKXJ]:Q7Q5ZP5KO%3N\5R[Q4[ MO$%.]Q?7T-WXSY'G/D7N+Z^AN_&?(\X&P@ Z:YW'Y 99^M*/JKKS"] M/<[C\@,L_6E'U5UYA7[H]L4>LN;=)]OGT@ ;Q7AW'@>;WI+B\%8Q5&=9133> MMTW*8F;FN(F-?^JZ<>]-'/R>R[]$M?0AH<=8YN>D^OV<\R>(ZND]%9PO-PS>JN(Q.DN!M4\9MX>NN?\)F'I M 5V>D%^G^Z/M"TQT:P^/[9^\NE,GYNFCUBJ*LUSS,<;J_P FS139IGQ_C3_% MV#HQR=:&:.337E>0X6+]/LQ?O1-VY$^_%5>N8_9J;4,*VQ&]6\:*ZYT?;)GW M?"[G=YTV=G$3]Y^\@#"9X \3\L'NHZ1_K"[Y7MAXGY8/=1TC_6%WRK+T8_G MU^GY5/I=L]'K^&J +JH([CYH_NAYE^J;GUUITX[CYH_NAYE^J;GUUIK<7V*T M]&UP3;[+U>H '-W50 'COG$>[)GWCL?]O;: W_G$>[)GWCL?]O;: Z?<-ELO MIC)R+$MLM?JJSD 9;"=HY%F7QUCZVE\<.VNR^J,V1BFQ6OTSD\B@.FN2 /;/(_[EVC MGZOM>1M3PO@]+]+,'A;>%P>D^=X?#VJ8IMVK6/NT444QNB(BK5$,O=SIKX7Z M0?\ [*]Z2H6W1NUM+2JN*X[YF5WL.E=C9V5-$V<]T1'C'R>XQX<[N=-?"_2# M_P#97O2.[G37POT@_P#V5[TGS_ABU_R1S?7^+K'_ !S]X>XQUKS<+F;XODXI MS/.!A MN9W[5TF_/PWDNN_707,[]JZ3?GX;R77?KG>.;=:<,H=1Z/?TZSXYR-)Y=?JF8WTR^U'-STGU^SGF3ZOWGHNV M^;Q[CF0_FW_K[C?E'O>.7RSMZZ*9C1$S'AY2Z%2MF8=315>J*:XTQ,Z/OW,'$ZK2BZ6E5 MG.B8C3]N]2T2Y>M$,UIHM9O3B,DQ,^Q/2T]):U]5=,:_\8AV?E699=FN$IQ> M68[#8W#U;KMB[%=/^,2\#+.6YAC\MQ$8C+L;B<'>C=>C5C M7WV-4T\X]\U/NO2RWH[K>F*OWCNGVR>^AXYRCEAY0LNU4TY_7BJ(_P G%6J+ MNOY4QM?Q;+@NK^#4VG1R]T_IF)X^[TO4(\XTIB9F9\7OP\:OIZ1Y_G.D68U9AG>8W\=B9 MC5%5RKV*8]ZF(]BF.J(B'S%MPK#NPV4TS.F9\5+QC%-86T5Q&BF.Z !LVH'K M;FQY=5@>2G#7JJ9IG'8F[B-4^]KBB)_PMP\L:/93C,\SS!Y1E]N;F)Q=VFU; MC5NU[YGJB-(I ML:;&/&9T\(6WHE=IJMJ[>?"(T<9_UFO *8OH #7=,]^$^7YKX]E]C3/? MA/E^:^/9!IV5RSO!:M[EBVKV]RQ;!FH9*-TL=#)1ND'.')QAR!,;@C M< A$I1(.$[I8ZF2=TL=0,-?%7K6*^*O6"M=XJ=WBN7>*G=X@IWN+Z^ MAN_&?(\Y\B]Q?7T-WXSY'G V$ '37.X_(#+/UI1]5=>87I[G*\/>FCGY/9=^B6OH0\%O>FCGY/9=^B6O MH0JG2C]%GQ_"Y=#_ -=KZ1^5\!4%X 'B?E@]U'2/]87?*]L/$_+![J. MD?ZPN^59>C'\^OT_*I]+MGH]?PU0!=5!'KU YNZJ \=\XCW9,^\=C_ +>VT!O_ #B/=DS[ MQV/^WMM =/N&RV7TQDY%B6V6OU59R ,MA.T.:_[J^'_1+WT7K-Y,YK_NKX?] M$O?1>LU$Z1[7'I'Y=%Z*[#/U3^!BQOM._P#%U>265BQOM._\75Y):&GQ62?! MX! =9<6 >E.:%^2^=_IM'T(=WND.:%^2^=_IM'T(=WN<8SMUIZ_AU/ ?Z?9 M>GYD=;Y.\J^_>G62Y7-.U1?QMN+D?[D5:Z_^F)>+2N**9JGPA[L[.;2N M*(\9G0]D30?)XYD/YM_Z^XWYS"_[5:_5.582=4U8C'4S;]C_=HF-JK_#5UP]" M\FG)3HYH5-.,MQ5F.:ZM4XR_3'X'O]'3NH\?LSUM3?<:NUUB8B?BJ\H_,MUA M^ WJ^3$S'PT^<_B/GD^#S?>3&O17"3G^>68C.L31LV[4^S]RVYX?GSQ]Z/8] M]VX"B7J]6EZM9M+2>^71KG=+.YV,65G'='_=( QV2 UW3/?A/E^:^/9 M?8TSWX3Y?FOCV07+*Y9WJ=EY8MJ]O*G=XKEWBIW>(* M=[B^OH;OQGR/.?(O<7U]#=^,^1YP-A !AQF$PN,MQ;Q>&LXBB)VHIN MVXJB)]_5*K]XLD[SY?\ -J/Z/H#U%=4=T2\S13/?,/G_ 'BR3O/E_P VH_H? M>+).\^7_ #:C^CZ GK*_-'54>4/G_>+).\^7_-J/Z+]----,4TQ%-,1JB(CV M(A(B:IGQE----/A \O0 I7LGRF]=JNWLKP-RY7.NJNO#TS,S[\S,+H MF*ICPE$TQ5XP^?\ >+).\^7_ #:C^A]XLD[SY?\ -J/Z/H#UUE?F\]51Y0^? M]XLD[SY?\VH_HS8/+]KB.I:$375/=,D6=$= M\0 /+V IXG*.(6P>9F9\7J*8I[H"8B8U3&N 0E\_P"\62=Y\O\ MFU']#[Q9)WGR_P";4?T?0'OK*_-XZJCRA\_[Q9)WGR_YM1_0^\62=Y\O^;4? MT?0#K*_,ZJCRA@P>#PF#HJHP>%L8>FJ==46K<41,]>IG!YF9GQ>HB(C1 QXG M#X?%69LXFQ:OVIWT7*(JIG]DL@B)T>"9C2^?]XLD[SY?\VH_H?>+).\^7_-J M/Z/H#WUE?F\=51Y0^?\ >+).\^7_ #:C^A]XLD[SY?\ -J/Z/H!UE?F=51Y0 M^?\ >+).\^7_ #:C^A]XLD[SY?\ -J/Z/H!UE?F=51Y0^?\ >+).\^7_ #:C M^C)ALIRO#7J;V'RW!V;M/XM=NQ335'#V)B%P.LJGYD6=$?( >'M\^?+_FU']'T![ZROS>.JH\H?/^\62=Y\O^;4?T/O%DG>?+_FU']'T ZROS.J MH\H8\-8LX:S39P]FW9M4_BT6Z8IICC[$0R \>+W$: !2S+*N MNS'^%%40^1B.0GD^NZ]C!XZQ^9BZI^EK=G#+IQ"]4>%I5]Y85>&7.OOJLJ?M M#J&[S>="*ZM=./SZW'O4XBUJ_C;ERPW-\T'M5:[F*SN_'O7,31$?]-N';@^F MM;YHT=9+Y:FN&G3U4.OQ[[.B(](@ M ?!D@ -;TTJ_^7!4^_%R?HODV7T--:XG,\%;U^S39N53'CFC^CY] ME*(7+*Y9WJ=EY8MJ]O*G=XKEWBIW>(*=[B^OH;OQG MR/.?(O<7U]#=^,^1YP-A M ! MUQI-C*[G*ABL%MZ[=C)\-7$>]57>OZ_X4TKMEHN4YG3FG+CIY7:O=+:P\83" MT>S[%,VZ*J:Z?V5Q6WJR^]XH^"J(_:,HEC76TZRB:OWJY3,+EE*G=X@IWN+Z^AN_&?(\Y\B]Q?7T-WXS MY'G V$ M !7S/&X?+O5SNIHIB9F?\ "%AU7SH])?O#R68K!V;LT8O-[D8.WLS&N*)_"N3J MGALQ-,_GP^UWLIMK6FSCYR^%YMHL+&JTGY0ZGYNF87\VTFTLS7%;/3XVY1B+ MNSNVJZ[E4ZOVR[RLN@N:U[=S[XNQY:W?MEF8O$1>ZHC]LH8&!S,W*B9_?.5R MRN6=ZG97+.]K6V6K>Y8MJ]O*G=XKEWBIW>(*=[B^OH;OQGR/. M?(O<7U]#=^,^1YP-A M >.N=- MI;&D7*/7EF&N[>!R2F<+1JG7$WIG7=J_QB*/W?6])%;MRY=NUW;M=5RY75-5554ZYJF=\S/& M5AP*ZZ:IMZOEW1^57Z1WS13%WIGQ[Y_#N;FM>W<^^+L>6MW[9=!*G=X@IWN+Z^AN_&?(\Y\B]Q?7T-WXSY'G V$ M M !CQ-^SAL-=Q.)NV[-BU1-=RY)BK T5:LQQ5N=?351/_ .*F?]6)CV9XS[&Z)VLJYW2N M]6D44\9\F'?K[1<[*;2OA'G+0.7?E KT]TRKQ&&KJC)\%KLY?1,3&NG7^%VKM[2;2N>^7<_-;]NY]\78\M;O MVRZ"YK?MW/OB['EK=^V5.QC;*^&4+U@6PT<*G=X@IWN+Z^AN_&?(\Y\B]Q?7T-WXSY'G V$ M M F8B-4>6SEMS'2_ILDT?Z;+LAG71[3X[2?]) M9+$=S\UOV[GWQ=CRUN_;+H+FM^W<^^+L>6MW[94K&-LKX90Z!@6PT<*G=X@IWN+Z^AN_&?(\Y\B M]Q?7T-WXSY'G V$ M ?,T@T@R/1_#1B<\ MS? Y=:G7LSB+U-&WJ]G53$SKJGJC7+IW37G)Z.8"BY8T6R_$9QB-U-^]$V+$ M>QOU3^'5JG5[$Q3XV1872VMY_P#G3IR^[%O%]L+M'_TJB,_L[TKJIHIFJJJ* M::8US,SJB(=.\IO+]HUH[3=P.CLT9]F<1,17;J__ (MJ=6^:X_'X>Q1UQM1+ MSGI]RFZ8Z:U56\YS6NG!3.N,%AHZ*Q&Z?9ICV:M4QKB:IJF.#3F_NF!4T_\ M*WG3^T*U?>D=56FF[QH_>?'[/OZ;Z8Z0Z99K.8:09AY8MJ]O*G=XKEWBIW>(*=[B^OH;OQGR/.?(O<6HZ;\J^6\F,X M7[X95B\?]\MO8Z"NFG8Z/5KUZ_?VX_P>[.SJM:HHHC3+Q:6E-E3-5WMGKK] M'?!3->WMFK;UN9&L;MOYO18\Z>NOT=\%,U[>V>NOT=\%,U[>V:MO6YDC65UW M\WHL>=/77Z.^"F:]O;/77Z/>"F:]O;-6WKBQYU]=?H]X*9KV]L] M==H]X*9IV]LU;>MS(UE==_-Z*'G7UUVCW@IFG;VSUUVCW@IFG;VS5MZW,C65 MUW\WHH>=?77:/>"F:=O;/76Z/>"F:=O;-6WKBAYV]=;H]X*9IV] ML]=;H]X*9IV]LU;>MS(UE==_-Z)'G;UUNCW@IFG;VSUUNCW@IFG;VS5MZW,C M6=UW\WHD>=O76Z/>"F:=O;/76:/>"N:=O;-6WKB1YV]=9H]X*YI MV]M/KK-'_!7-.WMFK;UN9&L[KOYO1 \[^NLT?\%V>NKT?\%V:MO6 MYDC6=UW\WH@>=_75Z/\ @KFG;VSUU>C_ (*YIV]LU;>MS(UG==_-Z('G?UU> MC_@KFG;VSUU>C_@KFG;VS5MZW,C6=UW\WH@>=_75Z/\ @KFG;VT^NJT?\%V:MO6YD:TNF_F]#CSQZZK1_P %V>NJT?\ !7-.WMFK;UN9&M+IOYO0 MX\\>NJT?\%@]=3H_X*YIV]LU;>MS(UI=-_-Z''GCUU.C_@KFG;VT^NIT M?\%V:MO6YD:TNF_F]##SSZZG1_P5S3M[9ZZG1_P5S3M[9JR];F1K2Z;^ M;T,///KJ='_!7-.WMGKJ='_!7-.WMFK+UN9&M+IOYO0P\\^NHT?\%LT[>A/K MJ-'_ 6S3MZ#5EZW,D:TNF_F]"CSUZZC1_P6S/MZ#UT^0>"V9]O0:LO6YD:U MNF_F]"CSUZZ?(/!;,^WH/73Y!X+9GV]!JR];F1K6Z;^;T*//7KI\@\%LS[>@ M]=/D'@MF?;T&K+UN9&M;IOYO0H\]>NGR#P6S/MZ$^NGR#P6S/MZ#5EZW,C6M MTW\WH0>>_739!X+9GV]!ZZ;(/!;,^WH-67KA!Y[]=-D'@MF?;T) M]=+D'@MF?;T&K+UN9&M;IOYO08\^>NER#P6S/MZ#UTN0>"V9]O0G5EZW,C6M MSW\WH,>?/72Y!X+9GV]!ZZ7(/!;,^WH-67K@QY\]=+D'@MF?;T' MKI<@\%LS[>@U9>MS(UM<]_-Z#'GWUTF0>"V9]O0>NDR#P6S/MZ#5EZW,D:VN M>_F]!#S[ZZ3(/!?,^WH/71Y!X+YGV]!JR];F1K:Y[^;T$//OKH\@\%\S[>@] M='D'@OF?;T&K+UN9&MKGOYO00\^^NCR#P7S/MZ#UT>0>"^9]O0:LO6YD:VN? M^3-Z"'GWUT>0^"^9]O0GUT>0^"^9]O0:LO6YD:VN?^3-Z!'G[UT60^"^9]O0 M>NBR'P7S/MZ#5EZW,C6US_R9O0(\_>NBR'P7S/MZ$^NBR'P7S/MZ#5=[W,C6 M]S_R1S>@!Y_]=#D/@OF?;T'KH@U7>]S(UO<_\D?_70Y#X+Y MGV]!ZZ'(?!?,^WH-5WOY_Y,WH >?_70Y#X+YGV]!ZZ'(?!?,^WH-5WO MN<>%4SPEZY'BC%\O'*A M?N554:148>FK_(M8&QJCQ3-$S_%KN9G ;>?U51'W]F+7TDN\?IIF?M[O=^9YEE^5X6K%9GC\+@L/3^-=Q%ZF MW1'CFJ8AH^?\M7)MD]5=NYI)9QEVFG:BC!6ZK\5=45TQL:_'4\17KER]=JNW MKE=RY7.NJJJ=[;NJKT1^W=DS8S%8K&XJYBL9B+ MV)Q%R==R[=KFNNJ??F9]F6$2SXC0UTSI 2E "0 ! (=S\UOV[GWQ=CRUN_; M+H/FN>W<^^+L>6MWY94K&-LKX90Z#@6PT<*G=X@IWN+SMSPO[L>/%_R7HF]Q>=N>#_=C_B_Y+88 M5M5''*6!BFRU\,X>?T@N"H @!(@!( )$"4)$"4) $) 3 D$I0 " !*$ M@)0D0)@ ! "1 "2 !*0!(@!(@ $"0 2 "2!,( $H 2 "1! ) @$@ " 0 M) !()A D!"0 $H2($H3 "4)$"4)$ "8$D E"0 2 ( ! E"0=S\USV[GW MQ=CRUN_++H/FN>W<^^+L>6MWY94K&-LKX90Z#@.PT<*G=X@IWN+SMSP?[L?\7_)>B;W%YWYX/\ M=C_B_P"2V&%;51QREK\4V6OAG#S^ N"H )$ ) !( )$ )$ @3 0F 2"02 M \@ ) !," $@ #R) @$@D$@($@(3 )$ ) 2A*80 )0 D $@"$@ D M 0 "!*$@)0D!,(2EY$@ "1 "0 2 "1Y $@D$P@2 "0 'D!, D'Y8MJ]O*G=XKEWBIW>(*=[B\[\\'^['_%_R7HB]Q>=^ M>#_=C_B_Y+885M5''*6OQ39:^&) !, D! D! D ! "0 2D$H2E M ( 2 (2 "0 ! E"1 E"4P"4)$"4)$"0 !(@!( )2 "7D 2 "0$"0 2 M \@) !( )3" $B 0) !( ) 0) 0 )A"4P@2A*02A( @ $) !( AW/ MS7?;N??%V/+6[[LNA.:[[=S[XNQY:W?=E2L8VROAE#H. [#1QSEIV5 MRSO:QN%JWN6+:O;W+%L&:ADHW2QT,E&Z0M8KXJ]8*UWBIW>*Y=XJ=WB"G>XO._/!_NQX\7_)>B+W% MYWYX/]V/'B_Y+885M5''*6OQ39*^&IV5RSO:QN%JWN6+:O;W+%L&:ADHW2QT,E&Z0M8KXJ]8*UWBIW>*Y=XJ=WB"G>XO._/!_NQX\ M7_)>B+W%YWYX']V/'B_Y+885M5''*6OQ39*^&<.@ 2N"G@) !(\@) $"0 M3 )!() >0 $@ D0 D >1($"0$B0@$) $) $"4) A*$@)!,( $H 2" M0 2( 2 ( ! D( 2! )!+R) $B $@ D $CR )!()0) !( #R D $@) M0D0)0F!#N7FO>W<]^+L>6MWW9="UC<+5OWN6+8,U#)1NECH9*-T@YPY.,.0)C<$;@ M $(E*)!PG=+'4R3NECJ!AKXJ]:Q7Q5ZP5KO%3N\5R[Q4[O$%.]Q>=^>!_=C MQXO^2]$7N+SOSP/[L>/%_P EL,*VJCCE+7XILE?#.'0"07!3Q("$@"$@ "! M*$D E"7H$H2( ! "0!"02! @2 @2"02 @2 @2 )$ ) !,)A E MD $P @3 ) 0 " $@ D $I0)0D0 "$@ D( 2 (2 ( $H2F$$)0E()0D M0 "$@ D$B $B $@[EYKWMW/?B['EK=]670O-?]NY[\78\M;OJRI6,;97PRAT M+ =AHXYRN65RSO4[*Y9WM8W"U;W+%M7M[EBV#-0R4;I8Z&2C=(.<.3C#D"8W M!&X !")2B0<)W2QU,D[I8Z@8:^*O6L5\5>L%:[Q4[O%XO/'.__ +L>/%_R6PPK:J..4M?BNR5\,X= )!<%.$@( M$@ "1 "4@"4H ! D $D @2 @!(@!*8 $@ D>1,(2 ($@ D 2 ]/ M( E"0$H2($H2 E"0 !Y 2 "0$PA, D0 ) 0) !("!(" $I@ 2E "0 M ! ($D "0 2 \B0 2 .Y>:_[=SWXNQY:W?5ET+S7_;N>_%V/+6[ZLJ5C&V5 M\,H="P'8*..Y8M@S4,E&Z6.ADHW2#G#DXP MY F-P1N 0B4HD'"=TL=3).Z6.H&&OBKUK%?%7K!6N\5.[Q7+O%3N\0 M4[W%YXYW_P#=CQXO^2]#WN+SQSO_ .['_%_R6PPK:J..4M?BNR5\,X= @E<% M- 2 ($@F!("02 \@ )@!*$B!*$@ #RD @2 D2 (2"1 ($@ D $@ MF$ "4 ) !(@!( ) $ @2 "0(0)!*!( D0 D $@ D>0 !(F $H2 "0! M ($H2 E"0$H2($H2($H2 F$.Y>:_[=SWXNQY:W?5ET+S7_ &[GOQ=CRUN^ MK*DXQME?#*'0\ V"CCG*[96[.]4LK=G>UC<+5OWN6+8,U#)1NECH9*- MT@YPY.,.0)C<$;@ $(E*)!PG=+'4R3NECJ!AKXL%QGKXL%P%6[Q4[O% M:_P"W<]^+L>6MWU9="\U_V[GO MQ=CRUN^K*D8QME?#*'0\ V"CCG*[96[.]4LK=G>UC<+5OWN6+8,U#)1 MNECH9*-T@YPY.,.0)C<$;@ $(E*)!PG=+'4R3Q8Z@8J^*O<6*^*O6"K M=XJEUXO/'.__NQ_Q?\ );#"MJHXY2U^ M*[)7PSAT"D%P4T !(@!*0!*4 @ 2 "0$"0 $ )$"4)3 )0F $H2/(E"0 M !"2 !() >GD 2A("0$"0 2A( \@) "$@ E,( 2( ! D $@ D! D! M "4P@!*0!( @ $"0 2 ) 'E(0 ) @ 'I E"0=R\U_V[GOQ=CRUN^;+H;F MO^W<]^+L>6MWS9A2,8VROAE#H> [!1QSE=LK=E4LKEIK&X6;:Q;5[:Q;W S4 M,E&Z6.ADIW YPY.,.0)C<$;@ $(E*)!PGBQRR3Q8Y!BKXJ]Q8J8+@*M MU4N\5R[NE4O3O!2O1O>>.=__ '8_XO\ DO0][B\\<[_^['CQ?\EL,*VJCCE+ M7XKLE?#.'0("X*: "$@)@2 D2 /( E"0$H2($PA( @!(@!) E( D0 D0 M "!( ) !) F$ "4 ) !(@@$@0"0 ! ($@ D$P@2 A( "4)$"4)@!*$B! M*$B !,"2 2A( ) $ @2A("4) 2 @2 @2 "4 )2 )!W+S7_;N>_%V/+6[ MYL.AN:_[=SWXNQY:W?-E2,8VROAE#H> ;!1QSE=LK=I4LKEEK&X6;:Q;5[:Q M;!EH9*=S'2RT[@*I=X@I7N+SQSO_P"[/CQ?\EZ'O<7GCG?_ -V?'B_Y3885M5'' M*6OQ79*^&<.@0%P4P2"8!()!(#R D $B $@ #R) @$@D$@($@(3 M)$ ) 2A*80 )0 D $@"$@ D 0 "!*$@)0D!,(2EY$@ "1 "0 2 "1Y M$@D$P@2 "0 'D!, D $B $B $@ )A D$@ D!#N7FO^W<]^+L>6MWS8=#< MU_V[GOQ=CRUN^;"D8QME?#*'1, V"CCG*[97+*G97++6-PM6EBA7M=2Q;!EI M9(W,=#) .4;W)$)!,;@ 1Q1*91P!QEPJ9)W,=8,-3!<9ZV"YQ!5N\5 M.[Q7+O%4O<04KSSSSP-VC'CQ?\EZ'N\7GCG@;M&/'B_Y+885M5''*6NQ79*^ M&<.@ 2N"FB4)2 )2@ $ )" $A (2 ($H2($H2F 2A(@2A(@2 )$ ) M!*0 2\@ "0 2 @2 "0 'D!( ) !*80 D0 "!( ) !("!(" !,(2F$"4) M2"4) $ A( ) $) $) !(! /2!) D! D!#N7FO>W<]^+L>6MWS9AT-S7O M;N>_%V/+6[YLJ1C&V5\,H=%P#8*..TL6P9J62&. MAD@'*$HC+_DO0UW'[AN8:C[G^Z-OIJIC7M= M'JU:HG_5EGX7.B]4\III! M\-E_:U>B>III!\-@.UJ]$ZRE'4U^32QNGJ::0?#8#M:O1/4TT@^&P':U>B?' M2=37Y-+2W/U-=(/AL!VM7HI]372#X; =K5Z)\=)U-?DTM+<_4UT@^&P':U>B MGU-=(/AL!VM7HGQTO/4U^32TMS]37/\ X; =K5Z)ZFV?_#8#M:O1/CI.IK\F MF#<_4VS_ .&P':U>B>IMG_PV [6KT3XZ3J:_)I@W/U-L_P#AL!VM7HGJ;9_\ M-@.UJ]$^.E'46GDTTAN?J;9_\-@.UJ]$]3?/_AL!VM7HIBNDZBT\FFCBGU-\_^&P':U>B=92=1:>331N7J;Y_\+@.UJ]$]3C/_ (7 =K5Z M)UE*.HM/)IPW+U.,^^%P':U>B>IQGWPN [6KT3K*3J+3R:<-Q]3C/OA<#VM7 MHGJ<9]\-@.UJ]$ZRDZBT\FG#B>ISGWPV![6KT3K*4=1:>33DMP]3G/OAL#VM7HI]3G/OAL M#VE7HG64G46GDTY+BGK*?,[/:>33AN/J=9]\-@>TJ]$]3K/?AL#VE7HG6 M4^9V>T\FGCIWGOPV![2 MKT3U.\]^&P/:5>B=93YG9[3R:@-P]3O/?AL#VE7HGJ>9[\-@>TJ]$ZRGS.SV MGDU ;?ZGF>_#8'M*O1/4\SWX; ]I5Z)UE/FCL]KY-0&W^IYGOPV![2KT3U/, M]^&P/:5>B=93YH[/:^341M_J>9Y\+@>TJ]$]3S//A<#VE7HG64^9V>U\FHC; MO4]SSX7 ]I5Z)ZGN>?"X'M*O1(M*?,[-:^34AMWJ>YY\+@>TJ]$]3W//A<#V ME7HIZVGS1V:UW6I#;?4^SSX7!=I5Z*?4^SSX7!=I5Z)UM/F=FM=UJ(V[U/L\ M^%P/:5>B>I]GGPV![2KT3K:?,[-:[K44MM]3[//AL#VE7HGJ?9W\+@>TJ]$Z MVGS1V:UW6I);;ZGV=_"X+M*O1/4_SOX7!=I5Z)UM/F=FM=UJ26V>I_G?PN"[ M2KT4^I_G?PN"[2KT3K:?-'9K7=:DEMGJ?YW\+@NTJ]$[@,[^%P7:5>B=;3YH M[+:[K4QMGX M#._A<%VE7HG64^9V6UW6IC;.X#._AL%VE7HGB=;1YH[+;;K5$MK[@B=P6=?"X+M*O1.MH\SLMMNM42VKN"SKX7!=I5Z*>X+.OA<%VE7HG6T> M9V6VW6J0EM7<%G/PV"[2KT3N#SGX7!=I5Z)UM'F\]EMMUJJ6U=P><_"X+M*O M1.X/.?A<%VE7HG6T>9V2VW6JI;3W!YS\+@NTJ]$[@\Y^%P7:5>B=;1YG9+;= M:L-I[@\Y^%P7:5>B=P><_"X+M*O13UM'FCLEMNM6&U=PF<_"X+M*O1.X3.?A M<'VE7HG6T>9V2VW6K#:NX3.?AL%VE7HG<)G'PV"[2KT4];1YG9+;=:L-JC03 M./AL%VE7HG<)G'P^"_YZO1.MH\T=DMMUJPVKN$SCX?!?\]7HG<)F_P#M&!_Y MZO1.MH\SLEMNM[YKWMW/?B['EK=]673G-^T?QN2XG.*\5+S%5[KF/VRA?L#HJHN-%-4=_?G*Y96[*G97++6MLM6EBVKVEB MV#-1N9*=S'0R4@Y1N3 F .""0'&ICJW,DL=0,-;!<9Z^+! M*I=XK=WBJ7>(*=W>:WR[NEH?*=_F'[SS6=ANTT\KAF MTL!:E; M ;ER9;\?^[\YOEAH? M)EOQ_P"[\YOEGGCG*W97+*I96[3!9BU:6+:O:6* 9J&2G MWV.ADIW YD(C>:WN]Q:'RF_YA^\\UG8;M-/'*6'?]GJX9M, M6I6P M &Y["JXEM-7#*%DP_9Z>.TL4 S4,D,=+) M2#E"81"8!( (1*42#C+'4R3Q8Z@8ZE>XSU,%?$%:[NE3N\5R[Q4[O$ M%*]Q:'RF[\!^\\UOM[BT+E-WX#]YYK.PW::>.4L._P"SU<,VF +4K8 M M #WNPJ MN);35PRA9,/V>GCG*[97+*G96[+!9BU:6*%>VL4 RTLE+'2R4@YPE$)!( M (1*42#A/%CJ9)XL=0,=2O6SU[I8+G$%:ZJ7N*W=XJET%.]Q:%RF[\!^\ M\UOE[BT3E-WX#]YYK.PW::>.4L._[/5PS:6 M2M@ M M -RY,_QL?^[\]O=B&B_'_ +OSV]V%5Q+::N&4+)A^ MST\X&:EDIW,=+)3N!SA+C&]R!,;@C< M A$I1(.$\6.KXM$Y3-^ _ M>>:WN]Q:)RF;\!^\\UG8;M-/'*6'?]GJX9M, 6I6P M M &X\FF_'_N_.;W9:)R:;\?^[\YO=A5<2VFKAE"R8?L] M/'.5VRMV5.RN66"S%JVL6]RO:6*-P,M+)3N8Z62G<#G&]R<8WN0)C<$;@ M $(E*)!PGBQU;F2>+'5N!BKXJ]:Q7Q5ZP5KNZ52]Q6[NZ52]Q!2O<6BXM$Y3-^!_>>:SL-VFGCE+#O^SU<,VF +4K8 M M #<>33?C_P!WYS>K#1>33?C_ -WYS>K"JXEM-7#* M%DP_9Z>.+'5N!BKXJ]:Q7Q5ZP5KNZ52]Q6[NY4O<04 MKW%HG*9OP'[SS6]WN+1.4S?@/WGFL[#=IIXY2P[_ +/5PS:8 M2M@ M M -QY--^/_=^K"JX MEM-7#*%DP_9Z>.*G=! M2O<6BAH?*;OP'[SS6=ANTT\KAFTP!:E; M M ;CR:;\?^[\YO=EHO)GOQ_[OSV]655Q+ M::N&4+)A^ST\ MY F-P1N 0B4HD'">+'4RSQ8Z@8:F"XL5,%8*MW=*I=7+D*EV-X*5[B MT/E._P P_>>:WZ]Q:%RG_P"8?O/-9V&[33QREAW_ &>KAFTH!:E; M M ;ER9?C8_\ =^_\ >^:SL-VFGCE+#O\ L]7#-HX"U*V M M W3DOCV>WVS#1.2R-U"U:A@LQGML]##;AGH!DI9*7"E MDI!RA*(2"0 1*."9 <)<*F2=SA4#%4PUPSU0Q50"M7&]6N0MUPP7(! M1NT[W7_*O&K[W?O?,=BW*77O*W&K[V_O?,9V&[33QREAW_9ZN&;0@%J5L M M !O')3&N>[ M0T+DEC7.9? MNO/=A6J55Q+::N&4+)A^ST\\R[C:4V5O377 M.B._*6-?+.JTL9II\?\ ;IT;[/)Q3RN/\ 2M/S?_V;_65V MWN4^S2=@O&[SAHHW>>3^Y'^E*>P_]G&= JX_TG3V'_L:RNV]RGV.P7C=YPTH M;G.@E??*.P_]G'N&K[Y1V/VFLKMO<-.&X=P]SOC'8_:=Q%SOC'8 M_::RNV]RGV.P7C=YPT\;?W$5]\8['[3N)K[XQV/VFLKMO<-0&W] MQ-??&.Q^T[B:^^,=C]IK*[;W*?8[!>-WG#4!M_<37WQCL?M.XFOOC'8_::RN MV]RGV.P7C=YPU ;?W$U]\8['[3N)K[XQV/VFLKMO<-0&W]Q-??& M.Q^T[B:^^,=C]IK*[;W*?8[!>-WG#4!M_<37WQCL?M.XFOOC'8_::RNV]RGV M.P7C=YPU ;?W$U]\8['[3N)K[XQV/VFLKMO<-0&W]Q-??&.Q^T[ MB:^^,=C]IK*[;W*?8[!>-WG#4!M_<37WQCL?M.XFOOC'8_::RNV]RGV.P7C= MYPU ;?W$U]\8['[3N)K[XQV/VFLKMO<-0&W]Q-??&.Q^T[B:^^, M=C]IK*[;W*?8[!>-WG#4!M_<37WQCL?M.XFOOC'8_::RNV]RGV.P7C=YPU ; M?W$U]\8['[3N)K[XQV/VFLKMO<-0&W]Q-??&.Q^T[B:^^,=C]IK M*[;W*?8[!>-WG#4!M_<37WQCL?M.XFOOC'8_::RNV]RGV.P7C=YPU ;?W$U] M\8['[3N)K[XQV/VFLKMO<-0&W]Q-??&.Q^T[B:^^,=C]IK*[;W* M?8[!>-WG#4!M_<37WQCL?M.XFOOC'8_::RNV]RGV.P7C=YPU ;?W$U]\8['[ M3N)K[XQV/VFLKMO<-0&W]Q-??&.Q^T[B:^^,=C]IK*[;W*?8[!> M-WG#4!M_<37WQCL?M.XFOOC'8_::RNV]RGV.P7C=YPU ;?W$U]\8['[3N)K[ MXQV/VFLKMO<-0&W]Q-??&.Q^T[B:^^,=C]IK*[;W*?8[!>-WG#4 M!M_<37WQCL?M.XFOOC'8_::RNV]RGV.P7C=YPU ;?W$U]\8['[3N)K[XQV/V MFLKMO<-0&W]Q-??&.Q^T[B:^^,=C]IK*[;W*?8[!>-WG#4!M_<3 M7WQCL?M.XFOOC'8_::RNV]RGV.P7C=YPU ;?W$U]\8['[3N)K[XQV/VFLKMO M<-0&W]Q-??&.Q^T[B:^^,=C]IK*[;W*?8[!>-WG#4!M_<37WQCL M?M.XFOOC'8_::RNV]RGV.P7C=YPU ;?W$U]\8['[3N)K[XQV/VFLKMO<-0&W]Q-??&.Q^T[B:^^,=C]IK*[;W*?8[!>-WG#4!M_<37WQCL?M.XF MOOC'8_::RNV]RGV.P7C=YPU ;?W$U]\8['[3N)K[XQV/VFLKMO< M-0&W]Q-??&.Q^T[B:^^,=C]IK*[;W*?8[!>-WG#4!M_<37WQCL?M.XFOOC'8 M_::RNV]RGV.P7C=YPU ;?W$U]\8['[3N)K[XQV/VFLKMO<-0&W] MQ-??&.Q^T[B:^^,=C]IK*[;W*?8[!>-WG#4!M_<37WQCL?M.XFOOC'8_::RN MV]RGV.P7C=YPU ;?W$U]\8['[3N)K[XQV/VFLKMO<-0&W]Q-??& M.Q^T[B:^^,=C]IK*[;W*?8[!>-WG#4!M_<37WQCL?M(T(K[XQV/VFLKMO<-0&W]Q%??&.Q^U,:#U]\8['[365VWN4^QV"\;O.&GC<8T&N=\8['_ M -G*-!*Y_P!)1V'_ +&LKMO<-,&Z1H%7/\ I..P_P#9SCD_N3_I M2GL/_8UE=M[E/L=@O&[SAI WF.3RN?\ 2M/8?^SG3RC-60?=>UC(Q/W1L;K>SL[.UUS[[9[= M+07ZTIM;>JNB=,=V3=W.SJL[&*:O'_;E;I9Z(<**6:B&(R7.B&6F'"F&2F < MJ7.-SC$.4 Y$"8W (2B01P1.YR<9!PF/8<)AEF'"8!AJABJI6)AC MJ@%:JEBJI6JJ6.JD%.JAAJH7:J&.J@%*JVQ3;7IH<)M@HS;<9M+LVW'HP4NB M<9M=2]T74CHP4NB.B7>B1T?4"ET1T7B7>CZCH^H%+HO$=%XEWH^HZ/J!2Z+Q M'1>)=Z/J.CZ@4NB\1T7B7>CZCH^H%+HO$=%XEWH^HZ/J!2Z+Q'1>)=Z/J.CZ M@4NB\1T7B7>CZCH^H%+HO$=%XEWH^HZ/J!2Z+Q'1>)=Z/J.CZ@4NB\1T7B7> MCZCH^H%+HO$=%XEWH^HZ/J!2Z+Q'1>)=Z/J.CZ@4NB\1T7B7>CZCH^H%+HO$ M=%XEWH^HZ/J!2Z+Q'1>)=Z/J.CZ@4NB\1T7B7>CZCH^H%+HO$=%XEWH^HZ/J M!2Z+Q'1>)=Z/J.CZ@4NB\1T7B7>CZCH^H%+HO$=%XEWH^HZ/J!2Z+Q'1>)=Z M/J.CZ@4NB\1T7B7>CZCH^H%+HO$=%XEWH^HZ/J!2Z+Q'1>)=Z/J.CZ@4NB\1 MT7B7>CZCH^H%+HO$=%XEWH^HZ/J!2Z+Q'1>)=Z/J.CZ@4NB\1T7B7>CZCH^H M%+HO$=%XEWH^HZ/J!2Z+Q'1>)=Z/J.CZ@4NB\1T7B7>CZCH^H%+HO$=%XEWH M^HZ/J!2Z+Q'1>)=Z/J.CZ@4NB\1T7B7>CZCH^H%+HO$=%XEWH^HZ/J!2Z+Q' M1>)=Z/J.CZ@4NB\1T7B7>CZCH^H%+HO$=%XEWH^HZ/J!2Z+Q'1>)=Z/J.CZ@ M4NB\1%I=Z/J.CZ@4^B.B7.CZD]$"E%I/1+G1IBWU J1;C.C6M@V 5>CZD]&L["=@%: M+:8MK&PF* 8(HKJ-74#ALFRYZNHU=0.&R;+GJZC5U X;)LN>KJ-74#ALFRYZNHU M=0.&R;+GJZC5U X;)LN>KJ-74#ALFRYZNHU=0.&R;+GJZC5U X;)LN>KJ-74 M#ALFRYZNHU=0.&R;+GJZC5U X;)LN>KJ-74#ALFRYZNHU=0.&R;+GJZC5U X M;)LN>KJ-74#ALFRYZNHU=0.&R;+GJZC5U X;)LN>KJ-74#ALFRYZNHU=0.&R M;+GJZC5U X;)LN>KJ-74#ALFRYZNHU=0.&R;+GJZC5U X;)LN>KJ-74#ALFR MYZNHU=0.&R;+GJZC5U X;)LN>KJ-74#ALFRYZNHU=0.&R;+GJZC5U X;)LN> MKJ-74#ALFRYZNHU=0.&R;+GJZC5U X;)LN>KJ-74#ALFRYZNHU=0.&R;+GJZ MC5U X;)LN>KJ-74#ALFRYZNHU=0.&R;+GJZC5U X;)LN>KJ-74#ALFRYZNHU M=0.&R;+GJZC5U X:C4YZNHU=0..J#5#EJ-0..KJ3J GRAPHIC 3 visual0002.jpg begin 644 visual0002.jpg M_]C_X 02D9)1@ ! 0 0 ! #_VP!# 4#! 0$ P4$! 0%!04&!PP(!P<' M!P\+"PD,$0\2$A$/$1$3%AP7$Q0:%1$1&"$8&AT='Q\?$Q)!P>'Q[_ MVP!# 04%!0<&!PX(" X>%!$4'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX> M'AX>'AX>'AX>'AX>'AX>'AX>'AX>'A[_P 1" ;H!?\# 2( A$! Q$!_\0 M'0 ! (" P$! <(!08#! D" ?_$ %H0 0 ! P, !04)" \% M!P0" P ! @,$!081!P@2(3$305%A<10B-W6!D:&QLQ4R0E)SLL'1%A@C,S96 M8G)T@I*3E*+"%R0U4U0E-$-58\/29-/A\$2#A+3Q_\0 &P$! (# 0$ M 4& P0' @'_Q !"$0$ 0(# @H(! 4$ P$ P 0(#! 41!B$2 M,4%1<8&1H;'1$S(S-&%RP>$B0E+P%!8U0U,5(V+Q@J+")6.2XO_: P# 0 " M$0,1 #\ N6 M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M #B MOY&/8IFJ_?M6HB.9FNN*?K--1RC$9.Z-LXO/NG<6D6.)XGRF;;I[_1WRQV7T MA['Q8YN[ITOPF?>7XK\/YO+-1A[U?JT3/5+'5>MT\=41UMH&A7^F/HWLU=FK M<]B9XYXIL7:OIBGACLSIWZ.[':[&HY.1QQ^]8U7?[.>&Q3E>-KXK579+#5CL M-3QW([82<(>O=8K8M%55-O%UJYQX3&/1$3_GY^ACLOK)[/P:JLZ._VQV/TL?E M=9?4)[7N7;.+1^+Y2_55Q[>.&Q3LSF=7]OOCS8ISK!1^?NGR64%6KW63W9-4 M^2T71:*)CNYHNS,?+V_T.ED=8G?%R>;>/I=F...*;,S\O?,L].R>8SQTQ'6Q M3GV#CEGL6R%.[_3QTCW(B*-6Q[7'GIP[4\_/3+J7^FOI(O454U;@FGM>,T8] MNF?DXI[F:G8['3QU4QUSY,4[0X6.*)[(\USQ2&_TK=(-ZJ*JMTZA3Q''O+G9 MCZ'1KZ0M\UQ,5;NURJ*O&)S;G'S*Y;E/?Y,<[1V.2B>[S7L%".Z M[]457]QZKJGM<^//>S1L5=Y;L=G MW>)VDHY+<]KT#KKHHCFNNFF/#F9X=>]J.GV:HIO9V+;F8YB*[M,?7+S[C(R( M\+]R/ZTOR;]^?&]9KJF?:_.9],LD;$V M^6]/9]WB=I:_\??]E\9WSLV)X_93HW^,H_6ZD])6Q(GC]E.F_P!ZHP,D;%8? MENSV0\3M)=_1'>N]5TL='E-4TSNG#YB>)XIKG_2ZUWIDZ-;5R:*MT6>8_%QK MU4?/%'"E0]QL7A.6Y5W>3S.T=_\ 3'?YKHU]-71K3'=N2BKV8MZ/KI?/^VSH MV_C!'^&N_P#Q4P'N-C,%RUU=L>3S_,6)_33W^:XL]._1WS_Q'*G_ /QJGS7T M\]'=-%549^75,1SQ&-/,J>#W_)V!_55VQY/G\PXKFCLGS6Z_;!='_P"-JG^& MC_Y'[8+H_P#QM4_PT?\ R5%'K^3\!SU=L>3Y_,.*YH[/NMM?ZP^PK<1V;6LW M>?Q,:CN^>N'%^V,V)_T6O?X>U_\ <5.'V-D,O_Y=OV?/Y@Q?P[/NMC^V,V)_ MT6O?X>U_]P_;&;$_Z+7O\/:_^XJ<'\H9?_R[?L^?S!B_AV?=;']L9L3_ *+7 MO\/:_P#N'[8S8G_1:]_A[7_W%3@_E#+_ /EV_8_F#%_#L^ZV/[8S8G_1:]_A M[7_W'8HZPFP*J(JG[JTS,<\3C4\Q_F5&'R=D,O\ ^7;]GV-H,7\.S[K=?M@N MC_\ &U3_ T?_)]6^L#T?U5Q3-S4Z(F>.U5C1Q'^94,?/Y/P'/5VQY/O\PXK MFCL^ZXG^W?H[_P#,9V M,P7)75VQY/4;18G],=_FNQ8Z8>C>_P!KL;HQ_>^/:L7:?KIAV+/2KT>WJ^Q1 MNG"Y_E153'SS"CX\3L7A>2Y5W>3U&T=_EICO\UZ;72/L6[6B%][6\=I7:XHM;HT M.Y5/A33J%J9_.=JSN#0;U4TV=;TVY,1S,495$_5+S_B9CPF7[%RN/"NJ/9+' M.Q-')>GL^[W&TM7+;[_L]";.?@WHF;.9CW(CQFB[3/'S2YZ*J:Z>U35%43YX MGEYXTY%^G[V]]VK' M3STCVZ9BO5<>[,SXU8=J./FIAAJV.Q\<55,]<^3)&T.%GCB>R/-<05.Q^L3O MBW5,W,?2[T3'=%5F8X^:8=RSUD]V4U1Y71=%KHB._BB[$S\O;_0PU;)YC'%3 M$];)&?8.>6>Q:45KQ.LOJ$=GW5MG%K_&\E?JIY]G/+(6NLUC\TQ=VC=XY]]5 M3GQ]$=C]+!5LSF=/]OOCS9:Z=!U&SW]_8N4U\1 MZ?,R-GK%[%KJBFYB:U;YGQ]ST3$?Y^?H:]60YC3QV9\?!EIS3!U<5R$Q",,/ MIWZ.[_9[>H96/SS^^XT]WMXY9&QTR=&UZJ*:=S6::ICGBK'NQ]/9X8*LKQM' M'9J[)9:<=AJN*Y';#?AJV)TB[&RJ>;.Z=+XXB??WXH[I_G<,CC;JVQDSQC[C MT>]//'%O.MU=_H[JFM5AKU'K43'5+-3>MU<543ULP.+'R<;(I[6/D6KT>FBN M*OJ%<\GE8FFY%^S7V8GLUT6ZJJ9XGNGOB/%[MT38M?F\,!J6Z]S:CS[OU[4LGGQ\IDU5>GU^N M5OM[%XF?7N4QT:SY*_7M'9CU:)GL^Z^.9J&!AT]K,S<;&B//=NTT?7+#9>^M MFXL53>W1H\=F>)BG+HKF)]'$3*B5>1?KCBJ]J::MRV:ZH\U%B[5]/9X8/,ZP6P,>8BB=4R>_Q MM8T?ZJH5%&Y1L=@J?6JJGKCR:U6T6)GBB([?-:'.ZR>W+?\ W/0M1R/RE=-O M];#9769JFF/?RF9VX^BF%=QMT;+9;3QT3/3,^;!5GF,G\VG5";\KK M);JJJXQ]%T>W3Q^%3>?WO%IJX_M<^"*!M49 M#EU'%9CKW^+!5FF+JX[DI"R^FGI'R8XKW#71^2L6Z/S8AALCI&WW?GFYNW6> M...(RZXCYHGAJPVZ,NPE'JVJ8ZH\F"K&8BKCKGMEEOYLS.7K.??F>9GM MWZI\?'SL?.3D3'$W[O'H[8JF/9+\ 'AYV,'B MJW15ZT1+U%=5/%+:&8Q.F?I&QHXHW%G_I!L1'E\K"R_RF+13S_9 MX9C'ZR6ZZ9B+^BZ-0Y=7QV8\/!FIS3%T\5R5B,7K, MU13/NK:<7*O-Y/,[$?33+-8762VW<_[YH>I6/YE=-S]2KHU*]ELMJXJ)CHF6 MQ3GF,I_-KU0MY@=8'H_R9XN7-3Q/7>QH_P!-4LYA],/1SE5Q1;W-8IJGNXN6 M;E'G],T\?2I.-.O8W!3ZM54=<>38IVBQ,<<1/;YKZ8F]=H944^0W/H]4U?>T MSF415/R3/+-8V5C9-';QLBS>I]-NN*H^AYXQ,QX3,.:WEY5NJ*K>1>IFF>8F M*YCB6G[8^[8HVDJ_-;[_L]#10W3]\;PT^FFC"W+JUBFGCBFC*KB.[ MU<^J$M=7WI)WEKG2'@Z%JVLW,S!NVKM5=-RBF:IFFW,Q[[CGQB/.BL9LGB,- M:JNQ7$Q3$SRQ.YO8;/K-ZNFWP9B9G3D68 55.@ M M #7>E#X,]T_$V7]C6V)KO2A\&>Z?B;+^QK;&$]O1TQXL5_V571*A MP#N#F0 M DWJO\ PQZ9^1R/LJD9)-ZK M_P ,>F?D^6?"6YE_O5OYH\5Q@'&'1@ M M !KO2A\&>Z?B;+^QK;$UWI0^#/=/Q-E_8UMC">WHZ8\6*_P"R MJZ)4. =PK?S1XKC .,.C M M #7>E#X,]T_$V7]C6V)KO2A\&>Z?B;+^QK;&$]O1TQXL5_V M571*AP#N#F0 M DWJO_ QZ9^1R/LJD M9)-ZK_PQZ9^1R/LJD=F_N%[Y9\);F7^]6_FCQ7& <8=& M M &N]*'P9[I^)LO[&ML37>E#X,]T_$V7]C6V,)[>CICQ8K M_LJNB5#@'<',@ 'U%%*XP#C#HP M U MWI0^#/=/Q-E_8UMB:[TH?!GNGXFR_L:VQA/;T=,>+%?]E5T2H< [@YD + MCXG05T=8\Q,Z5?NS'_,R:YB>_P!'*G#T34O:_%W\/%F+- MP]J]Z3TE,3IIQQKSM,Q.BOH_QZ8IIVMIU?$<CX%-,>$18I_4[' MW+TS_P NP_[BG]3MC#5_-C[>WGIM6)K.%17SBGN0V+V>MU1K8G2>:>+S\5$!NG2OT=ZOL+5XL9?^\:??F? MBY;\E7V9YFKCO1BGCJ:_P )M?\ Z';_ #T?GEZY8P%RY;G2 M8TW]<-O++=-S%445QK$^4M[_ &O&Q_\ FZC_ 'Q^UXV/_P W4?[Y, YE_KF8 M?YJNU=?],PG^.$/_ +7C8_\ S=1_OG%F]7S9%G#OW:;NH]JBW55'[MZ(E,KK MZI_PS*_(U_5+[3G>835'^]5VODY9A-/9P\] '8G/ &_=!&T=+WIO:O1]6JO M1CTX=R]'DJNS/:IJIB/SI3K^UXV/_P W4?[Y%?5)^%2[\6WOSK:VCGFTV9XO M#8W@6KDTQI'%UK=DN"L7L-PKE$3.LH?_ &O&Q_\ FZC_ 'Q^UXV/_P W4?[Y M, K_ /KF8?YJNU+?Z9A/\<(?_:\;'_YNH_WRJ^M8UO#UG-Q+7/D[&1KFK2(TUZU?S["V;%-'HZ8C75 MC@%U5M.'0#T5[ M-C_\W4?[X_:\;'_YNH_WR8!&_P"N9A_FJ[6[_IF$_P <*_=)70CM';VP]7UK M!N9TY.'CS#IR^"/X>U8O4Q;ITC3ZR +0@UG=E]!.SM7V=HNK95S/B_FZ?8R+O9N\1VJ[=-4\> MKF66_:\;'_YNH_WS?NB_X,]K_$V)]C2V)R+$9UCZ;U<1=G2)GE^*_P!G+<+- MNF9MQQ0A_P#:\;'_ .;J/]\?M>-C_P#-U'^^3 ,/^N9A_FJ[67_3,)_CA4OK M#=&^@[$PM'O:-7DU59ER[3<\K7VNZF*>./GE$"R77-_X9MK\MD?50K:Z3L[? MN8C+Z+EVK69UWSTRIN;6J+6+JHHC2-W@ )I&@ )EZOG1GM_?6C:IEZQ7E4W, M7(HMV_)7.S'$T\]Z3OVO&Q_^;J/]\P_4U_@SK_\ 3+?YB>',<\S;&VM=J[S':IIF8Y5H7HZ8?@K MW-\6WOS9477G93&7\58N57JIJF)Y>A6,]P]JQ=IBW3IN^H M2"68Z'.B#9.O M='FD:YJN%D7\S*MU5W)]T54T\Q+(X^V]OX],TV=%P*(GOGBQ3^IE1%U8F]5QU MS/7+>BS;CBICL=*G2=+IIBFG3<.(CPCR%/ZG[]RM,_\ +L/^XI_4[@Q3,SOE M[B(ATJ]'TFN.*],PJH]=BG]3$9VPMF9O_>MLZ9=GCCF;$?\ [YVR#)1?NV_4 MJF.B7FJU15ZT1*,=:Z"NC_4:;E5K3[V#=J\*\>],13[*?!&^[.K=J%BFN]MO M6;>5$?>V,JGL53_6CN^A982F&V@S##S^&Y,QS3O\6C>RG"78WT1'1N4$W3M? M7MLYGN37-,R,*OGWLUT^\K]E4=TL.]!->T;2]=TZYI^KX-C,QKD<31=IY^6/ M1*K/3=T.9.T8N:WH/E?TKMD^T]K&U1:O1P:YXN M:?+H[U:S#)+F&B;EN>%3WPB$!:4& G;H Z'*-:LV-T;JL3.G5<5XF'5S'EX\ MU=7\CT1Y_9XZ6/Q]G 69NWIW=\SS0V<+A;F*N>CMQ]D<["Z-MU[RKBO2M/JH MQ.??9=_WEJ/9/X7AYDW;5ZN&AXU%%W<.JY.?=_"M6/W*W\_WWTIQQK%G&QZ, M?'M46K5N.S1113Q%,>B(+L M:9I'17L'3+5-%C;6#4K^>6Q8V@Z+C411CZ3@VZ8CCBFQ3Z>?0R(@ M+F*OW?:5S/3,RE:+%JWZM,1U.G]RM,_\NP_[BG]3YN:-I%R.+FEX54>NQ3^I MWABBJ8G6)9)IB>-K6=L#9>;'^\[9TRYW<"2AM6LQQ=KU+M4=$L5^M1$]4*=]/?1MI_1]DZ3]SZ.(]%<(P6>ZY&'V]IZ'G\?O.=59Y_GVYG_ -M6%U+9_%W, M5@*+ER=:M\3/7/T4?-K%-C%5441I&[P $TC0 !)O5?\ ACTS\CD?95(R2;U7 M_ACTS\CD?95([-_<+WRSX2W,O]ZM_-'BN, XPZ, M M -=Z4/@SW3\39?V-;8FN]*'P9[I^)LO[&ML83V]'3'BQ7_ &57 M1*AP#N#F0 ]$WG8]$U#VW_L?^7_RM.S/]WJ^H H:TC#;NW/HFU--MZCKV M;&)C7+T6:*YHFKFN8JJB.Z)\U,_,S*&.N#\&>G?'-K[&^WLLPU.*Q5%FN=U4 MZ;FKC+U5BQ5(IN5 M^2JF>>.Z*^)E11^Q,Q,3$S$QYX7FYL7A9C\%RJ)^.D_2%9HVCOQ/XJ8GM^[T M2%->BKI>W!L[*MXV5>N:EH\SQ7C7:^9HCGQMS/A/CW>$K?:)J>%K.DXNJZ;? MIOXF5;BY:N4^>)^J?-,>:5/S;)K^6UQ%>^F>*8_>Z5@P&8VL;3/!W3''#N ( MA(,)OC;.F[MVUE:'J=OFU?I]Y7$>^M5_@UT^N)_4HSNC1 MRB%PV0S&JUB)PM4_AJXNF/./HK^?X2*[/IXXZ?! B>.IK_";7_Z';_/0.GCJ M:_PFU_\ H=O\];MHOZ9=Z(\85_*/?+?[Y)6; J/6A\GBEYZ .[.7 )?ZI/PJ7?BV]^=;6T5+ZI/PJ7?BV]^=;6 MT_/EZ!//W='\)M4_IE[\^5XV M)]I>Z(^JL[2^I;Z_HQP#H"IK6=3WX,]1^.;OV-E,Z&.I[\&>H_'-W[&RF=Q[ M/OZC>Z70\K]SM] B&^TSIR^"/U_B;$^QI;$X=BO;U] M,^+IMCV5/1 P,JOW7-_X9MK\MD?50K:LEUS?^&;:_+9'U4*VNL;+?TRWU^, MJ'G?OM?5X0 + B0 %F^IK_!G7_Z9;_,3P@?J:_P9U_\ IEO\Q/#D.T7]2N], M>$.@91[G;_?+( A4DU3IA^"O_-E1=>CIA^"O_-E1=T78KW:Y\W MT5#:/VU'1]0!_(W/M:V^-#ZOGP.;>_(W/M:V^.*9E[Y=^:KQ METG!>[V_ECP &DV77U/-QM-TW*U',N>2QL6S7>O5\<]FBF)JJGN]$1+1?]M/ M1O\ QBH_N+G_ ,6P=*'P9[I^)LO[&M0Y:MGLCL9E;KKNU3&DZ;M/*4'FV9W< M'7331$3K'+_VO!I72KT?ZG?BSB[GPXN3YKL56H^>J(CZ6WXU^QDV*,C&O6[U MFN.:+ENJ*J:H],3'=+SP;3L/?VY=FY].1I&?<\CVHF[BW:IJLW8CS33[//'? M"3Q>Q=/!F31L;1SKI>HW?#R7J&K=&&]=.WUMBWJ^#^Y7:9\GE8\ MSS59N>>/7$^,3YX^5M*C7K-=FY-NY&DQQK/;N4W*8KHG6)''E8]G*QKN-DVJ M+UF[1-%RW7'--5,QQ,3#D&.)TXGM2?IOV-5L?>=W$L4USI>7$W\&N>_BCGOH MY\\TSW>SB?.T1;OK3[>MZOT9W-4IHYR=(O4WZ)B._P G5,45Q[.^*OZJHCKN MS^83CL%377/XHW3U$0@+J:Z711I.OZU53$ MUW;]O%HJX[XBBGM51\O;I^9/ZD;5XRJ_CIM:_AHW=?'/EU++D.'BUAHKY:OW M K*:''DY%C%L57\F];L6J(YJKN5133'MF6+WKKMG;6T]3UZ_1Y2G"QZKD4< M\=NKPII^69B/E4DWCO/<6Z]2KS=9U*]>F9GL6HJ[-NW'XM-,=T0GM M45<&F.7CW_"$7F.:48+2--:I75JWKM"FJ:9W/H_,>C,MS^DHWIM"J9XW/HT< M>G-MQ];-%,<1;O5^5HC^K5S#3O[%78C_: MNQ/3&GFV+6TE$^THF.B=?)8SK58GNGHCOWN.?SF9H_UJA)=W%TWZCN M;86I;9U_2<>YF?D< MC[*I'9O[A>^6?"6YE_O5OYH\5Q@'&'1@ M M !KO2A\&>Z?B;+^QK;$UWI0^#/=/Q-E_8UMC">WHZ8\6*_[*KHE0X!W!S( M >B;SL>B:A[;_ -C_ ,O_ )6G9G^[U?4 4-:1#'7!^#/3OCFU]C?3.ACK M@_!GIWQS:^QOI;(?ZC:Z6AFGN=SH53 =B<\%F.IYN&[DZ+J^V[]R:HP[E.3C MQ,^%%?,51'JBJ(G^M*LZ:NIY',S;_P!:5T== M93X%-?\ _P#&_P#]FTD:?!3%/'4U_A-K_P#0 M[?YZ!T\=37^$VO\ ]#M_GNF[1?TR[T1XPI>4>^6_WR2LV Y"Z .OJG_#,K\C M7]4NPZ^J?\,ROR-?U2]4>M#Y/%+ST =V?NZ/X3:I M_3+WY\KQL3[2]T1]59VE]2WU_1C@'0%36LZGOP9ZC\Y/Z'/UPH^O!TY?!'N3^AS]<*/ MNC[%^Z7/F^D*?M'[>GH^L@"XJZOCT7_!GM?XFQ/L:6Q-=Z+_ (,]K_$V)]C2 MV)P[%>WKZ9\73;'LJ>B !@95?NN;_P ,VU^6R/JH5M62ZYO_ S;7Y;(^JA6 MUUC9;^F6^OQE0\[]]KZO" !8$2 LWU-?X,Z_P#TRW^8GA _4U_@SK_],M_F M)X[7/F^BH;1^VHZ/J +FKBZ_5\^!S;WY&Y]K6WQH?5\^!S;WY&Y]K6W MQQ3,O?+OS5>,NDX+W>W\L> TFRUWI0^#/=/Q-E_8UJ'+X]*'P9[I^)LO[&M M0YT38KV%WICP5':3VM'0 +HK:6.JQN"[I/2;;TN;G&+JUFJS73,]W;IB:Z*O M;W33_66[48Z&ZJJ>E7;,TS,3]TK,=WHFJ(E>=S7;&S31C*:X_-3OZIE<]G;D MU8>JF>20!44^Q&]L&G4]FZUIU4<^Z<"_:CVU451"@;T1NTT56JZ;D1-$TS%7 M/AQYWGIYN#WZ^2J;2TQPK=73]%J^I[5'^S74J>8[4:Q (5),%T@Z#^R?96K:#%<6Z\S'JHMU3X4UQWT3/J[40HKK6EZAHVI MW]-U3$NXF78JFFY:N1Q,3^F/7'=+T':QOO8>VMYXGDM:P**[U,<6\FCWMVW[ M*H\WAW+)L_GT9;,V[D:T5;]W'$H;-WPJGYD1[@VYKN@7ZK.LZ5EX545=GF[;F*9GT15X3\DNC M8/,\)C(_V:XGXJ_P##'IGY'(^R MJ1DDWJO_ QZ9^1R/LJD=F_N%[Y9\);F7^]6_FCQ7& <8=& M M &N]*'P9[I^)LO[&ML37>E#X,]T_$V7]C6V,)[>CIC MQ8K_ +*KHE0X!W!S( >B;SL>B:A[;_P!C_P O_E:=F?[O5]0!0UI$,=<' MX,].^.;7V-],Z&.N#\&>G?'-K[&^ELA_J-KI:&:>YW.A5,!V)SP3]U-=-N5Z MSK^L3'%NUCV\:)X\9KJ[4\>SL1\\(&P\;(S,NUBXEFN_?NU11;MT1S55,^$1 M"[/0ILW]A.P\73+_ &9SKU4Y&953X>5JB/>_U8B*?DY\ZL;5XVBQ@9M:_BKW M=7',_3K3>18:J[B8KY*6Z@.7+N(LZT^;3B]$.78JJXG,R[%FGO\ &8J\I_[< MI35PZXVOT7,K1=LVJ^9M4U9F13Z)GWMOY>(K^>$SL_AYOYC:B.2=>S>CLVNQ M:PE<\\:=NY7M/'4U_A-K_P#0[?YZ!T\=37^$VO\ ]#M_GNB[1?TR[T1XPJ&4 M>^6_WR2LV Y"Z /RNFFNB:*HB::HXF)\\/T!K/\ L^V3_%?2_P##P?[/MD_Q M7TO_ \-F&Q_%W_USVRQ?P]K],=C6?\ 9]LG^*^E_P"'@_V?;)_BOI?^'ALP M?Q=_]<]LG\/:_3'8PVC;4VYHV9.9I6BX6%D31-$W+-J*:NS/C'/R0S(,5=RJ MN=:IUE[IIIIC2F- !X>AY^[H_A-JG],O?GR] GG[NC^$VJ?TR]^?*\;$^TO= M$?56=I?4M]?T8X!T!4UK.I[\&>H_'-W[&RF=#'4]^#/4?CF[]C93.X]GW]1O M=+H>5^YV^@ 1#?:9TY?!'N3^AS]<*/KP=.7P1[D_H<_7"C[H^Q?NESYOI"G[ M1^WIZ/K( N*NKX]%_P &>U_B;$^QI;$UWHO^#/:_Q-B?8TMB<.Q7MZ^F?%TV MQ[*GH@ 8&57[KF_\,VU^6R/JH5M62ZYO_#-M?ELCZJ%;76-EOZ9;Z_&5#SOW MVOJ\( %@1( "S?4U_@SK_P#3+?YB>$#]37^#.O\ ],M_F)X[7/F^BH; M1^VHZ/J +FKBZ_5\^!S;WY&Y]K6WQH?5\^!S;WY&Y]K6WQQ3,O?+OS5>,NDX M+W>W\L> TFRUWI0^#/=/Q-E_8UJ'+X]*'P9[I^)LO[&M0YT38KV%WICP5': M3VM'0 +HK;?NKUIE>I]+VAT13,T8]VK)KGC[V+=,U1/]KLQ\JZJ#^JKL2_HN MD9&[-3LS;R]1MQ;Q:*HXJHL&JLX76KCJG7R %<3#%[NS:-.VIJ^H7)B*<;"O79F?Y-%4_H4 7#ZSF MOTZ-T69>)17VNGZ]:[55NS7V71]1PM M6TO&U/3LBC(Q,FW%RUKYN6J M>^JQ,^-='Z8\[/M+DE6.HB]9C\=/)SQYPQ9-F<86J;=SU9[I7$&-VWKVD;BT MNC4M%SK.9C5_A43WTSZ)CQB?5+).9UT545335&DPNE-451K$ZP /+Z.#/PL/ M/QZL?-QK.3:JB8FB[1%4=_MQ 72+T3[KV9V\C)QO=VG4S/&9C1,TQ'?WU1XT^'/H]:ZS\KHH MKHFBNFFJFJ.)B8YB5@R_:;&X28BJ>'3S3])X_%$8O)<-?B9IC@SSQY/.T62Z MQ[^X]G8TV\BF)KR<"B/>W([^:K<>:K^3Y_-W^-;9[IXET?+< 2#4 $F]5_P"&/3/R.1]E4C))O5?^&/3/R.1] ME4CLW]PO?+/A+*XP#C#HP M M UWI0^#/=/Q-E_8UMB:[TH?!GNGXFR_L:VQA/;T=,>+%?\ 95=$J' .X.9 M #T3>=CT34/;?^Q_Y?_*T[,_W>KZ@"AK2(KZSNW]9W'L'!P=#T^[G9-&J6 M[M5NWQS%$6KL3/?ZZH^=*@V<'BJL)?IO4QK-,ZL.(L1?M56ZN*5(*.BGI"KJ MBF-K9W,^GL_K;%M[H$WUJ5=$YEG&TNS,Q%55^YS73'I[,>/SK>BR7-LL;5&E M--,=4^:&HV=PU,ZU3,]GDCKHLZ(]O[(JISN_4-6XXG*NT]U'=WQ1'F\_?XI% M!6<3BKV*N3?)T1W44_)3$0D'K ]*D[QS?N)HERNG0L:OF:_"O1I75R<\O4I6=9C&)KBW;G\,=\B>.IK_"; M7_Z';_/0.GCJ:_PFU_\ H=O\](;1?TR[T1XPU,H]\M_ODE9L!R%T !P:C551 MI^3715--5-JJ8F/&)XE]B-9T?)G2'.*+?[1]^?QNUO\ QMS]9_M'WY_&[6_\ M;<_6N'\EXK_)3W^2O_S'8_1/=YKTBBW^T??G\;M;_P ;<_6?[1]^?QNUO_&W M/UG\EXK_ "4]_D?S'8_1/=YKTBLW5EW=N?7.D>YA:QK^I9^-&GW:XM9&1573 MVHJHXGB9\>^5F5>S/+J\OO\ H:YB9TUW);!8RG%VO24QI'Q $>VQY^[H_A-J MG],O?GR] GG[NC^$VJ?TR]^?*\;$^TO=$?56=I?4M]?T8X!T!4UK.I[\&>H_ M'-W[&RF=#'4]^#/4?CF[]C93.X]GW]1O=+H>5^YV^@ 1#?:9TY?!'N3^AS]< M*/KP=.7P1[D_H<_7"C[H^Q?NESYOI"G[1^WIZ/K( N*NKX]%_P &>U_B;$^Q MI;$UWHO^#/:_Q-B?8TMB<.Q7MZ^F?%TVQ[*GH@ 8&57[KF_\,VU^6R/JH5M6 M2ZYO_#-M?ELCZJ%;76-EOZ9;Z_&5#SOWVOJ\( %@1( "S?4U_@SK_P#3+?YB M>$#]37^#.O\ ],M_F)X[7/F^BH;1^VHZ/J +FKBZ_5\^!S;WY&Y]K6W MQH?5\^!S;WY&Y]K6WQQ3,O?+OS5>,NDX+W>W\L> TFRP?2#B9&=L'<.#B6J MKV3D:7DVK-NGQKKJM513$>V9A3O_ &5](7\5<_\ R_K7@$YE.>WLLHJHMTQ. MLZ[]49C\KMXVJ*JYF-.9331^A'I#U"]V*](IPJ?Q\F[%,?1RF'HUZ ='T/*M M:EN3(IU?+M^^HL13Q9HJ],Q^%,>ON34,N,VHQ^)IFC6*8G].[OF9ECP^286Q M5PM)JGXORFFFFF*:8BFF(XB(CNB'Z"O);F M6JNZW3/C11,>,SX3/FB?FWLOR^]C[T6K4=,\D1SRUL7B[>%MS8B_5?N57*N.0!LL++[6W+KFV=0C.T/4;^'>CQ[%7O:XYYXJCPF.Z.Z4[;& MZQUN:;>-N[3)IF(XG+Q//W>,T3Z9]$Q[%WS;N%S"_ MA?9U;N;D7TVOO/:^YJ*9T76L3*KJCGR45]FYZ_>SQ/J)5#&;&7*=:L-7K\ M)W3V\7@L&&VBHG=>IT^,>7_:Y8C3HQZ9=M[QO6]/O#/7Q=Z,S?#1?PM7/3OCJ^RGH#KB@ "3>J_\,>F?DJ_\,>F?D^6?"6YE_O5OYH\5Q@'&'1@ M M !KO2A\&>Z?B;+^QK;$UWI0^#/=/Q-E_8UMC">WHZ8\6*_[ M*KHE0X!W!S( >B;SL>B:A[;_V/_+_ .5IV9_N]7U %#6D!#W3MTKZUL'< M6#INFZ?I^3:R,3R]56137-43VZJ>([-4=WO6U@\%>QEV+5F-:NQ@Q&(MX>CT MER=(3"*M_MD]U_\ DFB?V+O_ ,WS7UDMV51Q&CZ/3/IBFY^FJ4S&RF93^2.V M$=.>X/\ 5/9*TSYN5T6[=5RY73113'-554\1$>F95 U'IZZ0LJ*J;6=C8M%4 M<<6L:CF/9,QS'_Y:3KN[]SZY,?=;7<_+B/"FY>F8CV0W+&QN+JG_ ':XICKF M?IXM>[M%8IC\%,SW+9;XZ9=E[9HKMTYT:KF1'=8PYBJ.>.[FO[V(]G*MG2=T MI;CWS=FSE78P],IJYMX5F>*/1S5/C5/M],\-$%LRS9["8">'$<*KGGZ1R>/Q M0.,S?$8J.#,Z4\T?4 3J+$\=37^$VO\ ]#M_GH'3QU-?X3:__0[?YZ%VB_IE MWHCQA)91[Y;_ 'R2LV Y"Z .OJG_ S*_(U_5+L.OJG_ S*_(U_5+U1ZT/D M\4O/0!W9RX !+_5)^%2[\6WOSK:VBI?5)^%2[\6WOSK:VCEVUW]0_P#&/JN^ MS_NG7( K";'G[NC^$VJ?TR]^?+T">?NZ/X3:I_3+WY\KQL3[2]T1]59VE]2W MU_1C@'0%36LZGOP9ZC\Y/Z'/UPH^O!TY?!'N3^AS]<*/NC[%^Z7/F^D*?M'[>GH^L@" MXJZOCT7_ 9[7^)L3[&EL37>B_X,]K_$V)]C2V)P[%>WKZ9\73;'LJ>B !@9 M5?NN;_PS;7Y;(^JA6U9?KBXV3DZ;MN,?'O7IIO9'/DZ)JX[J/0KG]R]3_P#+ MLO\ N:OU.K[+U1&66^OQE1,[B?XVOJ\(=0=O[EZG_P"79?\ =$\&74'9NZ?GVK$#]37^#.O_P!,M_F)X[7/F^BH;1^VHZ/J +FKBZ_5\^ M!S;WY&Y]K6WQH?5\^!S;WY&Y]K6WQQ3,O?+OS5>,NDX+W>W\L> TFR#1^FW M>>?L;9M&M:=C8V3>JRZ+$T9$533Q5%4S/O9B>?>PA/\ ;)[K_P#)-$_L7?\ MYI?!9'C,;:]+9IUCBXXA'XG,\/AJ^!B5I!5JKK)[KFF8^XNC1/IBFY_\ MV,U+K![]R9_W6O PN_G]SQXJ^3WW+>HV3S&KCB(Z_+5K59]@XXIF>I;AJ>[N MD;9VU[5: M7^E'ITUO:)1+N?H2WYHLUUV].IU*Q M3S,7,2OM3Q'GF)[X^E"X3:# 8G=%?!GFJW?;LE(W\IQ5G?-.L<\;_NC8=O4- M-U'3Z^QGX.3BU>B]:JH^N'43,3%4:PCIB8G20!]?'[155173715--5,\Q,3Q M,3Z5V>@?V:>.?7RIAI&FY^KZA:T_ M3,2]EY5ZJ*:+5JGF9F?JCU^"[G1'M:O9VP--T._537E6Z9N9-5,\QY2N9JJB M/3$<\<^I3=LZ[/\ #44SZ^N[GTTG7JXEBVFJJCU=-_3R-L :52 '9W. !)O5?\ ACTS\CD?95(R2;U7 M_ACTS\CD?95([-_<+WRSX2W,O]ZM_-'BN, XPZ, M M -=Z4/@SW3\39?V-;8FN]*'P9[I^)LO[&ML83V]'3'BQ7_ &57 M1*AP#N#F0 ]$WG8]$U#VW_L?^7_RM.S/]WJ^H H:TBKG7%_ASI'Q;'VM: MT:KG7%_ASI'Q;'VM:R;*?U*GHGP0^>^YSTP@\!U110 !/'4U_A-K_P#0 M[?YZ!T\=37^$VO\ ]#M_GH7:+^F7>B/&$EE'OEO]\DK-@.0N@#KZI_PS*_(U M_5+L.OJG_#,K\C7]4O5'K0^3Q2\] '=G+@ $O]4GX5+OQ;>_.MK:*E]4GX5+ MOQ;>_.MK:.7;7?U#_P 8^J[[/^Z=<@"L)L>?NZ/X3:I_3+WY\O0)Y^[H_A-J MG],O?GRO&Q/M+W1'U5G:7U+?7]&. = 5-:SJ>_!GJ/QS=^QLIG0QU/?@SU'X MYN_8V4SN/9]_4;W2Z'E?N=OH $0WVF=.7P1[D_H<_7"CZ\'3E\$>Y/Z'/UPH M^Z/L7[I<^;Z0I^T?MZ>CZR +BKJ^/1?\&>U_B;$^QI;$UWHO^#/:_P 38GV- M+8G#L5[>OIGQ=-L>RIZ( &!E?%RU:N\>4MT5\>':IB>'Q[DQ?^FL_P!B', X M?Y,7_IK/]B', B/K39^/I?19=Q;5JU1=U'*M8\333$3%,3-R M9_R1'RJD)^ZY&KQ,>YE7(B?&:ZNS3S[/)U?.@%U;97#^BRZF9X MZIF?IX0HN>7?28NJ.;2/WVK-]37^#.O_ -,M_F)X0/U-?X,Z_P#TRW^8GA0] MHOZE=Z8\(6C*/<[?[Y9 $*DFJ=,/P5[F^+;WYLJ+KT=,/P5[F^+;WYLJ+NB[ M%>[7/F^BH;1^VHZ/J +FKBZ_5\^!S;WY&Y]K6WQH?5\^!S;WY&Y]K6WQQ3,O M?+OS5>,NDX+W>W\L> TFRB'K;?!7:^,K/YMQ4I;7K;?!7:^,K/YMQ4IU'9' M^G_^4_12,_\ >^J !9T( O9T2YWW1Z,MN97:[54Z=9HJGTU4TQ3/TQ+ M9T8=5[.C,Z'\"SVNU5AW[]B?5[^:XCYJX2>XIF5KT6+NT(\'7S,'"S(XR\3'OQQQ^Z6XJ[OE:QJ71CL//[4Y&V=/[=4\S71;[-7T-O&" MUB+MGV=4QT3,,M=JW<]>F)Z81E?Z">CJ[7VON9DT>JC)JB'[B]!?1W8N=O[E MW[OJN9%4Q\R3!M?ZMC]-/35?_P!I\V#^ PO^.GLAB-O;8V_MZW-&BZ1AX,5= M\S:MQ$SYO'Q9<&C7755O<^^ON?A78N: M?H\56+=5,\TUW9G]TJCUZ::)\]<^F/#V^%8W0-E,EKM3_ !EZ-)_+'U\E4SW,::X_A[F?D^6?"6YE_O5OYH\5Q@ M'&'1@ M !KO2A\&>Z?B;+^QK;$UWI0^# M/=/Q-E_8UMC">WHZ8\6*_P"RJZ)4. =P#KWZ>23R[,JL#PN#3KKIW:^:^W[,MI?QETC_%T?K/V9;2_C+I M'^+H_6H2(7^2K/\ EGLA)?S)<_1':OM^S+:7\9=(_P 71^M6WK8:IINJ[STJ M]IF?C9MNC3^S558NQ7$3Y2N>)F//WH;&_EFS5O+\1%^FY,S&O)SM3&YS7B[4 MVIIB !9D* )LZI>K:7I.XMINQ&NB^W[,MI?QETC_ !='ZS]F6TOXRZ1_BZ/U MJ$BK?R59_P L]D)W^9+GZ([5]OV9;2_C+I'^+H_6Z^I;QVI5IV333N329F;5 M41$9='HGUJ(A&Q=F)U]+/9#Y.T=R8]2.T 756P $J]5S4<#2^DN[DZEFX^'9 MG3KM,7+UR**>9JH[N9\_=*T/[,MI?QETC_%T?K4)%;S39NWF-_TU5)AT!,Y/ MD=&5U5S37-7"T[D=F&9U8V*8JITT $XBUFNJEN#0]*Z.\_'U/5\'#O5:M9T6[@Q<37M-OW[F)--%NWDT5553S'=$1/>IN"?RC*:/D;@TNU>M:3BT7**\J MB*J:HM4Q,3'/=,2S_P"S+:7\9=(_Q='ZU"13;NQMFY7-?I9WSKQ0L5&T5RBF M*>!&[XK[?LRVE_&72/\ %T?K/V9;2_C+I'^+H_6H2/'\E6?\L]D/?\R7/T1V MK[?LRVE_&72/\71^L_9EM+^,ND?XNC]:A(?R59_RSV0?S)<_1':OM^S+:7\9 M=(_Q='ZS]F6TOXRZ1_BZ/UJ$A_)5G_+/9!_,ES]$=K>^GS7+.O\ 2IJ^9BWZ M+^+:JHQ[%=%7-,TT4Q$S$QXQ-7:GY6B M^&L4X>S3:IXJ8B.Q7[UV;MRJY/' M,ZK%=4O7-&TG;NN6]3U7"PJ[F7;JHIOWJ:)JCL>,R&Q_,ES]$=JY_2MNO;.5T:;BQL;7],O7KNG7J;=NC)H MFJJ9IGB(B)[Y4P!/91E-&66ZJ*:N%K.J*S#'U8VN*JHTT $NCUP.@K<^W,'H MFT'$S==TW'R+=FN*[=S)IIJI_=:Y[XF>YNW[,MI?QETC_%T?K4)%/Q&R%J_= MJNS+]-SP]DR[CSQLY.19CBS?NVX_DUS#,Z?O/=>GTQ3A;AU*Q$1QQ1D M51^E!7-BJ_[=WMC[I2C:2G\]OLE?44;L=)V_K,S-.[-6JY_'R:JOKE^WNE#? M]VF*:MUZK3$3S[S(JI^J6M_)>+_R4]_DS?S'A_TSW>:\;I:EJ^E:93VM1U+# MPXXY_=KU-'URHUG[WW?GV_)YFY-4OT^BO(JG]+!W\G(O_O\ ?NW?Y]-3,4]KT35/A M[8B4%](_39NC=5NYA8=4:1IU7,3:QZI[=R._[ZOQ\)\(XA%XL. V;P.#F*XI MX57/._NXD3BLXQ.(C@ZZ1\"9F9YF>9D!/(H 2;U7_ (8],_(Y'V52,DF] M5_X8],_(Y'V52.S?W"]\L^$MS+_>K?S1XKC .,.C M M #7>E#X,]T_$V7]C6V)KO2A\&>Z?B;+^QK;&$]O1TQXL5_P!E M5T2H< [@YD M )-ZK_PQZ9^1R/LJD9) M-ZK_ ,,>F?D^6?"6YE_O5OYH\5Q@'&'1@ M M !KO2A\&>Z?B;+^QK;$UWI0^#/=/Q-E_8UMC">WHZ8\6*_ M[*KHE0X!W!S( M 2;U7_ACTS\CD?95( MR2;U7_ACTS\CD?95([-_<+WRSX2W,O\ >K?S1XKC .,.C M M #7>E#X,]T_$V7]C6V)KO2A\&>Z?B;+^QK;&$]O1TQXL M5_V571*AP#N#F0 .?#PLS,N M>3Q,6_D5S^#:MS5/T-ATKH\WMJ=/:PMMZA;GR5CY_%E+?5IT**? M?[CU&9Y_Y5#4JVHRRGBN:]4^3/3DF-G\NG7'FK&+31U;]K<]^L:G/]G]3M?M M=ME_]3J/]XPSM;ET5 MF9]R9FG9<>;W\T<_.US4NA;I$PJNS&ASE>O'N15'Z&Y;SG 7/5O4]+7KR M[%4<=N>S5'@SFI[0W1IM=5&;H&HVIIYY_<*IB/EB.&%N45VZYHN45451XQ5' M$PD*+E%R-:)B>AJ54543I5&CY >WD M 2;U7_ACTS\CD?95(R2;U7_ACTS\CD?95([-_<+WRSX2W,O]ZM_-'BN, M XPZ, M -=Z4/@SW3\39?V-;8FN]*'P M9[I^)LO[&ML83V]'3'BQ7_95=$J' .X.9 M ,YMC:.Y-R7HMZ+H^5EQ/X=-'%$>GWT]SQ%7.D<\O5%%5<\&F-9 M8,3QM/JX:OD]F[N/5;.%1Y[6/'E*_G\$M;6Z&]B:#%-=.DTYU^GB?*Y<]N>? M3$>$*]B]JL!8W43-<_#B[9^FJ7P^18J[OJC@Q\?)4+0MMZ]KEZFUI&DYF957 M/%,V[<\3\O@R?1WLO,WCN_\ 8Y:RK.%D117557=CM1'8\8XCQG]2[N95BZ/H M^7DV;%FS:Q[-=Z::*(ICWM,SYO8IWU>,ZK%Z9=#NUUS/EKEVU7,_A37;KB/I MF&'!9[>Q^&Q%VW3P>!&L@SH_P!3FNNUIUS N3'=.-K=F>G?XZM&[E6$N\=$=6[P4 MOW%T,[_T:*JZM'G-M4Q-4UXM<5\1'ICQ:'FX>7A7O(YF+?QKGXEVW-,_-+T, M8[6="T;6;%=C5=,Q\_1;7=/5^V;JDUW=,JR=)O53,\6JNU1ZH[,^$>Q$6[N@3>>C17>TZFSK& M/3QWV)[-S^S/H]JR8/:3+\3NX?!GFJW=_%WH7$9-B[._@ZQ\-_W1..SJ.!G: M=DSC9^)?Q;T>-%ZW-,_2ZR=B8F-81DQ,;I 'U\ M $F]5_X8],_(Y'V52,DF]5_X8],_(Y'V52.S?W"]\L^$MS+_>K?S1XK MC .,.C M #7>E#X,]T_$V7]C6V)KO2A M\&>Z?B;+^QK;&$]O1TQXL5_V571*AP#N#F0 M .3&L7\F_1CXUFY>O5SQ1;MTS555/HB([Y3!T?\ 0#N+6HMY>X+OW&PYF)\G M,=J_5'JCPCY6IC,?A\'1PK]<1XST1QMC#X6]B:N#:IU0]9MW+UVFU9MUW+E< M\4TTQS,SZ(A)>QNA'>.Y**,G(L4:1AU1$Q*S&R.CG:>T;,?< MK2[4Y'$15DWH[=RKP\\^'?'/Q>S;%>L94?AY7WD3ZJ([N[TI-Q<;'Q+,6<6Q:L6H\*+=$4 MQ'R0Y14,3C;^*JX5ZN:I^/[W+!8PUJQ&ENF( &LS-5Z7LW[G]%VY,F*NS/W. MO6Z9]$UTS1'TU0IIT=9GW/W]M_-YXBSJ6/75_-\I'/T9[5B.;=4]_C3[9\87++]L:*M*<73I\8X MNSC[-5=Q>SU5/XK%6OPGS5#&\[^Z+-V[/KKN9F#5EX,3[W+QHFJCCO\ &/&G MPY[VC+C8Q%K$4<.U5%4?!7KMFNU5P:XTD 9F( M 2;U7_ACTS\CD?95(R2;U7_ACTS\CD?95([-_<+WRSX2W,O]ZM_-'BN, XPZ M, M -=Z4/@SW3\39?V-;8FN]*'P9[I^ M)LO[&ML83V]'3'BQ7_95=$J' .X.9 -HV!L/<> M],^,?1\.KR,3Q=RKD33:M^GFKSSZH8[UZW9HFNY.D1RR]V[=5RJ*:(UEJ[;^ MB/9D;ZW?1HE6=&%1%FJ_J[3'$5S15-,S'JYB6[=6K,]R=,>CQ,\49$7K-7RVJICZ8AJ8^]7&"N7;,[X MIF8GJUY6?"VZ9Q--NY&[6(GM6@V'T>;7V=C4TZ3I]NCRE?9_P#;0.ZSLQ:]'EMO MXZSWS]%"SJOAXROX:1W+T=#^=]T>BW;>3,\S]S[5NJ?3-%/8GZ:6UHLZK&?& M9T0XECGF<'*OX\^KFKRGU7(2FYIF=KT6,NTM%'2+T%[9W'Y3,TC MC1M0JYGFU3S:KJ_E4_J2R-K"8V_@Z^'9JF)_?''*P7\-:Q%/!N4ZPHIOO86Y M=FY:?5+5WH9J&%B:AAW,/.QK63CW*9IKMW*8J MIF)0'TH]7VU=\MJ>RKD6J^^NK NU>]GS\6ZO-Y^Z?4ON5;6VKVEO%1P:N?D^ MWAT*MCLAKMZUV/Q1S.W5/=1;B?PJJO-"V/1-T1Z'LFS1EWZ:-1UF8CM95=/O;?J MHB?#V^*&S;/,/EM.E6^ODB/KS0DL!EEW&3NW4\_[XT7]$W0'D9U-G5MYS7C8 MTQVK>#1/%ROT=N?P8\>Z._P6.TK3L#2<"W@Z=B6<3%M1Q1;M4Q333$?_ /': M8G>>;]SMGZSJ':[/N; OW>?YMNJ?T.:8[,\3F=V/2SR[HY(_?:N6%P5G!6YX M$=,\LJ':YESGZWG9\SS.3DW+TSZ>U5,_I9GHJS/<'25MS*YXIIU*Q35/\FJN M*9^B9:TYL'(KQ,VQE6_O[-RFY3[8GF'7KMF*[,VN28T[G/Z+DTW(K^.KT-'Q M8NT7K%N];GFBY3%5,^F)CF'VX:Z< P>^]SZ?M':^9KNHU1V+%'[G;YXJ MNW)^]HCUS/Z9\SW;MU7:XHHC69W0\UUTT4S55.D0JEUE]3C4NE[4Z*:NU;PJ M+6+3//XM$35']JJI&KM:MGY.J:IEZEF5^4RNU>FNJ9F9^>75=LP6'_A ML/19_3$1V.;8B[Z:[5#JLXZ;NGX:]_7Q3Y]:XY#B(N86*.6G]P^P%930 M #5ND#86W-ZX$V-8PZ?+TTS%K*MQQ=MSZ8GS MQX=TJJ=*715N'8]^J_::H]<2G,IS[$9=/!C\5'-/TYD9C\JLXN->*KG\^=YX"Q'3#T#=F+N MM;(MF.6.E2\7@[N$KX-R.ODE\ -]J "3>J_\,>F M?DJ_P##'IGY'(^RJ1V;^X7OEGPEN9?[U;^:/%<8!QAT8 M M :[TH?!GNGXFR_L:VQ-=Z4/@SW3\39?V-;8P MGMZ.F/%BO^RJZ)4. =P%H] M%?%[,JI\>/&FB/PJO-Z(;'T(=#65NKR6N[AHNXFB\\VK?WMS*]<>BCU^?S+5 M:=A8FG8-G!P,>UC8UBB*+5JW3V::*8\T0J&>[2TX76QAIUKY9Y(\Y\%@RO)I MOZ7;VZGFY_LQ>RMJZ+M'1J-+T7%ILVH[ZZY[Z[M7XU4^>6;!SFYORE=-'U5-Y1%UL\WW-T5TX\ M3WY>H6;4QZHBNO\ T0WC MW;V;,\U7=-L37_.\G$5?3RV!4[9O3QJ>V-EZ=H&+HV+D7,.BJW%Z]75Q5':F M8[HF/")X^1^:IUA][9//N.SI^#_,M=OC^URYA=V5Q]R]7--,13K.FLQQ:KM; MSS"TVZ>%,ZZ1KN6R%*]4Z8^D/4.>WN"]C\_]-3%KZFN:KN_=&J3,ZAKVH9// MCV[TMBWL7BI]>Y3'1K/TAAKVCL1ZM$SV?=>G-UG2,&>,W5<'>7Y5Q7:CGF>Q5 MYO/W3W=Z,AKXK"6<7;FW>IUAFL7[EBOAVYTE;O0.G[8NH4T4YES+TV[,1VHO M6^U1$_SH\?F;CI72%LG4XF9CY-/IM7(KCZ)=AYZ6,W,L1Q9R[]N/13F]8IKGYY;#I_6.W=8M]G*TW3,NK\:JFJGZ*9AH7-D,PH M]7@ST3YQ#;HV@PE7'K'5Y+4BNVG]9?WO&=M?MU_^CD=F/IB?4GK;NI4:SM[3 MM8MVJK-&=B6LFFW5/,T171%41/KCE#XW*L7@8B;]&D3\8GP2&&QUC%:Q:JUT MZ7? 1[; $9=,'1%I&]<>YGX5-&!KE, MJY'G]OBDT;&%Q=["7(NV:M)AAOV+=^B:+D:P\_\ M--4=U4>:JF?/$^EC%ZND?8FA[YTB<+5;78O41/D,JB(\I9GU>F/4IWTB[(UO M9&MU:=JUKM6ZN_'R:(_<[]/ICT3Z8GP=0R7/K68T\"K\-R.3G^,>7(I.9957 M@YX4;Z>?S:R L") $F]5_X8],_(Y'V52,DF]5_P"&/3/R M.1]E4CLW]PO?+/A+*XP#C#HP M M UWI0^#/=/Q-E_8UMB:[TH?!GNGXFR_L:VQA/;T=,>+%?]E5T2H< [@Y MD )[Z!^A>=2IL;EW;8FG#GW^-@UQQ-V/-57Z*?5YWM6-V;MQNU15$7,'!N1XQYKER/JI^65C(B(B(B(B([HB%%VAVDX.N&PL[ M^6KZ1]9[%HRC)]=+U^.B/K/D_***;=%-%%,4T4QQ33$<1$>B'Z"@K4 *^]< MS.BG3]N:;$]]R[?OU1Z.S%-,?G3\RP2JW6_SO+](.GX-,\TXNG4S/JJKN5S/ MT12L.RUKTF943S:SW:?5$YW7P<'5'/I'>A4!U=0UC>K!MO:^YMBY]O6]%PL[ M(Q=1JB*[E'-445443$<^V*F_:CT(='>;5VON17C>JQ>FB$<=3+.[.;N33:JO MO[=B_3'\V:Z:OSJ5CW+<]Q6*PN8W*;=RJ(W3NF8XXB5XRNQ8OX.B:Z(F>B.= M"FI=7':E^KG"U/4<./1W7/K:WJ75HRHJG[F[DLS3YHOV9B?H^18\:EO:/,K? M%=F>F(GQAL5Y/@Z^.CQA4G4^KWOG&JJ]RU8&91'A--[LS/R2U75.BS?NG4W* M\C;>;5;M_?5VZ8JCZ%X!(VML<=1Z]--75,>$_1IW-GL-5ZLS#SUSL#.P:^QF MX>1C5>:+MN:>?G=9Z"ZQH^E:OC5XVJ:?C9=JNGLU1=MQ5S'M\85OZ>.ABSH. M#>W-M:BY.!;GM9>)/-4V:?QZ9_%CSQYH]4+%E>U5C%W(M7:>!5/%OUB?)$8W M(KN'HFY1/"B.U!0"U((')BV+V5DVL;&M5W;UVN*+=%,;5B?'B(_"F/3*,S3-K&6V^%=XYXHCCEO8' 7 M<97P:.*..59-,T'6M3FF-/TK,R>U][-NS5,3\O@VW2^AOI#SZXIC0+N-$_A9 M%440NACX]C&MQ;Q[-NS1'A3;IBF/FAR*;>VTQ$^RMQ'3K/DL-O9RU'KUS/1N M\U4]*ZNF[\C_ +]G:=A?UYN?4V;2^K19[/\ VGN6OM?_ $]F./\ ,L,(V[M3 MF5?%7IT1'UU;M&1X.GCIUZ9E#NF]7?96/3QEY&HY=7I\K%'U0V33NASH\PJ> MS&W[-_UWJZJI\_ZV_"/NYOCKOK7JNV8\&U1E^%H]6W'8P>G;/VMI]/9P] TZ MU'''[Q3/U^UFK=%%NW3;MT4T44Q%---,<1$1X1$/H:-=RNN=:IUZ6U3133&E M,: #P] ##;QVSH^Z]$NZ3K.+3?LUQ/9J_"MU? MC4SYI9D>[=RJW5%=$Z3#S53373--4:Q*D/2ST=ZML'6O(9/.1IU^9G$S*:>* M:X_%J]%4>CY8:4] MRZ'I>XM&OZ1K&)1E8E^GBJFJ.^)\U43YICS3"FW2_T< M:GL'6O)W.UDZ5D53[CR^/OH_$J]%W7(_\ ;[\\=GPI M6:Y3.%GTEO?1X-& 6A" "3>J_\ #'IGY'(^RJ1DDWJO_#'I MGY'(^RJ1V;^X7OEGPEN9?[U;^:/%<8!QAT8 M M :[TH?!GNGXFR_L:VQ-=Z4/@SW3\39?V-;8PGMZ.F/%BO^RJZ)4. = MP_]2J/Q?1'G8CJ[ M]%?[*O69^XN-7^Y6:H_[U?T^'I6NMT4VZ*:**:::*8B*::8 MXB(CS0I.TN?^BUPN'G\7YIYOA'QY^;IXK+DN5C=R1S_ !?L1$1$1$1$ M=T1 #GJV@ "EW6+S_=_3#KE5-7-%BJW8I]78MTQ/\ F[2Z*@.\-0^ZV[=7 MU3M=J,O.O7HGU55U3'UKEL79X6)N7.:-.V?LKNT=S2S11SSX?]L4 Z,IZ6^J M=G^Y.E7W--7$9N!>L\>F8[-S_1*W"C?0MJ/W+Z5MN97:[,3G469GT1_;IN6KM$T5T M51S%5,QQ,3ZN'V$3H*%=(6@SMG>^KZ%':[&)DU4VIJ\9MSWT3/KFF:98%+G6 MPTZ,/I4]UTT\1GX-J],^FJGM6_JHA$;M>6XB<3A+=V>.8C7IY>]S;&6HLWZZ M(Y)E,75.VW:U??U_6,FWV[6CV(N6XGP\M7/9HF?9$5S[8A;%"'4\TZ+&R-6U M.8XJR\_R<=WC3;HIX^FNI-[F>TV(F]F-<:[J=(CZ]^JZ9)9BW@Z9Y9W_ +Z@ M! )4 8S=.@:7N70\C1M8QJ:63'JBNJBJ*J9TF'FJF*HFFJ-8E1[I8V!J6P]PU861V[^ M!=F:L/*[/$7:?1/HJCSPTU?;?6U=*WAMZ_HVK6NU;N1S;N4Q[^S7QW5TSZ8^ ME2KI!VCJFR]R7]&U.CF:)[5F]3'O+UOS51^F/-/F?D^6?"6YE_O5OYH\5Q@'&'1@ M M !KO2A\&>Z?B;+^QK;$UWI0^#/=/Q-E_8UMC">WHZ8\6*_P"RJZ)4 M. =P3KQ\&[-NKG_P 2:9BC_-,0H6L[UNMU48FW/<_WC.KC(R:8 MGPLT3/9B?;7'/]258G3-C\)-G!U7:OSSW1N\=5+V@OQS=LW*;E$^B8GF'H)H^=9U/2,/4L>>;.78HOVY]--5,51];SV M6XZK.ZJ-;Z/HT6]E3MLL)-S#T7X_+.D]$ M_>([5BV=OQ1=JM3^:/!+8#G"X *Y]%K MNMWA>Z.C;$RZ8]]BZE;F9_DU45TS]/951=6V5N\/+:(YIF._7ZJ)GE'!QE4\ M^D]RY_5OP?6=J9[Y73"T>CL44:?U M3XQ/HETEM^L9T:1NO19U[2+-/W:P+ M,.NY/FE&98>+D;JHXXYI\IY% S# U8.[P)XN20!*M 2;U7_ACT MS\CD?95(R2;U7_ACTS\CD?95([-_<+WRSX2W,O\ >K?S1XKC .,.C M M #7>E#X,]T_$V7]C6V)KO2A\&>Z?B;+^QK;& M$]O1TQXL5_V571*AP#N#F0 ^[-JY>O46;-NJY1EY/[-]6LK MY.*.>>2&U@\+7BKL6Z?^H2?T#]'EK8^UXN9=%-6LYU,5Y=?'[W'FM1/HCS^F M>?4D4''<5B;F*NU7KLZS+H=BS18MQ;HC= UV4 !C]5UO1]*HFK4M4P\2(C MGB[>IIGY(F>9?::9JG2(?)F(C6608#?F[=)V;M^]J^K7>*:8F+5FF??WJ_-3 M3'Z?,CO?76 VQI%JNQM^BK6V9[Y^16W>V[]=WAJTZCKF;7?KB. M+=N.ZW:I]%-/A"T93LQB,55%>(C@4?'CGJY.F4)C\[M6:9IM3PJNZ'%O7<>H M;KW-F:[J57-[)KYBB)YIMT1][13ZHCN88'3+=NFW3%%$:1&Z%+JJFNJ:JIWR M /;R-GZ,-XYNR-VX^M8L57+7[WE6(GCRUJ9CM4^WNB8GTQ#6!CO6:+UN;=<: MQ.Z7NWY-$Q]8T?*IR,2_3S35'C3/GIJCS51YX9)17H M\WYN#9&HSDZ/D_N-RJ)OXMSOM7>/3'FGUQWK([(Z>=H:W:MVM6KKT;,F/?1> M[[4SZJH],\]TN89KLSB<)5-5F)KH^'''3'UCN7; YU9Q%,1HB.:K5 M%N]3ZNQ=IF?HY4UTK%JSM3Q<*GGM9%ZBU''IJJB/TKV](>'&H;!U_"XYF]IN M113_ #IMU<3\_"FG0[A^[^E+;6/QS$:C:N3'IBBKMS]%+H.R>)]'@+W_ !F9 M[OLJ>?6>'BK?QW=_W7GHIIHHIHICBFF.(CT0_0<^6P M 5>ZSW1O&CZA5O'1K$4Z?EW.,VU13Q%F[/X?\VJ M?FGVK0NKJ^GX>JZ7DZ9GV*;^+DVYM7;=4=U5,QWI/*/WQ- M+'X*G%V9HGCY)YI>>PVOI4V7F;'W=D:1D177C5K?S1XKC .,.C M M #7>E#X,]T_$V7]C6V)KO2A\&>Z?B;+^QK;&$]O1TQXL5_ MV571*AP#N#F0 #:^BK9N5O?>.-H]F*Z<:)\KF7J8_>K,3':GVSS$ M1ZY7@TO!Q-,T['T[!LT6,7&MTVK5NF.(IIB.(A13:F\]P[6QLFSH.=.%[IJI MF]C\<4 MT4\4;]=>69W?5.Y;F6'P5N?PS-4\?%V+SY>;A8D7CX\>F[X]-HCCGWMZ*^[^KRHO?S\Z_'%_,R+L>BN[,_7+K-"WL31'M+T]4?> M6U7M)5^6WWKF:ITV]'F#3S3K%67ZL>S,S]/'H:WJO6.VK8Y^Y^EZAF_SN+7Z MU5Q(6MD,!1ZTU3U^40U*]H,55Q:1U>:P&J=9;/JJG[F;& MKZGT_P"_PL.BKF.S18BKCY9[T3B1M;/Y=:]6U'7K/CJU*\UQE?'#:]5Z2-\:G371E[EU"JW5/,T4W9II^:&M9&5DY,\Y&1=O3'AVZYJ^MPB3 MM8>U9C2W3$=$1#2KNUW/7JF>D 96, !SXN;EXD\XN5>L3SS^YUS3]3 M:-)Z3=]Z9311C;ES_)T1Q3;KN=JGYI:@,-W#6;WM*(JZ8B66W>N6_4JF.B4N M:7U@]]XUSG+G S:/Q:[$4?33WMITKK+Y$5?]J;:M54\__P :],3_ )N5>A&7 M=GLMN\=J.K6/!N49MC*.*Y/7O\5J,#K$[/S+%5O4]-U'%BNB::J::8N\\QX> M9"?03J.C:-TJ:=JFL9U&+@XL7JHNW*9XF9MU4T]TKHKN:3-,ZQ^^I?33MZ[2S[?;Q=Q:973_*R*:?SN&9Q< MK%RJ>WC9-F_3Z;=<51]#SRB9B>8GAVL?4M1Q^(L9V5:B/-1=JC]*O7-B:?[= M[MC[I:C:2K\UOLG[/0D44T[I"WMI]$6\3F]8IKGYY:%S8S%T^I73/;'T;5&T>'GUJ9CL\URA5?3^L=NRQ1VCL?]H;8F:_\ TIFF9YV_8Q-K$1PK=6L #59P &@ M].>P[>^-G7+5BBF-6PHJO8-?'?-7'?;]E7$1[8B5++UNY9NUVKM%5NY15--= M-4<33,=TQ,>EZ(JM]:C8<:1KE&[M-L]G"U&OLY=-,=UN_P 3/:]E<1,^V)]* M[[(YKP*_X.Y.Z=]/3RQU^/2K6?X#A4_Q%$;XX_/]_1" #H*I "3>J M_P##'IGY'(^RJ1DDWJO_ QZ9^1R/LJD=F_N%[Y9\);F7^]6_FCQ7& <8=& M M &N]*'P9[I^)LO[&ML37>E#X,]T_$V M7]C6V,)[>CICQ8K_ +*KHE0X!W!S( ;#M796YMT8F5E:%I5_-M8U5 M--R:(\\Q,Q$>F>[Z8]+!XF/>RLJUBXUNJ[>O5Q;MT4QS-54SQ$1[97GZ+=IV M-F;)P=$M13-^FCRF5P=Y:;3VLW;>HVHXYYFS,_4PF3IVH8T MA+@RL+#RHXRL2Q?CT7+<5?6KEO;6Y'M+43T3I])2]>S=$^K>8OGJ6R M=I:C3V+5ZIU<]H7X_W'4-1PY]=47/3Z>&MZIU:+G:G[F;E MHFGGN]T6>)_RI"UM5EM?'7,=,3]-6I7D>,IXJ=>B85X$P:GU>=[X]V$C:S? W?4NT]L1XM2O 8 MFWZUN>QI [^=HVK84U1F:9F6.S/%4UV:HB/EX=!(4U15&M,ZPU)B8G20!]? M &1P-!UK.KIIP]*S;\U?>]BS5,3]#S5731&M4Z0]4TS5.D0QPWO2^ MB'I!U"N*:-NY-B)_"O\ %%/SRVG2NKMO3)KXSLG3L&GGQFYY3\U'WQ#8L5I75H[O^U-R\3_\ 3V.8_P W'K;+IG5UV9CT\9N7 MJ.95Z?*1;^I'7=JLMHXJIGHB?KHW*,BQE7'3$=,Q]-54"(F9XB.5T].Z&NCS M#IX^X%O(]=^Y55/G]GI;'I^S=JX%OL8FWM-MT^B<>FKZXEH7-M,-'J6ZIZ=( M\VW1LY>GUJXCMGR44Q],U+(CFQ@95V/319JF/J9W3NCS>VH4=O$VSJ5RGT^1 MF/K7FQL7&QJ>SC8]FS'HMT13]3E1]S;6[/L[41TS,^3:HV;HCU[DST1IYJ:Z M=T'](>91VON3;Q_5>O4T3Y_U-BTWJX[LOT\YFIZ;B3Z.9K^I:@:-S:[,*_5X M,=$>9N"+UW!R*+]-NS9XIJFF8GB9GS) MU!"8W,,1CJXKOU:S'PB/!)8;"6<+3--J-(D :39 M &*W?H.#N;;>=H6HT=K'R[4T3/',T5?@U1ZXGB8]C*CU175; MJBJF=)AYJIBJ)IGBEY_;HT7-V]N'.T34*.SDX=Z;5?'A5QX51ZICB8]4L:LG MUM=E>7PL?>N!9_=,?BQG]F/&B9XHKGV3/9_K1Z%;'9,IS"G'X6F]''Q3T\OF MYYC\).%OS;GBY.@ 232 $F]5_X8],_(Y'V52,DF]5_X8],_(Y'V52.S M?W"]\L^$MS+_ 'JW\T>*XP#C#HP M U MWI0^#/=/Q-E_8UMB:[TH?!GNGXFR_L:VQA/;T=,>+%?]E5T2H< [@YD M ^[-JY>O46;-%5RY75%-%-,9]LTK4-7Z*]JV]G;%T[0XBGR]%'E,JNG\.]5WUSSY^)[H]40VA MQ[.\P_CL95(][1'IJGPB%A-D=732\>U1D;JU"YF7YCF@VM+TBQ3$\1-^_,?NE^OSU53]4>$-B(Y]_=:B[BY=FJS=H]--43$_6HAO;;^7M;=>H:!F:>?Y5*U[)9A_#XJ;%4_A MK\>3MXNQ!9]A/2V/2QQT^"MX#IJE "3>J_\,>F?DJ_\,>F M?D^6?"6YE_O5OYH\5Q@'&'1@ M M !KO2A\&>Z?B;+^QK;$UWI0^#/=/Q-E_8UMC">WHZ8\6*_[*KHE0X!W M!S( 2KU8=J1N#I$HU+(M]K"T:F,FOF.Z;O/%J/GB:OZB*ER.K9MC]CO M1GB7[UOLYFJS[LN\QWQ35$>3C^S$3QZ:I0&TF._A,#5%,_BJW1U\?;2HJQ,'>6+;XN451B9G$>-,\S;J MGV3S3SZZ?0K@O9TKZ13KG1MK^FU4=NJO"N5VH_\ 4HCMT?YJ843=/V1QDW\% M-NKCHG3JGB^JDY_AXM8CAQ^:.\ 6E!BU/5-VE1IFS[VY\BW'NO5:IILS,=]% MBB>/D[543/KB*56+5NN[=HM6Z9JKKJBFFF/&9GNB'H%MO3+6C;?T_2+$1%O# MQK=BGCS]FF(Y^A4-L,9-K#4V*?SSOZ(^^BP;/8>*[U5R?RQWR[X#FRY M /FY71:MU7+E=-%%, MMVLB]3,1-G%_=:N_S]W=]**]S]9.N>U:V[H44QWQ%W+KYY]$Q$?5*5PF28[% M[[=N=.>=T=_T:-_,L+8W5UQK\-_@L6QVK:[HNDTU5:GJF'B=F.9B[>IIJX]G MBION/I;WYKG:IR-5E9.57V\G(NWJO3S1J=S/JX_P#XMJ:H^69X M:/K'65Q*::Z=)VY=KKB?>UY%[WLQ[([U;A.6-DLOM^M$U=,^6B,NY]BZ_5F( MZ(\]4Q:KUB-ZY-43A6-.P8]%-KM\_P!IK&I]+W2%G7)KKW'E6.?P;$^3CYH: M()2UD^ M>K9I[-?%HUYABJ^.Y/;IX,UJ&Z]RZA5-69KF?>F9YGM7I[^_ECKV MH9][GRN=DW.?QKM4_I=8;U%JW1ZM,1U-:JY55QSJ^IN5SXUU3[9?(,CP ^H MN5QX5U1[)=BUJ.H6HXM9V51'HINU1^EU1\F(GC?8G3B9W3=X[ITV8G!U_4+' M'AV;T_\ [YVR:3TS=(>GS$TZ]W3/5#/1BK]'JU MS'7*:M(ZQN[,:CLY^G:?G3W>_FF:)]?=3W-ST;K):)>JIHU70\O%C\*Y:KBN M/F\?I5B$;>V:RV[_ &].B9C[-RWG.,M_GUZ5U]!Z7]@:O31Y/7;>-/E41W359N17'SP\]'>TS5]4TR[1=T_4,K%KHGM4 MS;N33Q/I0N(V+M3OLW)CIC7PT2-G:2N/:41/1N\WH**>;9Z==]Z1533E9EO5 M;,3S51E4\U5?UH[TI;6ZQN@Y?8M:_I>1I]R8]]=LSY2CGGT>,0K^*V7S##[X MIX4?\=_=Q]R6L9WA+NZ9X,_'SXDXC";;W;MS<5N*]&UC$RYGPHIKXK]?O9[V M;0-=NJW5P:XTGXI6FJFN-:9U@ >'H8S=>BXNX=MZAHF;3$V,VQ5:JGC[V9CN MJCUQ/$QZX9,>J*ZJ*HJIG28?*J8JB:9XI>>^LZ?DZ3J^7I>;1V,G$O5V;M/H MJIF8GZG435UM=L?6+N+'M\6-5M=F[,1X7K<1$_/3V?FE"KM.78N,9AJ+\ M3]P -UK "3>J_\ #'IGY'(^RJ1DDWJO_#'IGY'( M^RJ1V;^X7OEGPEN9?[U;^:/%<8!QAT8 M M :[TH?!GNGXFR_L:VQ-=Z4/@SW3\39?V-;8PGMZ.F/%BO^RJZ)4. =PKW3OC2="B*IHRWO*ZGK&Y[U'O<>W&'8F?QJN*JY]L1%/]I91S+:[&>FQD68XJ M([YWS]%UV?P_H\/-R>.KPC]R *HG0 "8B8F)B)B>Z8EY^;ET^= M)W'J>ESSSAY=W'[_ !]Y7-/Z'H&I1U@,#[G=+^X+44\4W;].1'K\I137/TS* MZ;%7M,1=M\\1/9/W5S:2WK:HKYIT[?\ IH8#HBH-JZ(=.^ZG2?MW#FGM4SGV MKE<<<\TT3VZOHIE>E4+JJ8$9G2U8R)IY]Q8=Z_SQXYAOXFU8IX5RK1*C6=W;\VIM:U7.L:QCVKM,3^X45=N[,QYNS'G]O" MKN]>FS>FXHKLV?13#6!;L'DV"P?LK<:\\ M[Y[9^B Q&8XG$>O5NYN* !)M( !RXN1D8MV+N-?N M6;D>%5NJ:9^>$D[-Z<-[:!%-G(RJ-6Q:>[R>7'-41$<1$51WQ",1K8G!V,53 MP;U$51\6>SB+MB=;=4PMWLKIXV?KDT6-2JN:-E5>:_WVYGU51Z?0E/%R,?*L M4W\6_:OVJO"NW7%5,_+#SQ;'L[?&Y]IY,7=$U2]9HYCM6:I[5JN(\TTSYE2Q M^QMNK6K"U:3S3OCMX_%/87:*NG=?IU^,'TJIO1R[I^C7 %Y5@ 2;U7_ACTS\CD?95 M(R2;U7_ACTS\CD?95([-_<+WRSX2W,O]ZM_-'BN, XPZ, M M -=Z4/@SW3\39?V-;8FN]*'P9[I^)LO[&ML83V]'3'BQ M7_95=$J' .X.9 ,WL/1:MP[STC1(B9IR\NW;N<>:CGFN?DIB9^1XN7*; M=$UU<4;WJBF:ZHICCE;_ *!M _8[T6:/BUT=C(R;7NN_S'?VKGOHY]<4]F/D M;R_**::*(HHIBFFF.(B/"(?KB&)OU8B]5=JXZIF>UTRS:BU;IMQQ1&@ PL@ M JAUNL'W/TE8N93'O\VWJ--/ MA.18KJ_L54Q]%2Q;*W>!F5$<\3'=K]$1GE'"P=4\VD]ZN@#JRB)_ZF>#V]7W M%J4Q^\X]FQ$_SZJJI_,A91"74\PO);#U7/FF8JR-1FB)]--%NCCZ:JDVN1[2 M7?29E=GFTCLB%_R:C@8.CX[^\ 0:3 !CMP:]H^@84YFLZCC MX-B/PKM?'/LCQGY$&[_ZQ=FU-S$V?@^5J\/=F5'%,3Z:://Y_%(8'*L5CITL MT:QS\G:U,5CK&%C6Y5U-6U33M)PZLO4\VQAV*8F9KNUQ3'='/=Z?9"&-] M]8?1M/FYB[7PZM3OQW>Z+OO+43W^$>,^:5=MS[GU[IY&9<\T5U>]I MCO[HCPCQ8==\OV0L6M*L35PIYHW1YSW*UB]H+M?X;,<&.?E^S9]X[^W5NN[5 M.LZM>N6IGNL43V+4?U8[FL MMJS;LT\"W3$1S0@+ERNY5PJYUD 9'@ M 9_9V\=Q;3S8R=#U*]C=_-=KGFW7ZJJ?"?"& M'BY:HNTS17&L3R2]T5U45<*F=)6IZ->G[1M9FW@;GM4Z3F3Q$7XF9LUSZ_/3 M_P#EJ'6]T6U.IZ+NK#FBY8S+-6+=N6YB:9JHF:J)YCQYBJJ/ZB!63G7]6JV] M.@7*XP#C#HP M UWI M0^#/=/Q-E_8UMB:[TH?!GNGXFR_L:VQA/;T=,>+%?]E5T2H< [@YD )DZ MI&B^[^D3)U:NGFWIF'553/HN7/>1_E\HAM:CJ@:1[DV)J.K5T\5Y^;V:9X\: M+=,1'^:JM!;28CT&77-..K=V\?=JE,FL^EQ=/PW]GW36 Y(OP M AOK=87NCHTQJ?&72L)1P+%%/-$> TVP #H:[K6E:'@U9NKZACX6/3',UW: M^/FCQGY$#](O6(IIFO"V9B]J?"T?;^!5FZSJ&/A6*8YYN5<3/LCQGY$!=(/6)O7/*8>SL+R5 M/A[LR:>:I_FT>;S^*#=P:]K&OYU6;K.H9&;?JG[Z[7,\>R/"&-7O+=DL/8TK MQ$\.KFY/OU]BKXS/KUW\-G\,=_V_>]DMP:[K&OYU6;K&H9&;?JG[Z[7,\>R/ M,QH+711313%-,:1""JJFJ=9G60!Z>0 '-B8F5EW?)8F/>OU_BVZ)J MGZ'R9B(UE]B-7")!VWT-[^UN(KHT>K#M3$3V\JJ+?,3YXY\4CZ!U:JICM:YN M*F)[IBC%M<^V)FI%8G/J]>N([_)1W3=L;BU*[%K!T7/OU MSQW4V:O.V33>B'I"SJXIHV[DV(G\*_[R/-Z?:NO33333%-,13$>$1#]1EW;3 M$S[.W3'3K/DWJ-G+,>O7,]D>:HN)U?M_W:HB]9P;%/=[ZUN8U<4Q'5YZMBG(<'''$SUJT6NK3JW9CRNX\** MO/%-JJ8^IW?VM$_QFC^X6*&&=I\SG^YW4^3+&28*/R=\^:NO[6B?XS1_<.+( MZM&1V8]S[EM35SW]NS/''R+'CY&T^9Q_<[J?(_T7!?H[Y\U8[W5JUZ*I\EN' M39I\W:HKB?J8O/ZNV]+//N;(T[*XYXXN=CGYUL!EHVKS*GCJB>J/IH\59%@Y MXHF.N5--0Z$>D3#I[4Z/3?\ 58O4US]#6]3V'O'3:.WF[B;8&J17-[;V/:N5^-RS,T51[/-]"2L[:V9]K:F.B M8GR:5S9NY'J5Q/3&GFI(+2:YU<-MY'-6E:MG84]GNIN1%R)GUSW(^U[J\;QP MH[6G9&#J5/?,Q17V)B/ZWC/L3.'VDRZ_N])P9^.[OXN]'7V=NC0J^SJNAYV-X^^JLSQ,1Y^8\S IJW=HNT\*B8F/AO1U=%5$Z51I( ] MO DWJO_#'IGY'(^RJ1DDWJO_#'IGY'(^RJ1V;^X7OEGPEN9?[U M;^:/%<8!QAT8 M :[TH?!GNGXFR_L:V MQ-=Z4/@SW3\39?V-;8PGMZ.F/%BO^RJZ)4. =PP^Q MV*IPZ;]<<=\57.;D\^OFI232<.YJ.JXFGV8F;F3?HLT1'IJJB(^MZ#XUFWCX M]O'M4]FW;HBBB/1$1Q"C[:W]+=JUSS,]F[ZK-LW:UKKN:Z>'3-/.\[G)C6J\C(MV+<LZCCX5FF.>;M?$S[(\9^1!O2!UBK5$5XFSL+RE7A[LRJ>Z/Y MM'G\_BD,#E6*QTZ6:-8Y^3M:F*QUC"QK;JV=CX6/1',W M+M<4Q_\ E!G2#UB<:QY3#V=A^Z+D=WNS)IXHCUTT^?Y4![GW+KNY'/-R??][E8QF?W;GX;,<&.?E^S*[FW M'K6Y,^K-UK4;^9>JGF.W5[VGU1'A#% MM%%-%,4TQI$(&JJ:IUJG60!Z>0 M 9K:^U=P;ERHQ]$TO)RZIGOJHHGLT]_',U>$)MV1U<:Y\GD[MU.*8[I MJQ<2>9]<37\W@C<=F^$P,?[U>_FXY[&YAL!B,3[.G=S\BOF-8O9-V+./9N7K ME7A313-4S\D))V?T(;WU^*+U_$HTK&JX_=,N>)F)CF)BF.^86FVILO;&V+,6 M]%TC&QZHXF;O9[5R9XXY[4]_S-@4_&[97*M:<-1I\9WSV<7BL.&V=HIWWJM? MA'G_ -(8VGU>=KZ=V+VMY>1JMZ.)FC][M\^>./&8^9*>A;=T/0[%-G2-*Q,. MFB.(FW;B*O[7C/SLH*MBLQQ6+G_>N3/AV<2VUK45 M>,Q8RZ>/9$51][NVON%CP>UN-L;KNE[L>=PNAO?H M=V7N:+MZ<"-.S:^9]T8OO>_TS3X3[.Y!>^^@;=>A>4R=([.M8<=\>2CB[3'? MXT^?NCS+=@-IL#B_PU3P*N:?/B\$!BLEQ-C?$<*/AY(C')D6+V/=JLW[5=JY M3XTUTS$Q\DN-88G5$@ ^ "3>J_P##'IGY'(^RJ1DDWJO_ QZ9^1R/LJD M=F_N%[Y9\);F7^]6_FCQ7& <8=& M & MN]*'P9[I^)LO[&ML37>E#X,]T_$V7]C6V,)[>CICQ8K_ +*KHE0X!W!S( M!NG0;@1J/2WMS'FGM11F1?F./^7$W/\ 2N^I9U?M=T3;G21C:KKV3.-CV[%R MBW<[',175'9CGT1Q-7>N+HNLZ5K.+3E:5J&-F6:J8JBJU,?*YQME% MR<53.D\&*>/DUUGE[%QV=FB+%4:[YEW@%.6$ !1+I5P_LS$<4WXLWJ?EM4Q/TQ+/=43#\OTEY>3,>]QM-N51/\ *JKMTQ]$U.M8 MC$?_ (LW>>WXQHH5FS_^C%'-5X2M> Y*OH #BR\K&Q+$W\O(M8]J/&N[7%- M,?+)$:\0Y1%N\NG39>A17:PK]S6,JGN[&-'%'CQ/-4]R$]Z].N\=>\I8P+M& MCXE4<=C'[ZYCO\:Y[^_T)W [.8[%Z3P>#3SSN[N-%XG.,+8W<+6>:/WHLWN_ M?&U]JX]5W6=6L6:XYXLTU=J[5,>:*8[^?:@O?76+U#)BYB[3T^G#MSS'NK(] M]7,=\C?=>\+D3I>FUTXW/OLF][RW'AYY\>Z M>>Y87H]Z!=M:#Y/+UVK[M9U/?Q7'%FF?53Y_E0V89]@\#K%=6M7-&^>OFZTC MA,KQ&*WTQI'//[WJZ[(Z/MU;ON\:-IERJS'WV1=]Y:C^M/L3[L+J]Z#IA-./9LX]FFSCVK=JU1'%-%%,4TQ[(A]J+F&U M.,Q6M-N>!3\./M\M%HPF1X>QOK_%/QXNSS=?3L#"T[$IQ<#%LXMBGPMVJ(IC MZ'8!6YF9G64Q$1$:0 /CZ U;>VP-K;OQY MHUC3+=5[\'(M1V+M/]:/'P\_*NO2-T#[BT#RN;H4SK.!3S/%$<7J(X\]/G\_ M@MF)C+L\Q> G2BK6GFGB^W4C\9EF'Q4:U1I//'']WG==MW+5RJU=HJMUTSQ5 M35'$Q/HF'RNKTE=%&V=Z6J[]ZQ&#J53LPRZY@JHBJ=8GBEQ@)A' M"3>J_P##'IGY'(^RJ1DDWJO_ QZ9^1R/LJD=F_N%[Y9\);F7^]6_FCQ7& < M8=& M &N]*'P9[I^)LO[&ML37>E#X,] MT_$V7]C6V,)[>CICQ8K_ +*KHE0X!W!S( =W2-7U32,F,C2\_)P[L3SVK M5R:?G]+I#Y53%4:3&L/L3,3K"7]I=8#>&DT4V=4HQ]8LQ$1VKL=FYX]\]J/& M?:EC:W3_ +,U6:+6I>Z-(O53Q^[4]JW'KFJ/!4@0.+V:R_$[^!P9_P".[NXN MY*6,YQ=G=PM8^._OXWH!HNX-$UJS1=TK5<3,IKCFGR=V)F8]GBR;SRQ,K)Q+ MOE<7(NV*_P :W7-,_0W7;W2YO[1>S3CZ[>R+=-/9IMY,1NP*SZ#UD]4M>3HUK0D[6;X.YQ5Z=.Y+XU+2>D MK8VIU4T8FY<"JNJ.>S57V9CV\MDQ-0P,O_NF=C9'Y*[35]4HF[8NVITN4S'3 M&C>HNT7-]%43T.R Q,@ #YN5T6Z)KN5TT4QXS5/$ JIUO/9IG^=->D/:FQMJZG1K5_(C,RLSM4V[-GM3 MV*:*>)F?7,U0Z)I=Q&SU-%NF9JG2-(^%7E"HQZ.UF]55*:H]D=\(_P!P].V_=4[=&/FV=-M35S3&-;B*J?5V MI[U>P^RN8WO6IBF/C/EK*6NYYA+?%.O1'GHMWFYN'@V?+9N58QK?XUVY%,?/ M*/MS]->P]%IJIHU.=1OQ$\6\6F:N^/-,^$*B:OKFL:O=JNZGJ>7EU5SS/E;L MS'/L\&/6#"[&6J=]^Y,_"-W?O^B*O[1W)W6J-.G>G3=G6-UO+[=K;NEV-/MS M][=O_NESYO!$NY-U[BW%>F[K.KY>9,_@UW)[/'F[H[F%%FP>5X3!^QMQ$\_' M/;.]"XC'8C$>TJF?#L &^U ;;L3H[W3O&]'W(TZOW-SQ7E7?>6 MJ?EGQ^18?H[Z!MMZ!5:S-X/ :Q75K5S1Q_ M;K2.#RO$8K?3&D<\_O>KWL3HWW7O&]3]R].KHQ>>*\J]'8MTQW>>?'NGGB%A MNCSH'VUH'D\O6I^[.?3Q/%<<6:)[O"GS]\>,_,EJQ9M6+-%FQ:HM6J(XIHHI MBFFF/1$1X/M0LQVFQF,UIHG@4\T#[!7$P #I:IJVF:7:FYJ.H8V)3%/:_=; ML4]WIXGQ:!N#IRV!I7:ILZC9Y],12T76NG3I U&FNBWJ-K"HJ MGN]SVHIJCY?%-V-E,QN^M$4],^6J,NY]A*.*9GHCST7&GNCF70RM:T?%J[.3 MJN#9J]%>133/TRHSJV\]U:K7V]0U_4+]7KO3'U,+>OW[U7:O7KER?375,_6E M;6Q-4^TO=D?>&C7M)3^2WVS]EX\WI)V+AU]C(W/I]%7HBN:OJAA\WIJZ.\;G M_MOR_''[S:FKE3 ;]&QF$CUJZI[(^DM6K:._/JTQW^:WMSI_Z/J)JB+^HU<> M>,;NGZ7%^V$V#Z=2_P -_P#E4<9XV/R^.6J>N/)BG:#%SS=GW6QHZQ&R9O\ M8JQ]2IM\S[_R7/=YIXY<_P"V$V#Z=2_PW_Y5''J=D*J MKMCR9(VBQ4<<4]D^:]>G=(>R=0JBG$W+I]9\O9B:JO5 MVD;>V-Q=/LZZ9[8^GU;EO:*Q5Z],QWKABN>B=9:Y%4QK6W*9CCNG%O<3SZ^T MW[0.G38&J331>S[VG7)IYJC)M3%,3Z.8YY0^(R#,+&^JU,Q\-_AJD+6:X2[Z MM<=>[Q2<.AI.LZ3JUJFYINI8N7353VH\E=BJ>/3QXP[Z)JIFF=)C26_$Q,:P M /CZ *%](V+&#T@[AQ(CBFUJ>133'\GRE7'T<+Z*2=/5B,?I?W';CSY,7/# MC[ZBFK]*Y[%UZ8FY1STZ]D_=7=HZ?]FBKX_1HX#HJG@ "3>J_P##'IGY'(^R MJ1DDWJO_ QZ9^1R/LJD=F_N%[Y9\);F7^]6_FCQ7& <8=& M M &N]*'P9[I^)LO[&ML37>E#X,]T_$V7]C6V,)[>CIC MQ8K_ +*KHE0X!W!S( =C%S\[%GG%S,BQ/_IW:J?JEUQ\F(G=+ M[&YL>F;ZWAIO$86X]1LQ'AQ>F?1Z?9#.8/3'TAXDQQN"]>X\UZF*_.T :MS+ M\+<]>U3/5#/3B[]'JUS'7*5K73_TA433VLG!KB/&)Q:>]W/F0X-6K(\OJX[-/8S1F>+C^Y*:/VQF[_ /R_3O[,G[8S=_\ Y?IW M]F4+CS_H.7?XH>O]5QG^24N7NL)ORN)BW5I]OF>Z8QXGCYW0R^G7I$R(X^Z6 M/:[_ !MX]-,HR&2G)C:7>N6OPK]<=FU3[:I M[E@^C[J_:#I'8R]RWONOEQW^1CFFQ3/?\M7F]"(S#/,'@(TN5:U]E;$W/N_(BWHNF7;EOGWU^N.S:I\?&J>[S+$]'O0%MW18 MMY>X;GW9S8[_ "?$TV*9]GC5YO%+^'BXV'C48V)8M8]FB.*;=NB*:8]D0Y5# MS':C%XO6FW^"GX(B/7*.-[]-.S- MM5UX]&5.J9E',39Q)BJ(F)\)J\(;&&PE_%5<"S3-4_!BO7[=BGA7*HB$DL7K M^X]"T&Q-_6=5Q,*B..?*W(B>_P!7BJWO/I[W?K/;L:5-K1L:?#R/?=\?QI\$ M6:AG9NH9$Y&=EW\F[/C7=KFJ?I6O!;&WZ_Q8FO@QS1OGR\4#B=HK=.ZS3K\9 MW1Y^"SN[.L5MW"BNUH&!D:E>XGBY<_<[<3S\\Q[$4;IZR_"[XHX4\]6_[=R#Q&;XN_QU:1\-WW=G4-0SM0 MN^5SLR_DU\S/-VY-7C[76!-1$4QI"-F9F=9 'U\ =C!SL MW!N^5PLN_C5_C6KDTS]"0-L=-F_-%JIIN:G&HV8XYMY5,5=T>:)\81N-;$8. MQB8TO415TPS6<1=LSK;JF%H=I]8W0LOLVMPZ9?TZY/C=L_NEOYO%+.V]U;>W M%9B[HNK8N9S^#17[[^S/>H*YL++RL*_%_#R+N/=I\*[=&B318U.Y;UG$CNF+\<7(CN\*H]4> M=.VQ>F79NZ*[>/[KG3LS3PJ>>-_WA8,+F^& MQ&Z)TGFG]Z)%4VZS=J+?3-J]<<_NEO'JGG\C1'Z%R*:J:J8JIF*J9CF)B>8F M%0^M7$QTMW^[QPK''K[I;VQTZ8^?EGQAJ[0QKA8Z8^J*0'3E* $F]5_X8], M_(Y'V52,DF]5_P"&/3/R.1]E4CLW]PO?+/A+*XP#C#HP M M UWI0^#/=/Q-E_8UMB83?]-->P]P45Q%5-6F M9,3$^>/)5,^%G2]1/QCQ8KT:VZNB5!P'<7,@ 'W-F[%FF]-JN+54S%-#,QKQQYQWIN,CO7+--V MU,3K&NG$JD)*W?T);XT#MW;6#3JF-3S^ZXD]J>(CF9FGQB$%9KBJ/A**O8>[9G2Y3,.,!LL( M #DQ[-[(NQ:L6J[MR?"FBF9F?D@F='UQB4]D=!F\M?FW?SK%.CX= M4<^4R?OYCN\*([^^/.G;8W0KLW;-5O(NXU6K9M'$Q>RHB:8F.>^*/#Y^4!C] MI,#A-8BKA5?$E<+DV)Q&_3@QSSY*T['Z,MW;MN45:?IERUBS/%65?CL6X MCVSX^GN3]L#H"VUHL6\K7ZYUG-COFB>:;%,^J/&?3WIAMT46[=-NW33113$1 M333'$1$>$0_5)S#:?&8O6FB>!3S1Q]O'V:+)A,DP]C?5'"GX^7_;CQK%C&L4 M6,:S;LV:(XIMVZ8IIICU1'=#D!7)G5, Z>L:KINCX5>;JF;8P\>B M.:J[M<4Q_P#E!_2'UA\+%\KA;0Q/==V.:?=E^.+<3W]]-/G\WCW-_!99BL=5 MP;%&OQY(ZVKB<;8PT:W*M/'L3IJ.?A:=B5Y6?E6<6Q1$S57=KBF(XCGSH;WY MUA-"TNJO%VUC3J^13W>6JF:+,3SYO/5W>>%=-V;NW#NG+G(US5+^5/X-$U<4 M4^J*?!@UVR_8^S;TJQ57"GFC='G/$^-/A M$.OTQ[SQ]];HQ];L8ES$F,&W8NVZYB>*Z:JIGB?1[Z&EC3IR_#4W_P"(IHB* M^>.7I;,XN]-KT4U:T@#<:P DWJO_#'IGY'(^RJ1DDWJO_#'IGY'(^RJ1V;^ MX7OEGPEN9?[U;^:/%<8!QAT8 M 8C>M MNJ]LS6[-'':KT^_3'/IFW5#+NIK=J+^BYUBKGBYCW*)X\>^F89+4\&NF?C#Q M7&M,P\]P'=', %L^J-737T6Y%-,\S1JEVFKU3V+<_5,)@0CU.KW:V%J^/ MS'O-4FOCS^^M6X_TIN<>SZG@YC>CXNAY5.N#M] PNXMJ;@Y=-=W;VI9&GW> M)FFU>_=+A#?>B377:T^G4\>F>ZYB5=J9CT]GQA<@3^$VHQ^ M'W55<./CY\:*OY)A+N^(X,_#RXGGGFX67A79M9F->QZXF8FFY1-,]WM<#T"U MG0M&UFU5;U73,3,IFGL\W;453$>B)\8^1&VYN@'9.J>4N:?&3I-ZK[WR-7:M MT_U9_6LF%VRP]>Z_1-,_#?'TGQ0U_9V]3OM51/P&)L^O1/[Z&KCZN6Z[=)?R*IGCBW;FKO^1\F8B-9?8B9W0ZPD+;W0SO\ UB8F-%KP MK?=[_+JBWW3YXB?%)FV.K99I[%W<6NS7,5V96WVKT8;)VY31.!HEBY>ICCR^1'E*Y]O/=]#<*8BFF*:8B(B.(B/, MK6+VTY,-;ZZO*/-,X?9SEO5]4><^2O6S>K?;IFB_NK5YK\)G&Q(XYCCOB:Y\ M)Y]'*9=I[)VOM>U%.BZ/C8]<<? MS^Q"/2'UA=,P9NX6TL;[H7XYI]UW>ZU$]\:?0WL%EV)QU7!L4:_'DC MIEK8G&6<-3K=JT\4U:QJFG:1A5YNJ9MC#QZ(F:KEVN*8[OK0ATA=8?"Q?*X6 MT,2,N]'-/NN_'%N)[^^FGQGS("W=NO7]U9]69K>HW**/533X1XL M(O.6[(V+.E>*GASST^RGPAAP6ZBW3;IBFB-(CF0%555/$K!: M?U:=-I[%6=N7)KF)]]1;QXB)]DS/Z&GCMQ;IG5L8;+[^)F8MQ MQ<:M0MMA]7K8EJ*9O5ZG?JCQYOQ$3\G9_2SF'T,='6/3Q.@47_7=NU3/T3"' MKVQP-/JTU3U1YI&G9[%3QS$=<^2EHO#C=%O1_C]GR6U\+WL]J.UVJN_Y99"S ML79]FY%RWMS38JCPF;$3];6G;3#\EN>YEC9N[RUQWJ'"_/[$]L?Q>TO_ M' MZGY?YUL_XI[8>OY;N?KCL4'%Z M;Q.SE_DKCO4G%OLWH!Z/\BOM46-0Q_Y-K([OIB6O:AU:]"NW.UA;@S<>G\6N MS37]/,-NWM=E]?',QTQY:L%>08NGBTGK\]%8A.NI]6S7[45U8&N8&1$?>TUT MU4U3]'#3]9Z%.D/3:.W.BSET]_\ W6Y%R?FCO25G/,OO>K=CKW>.C3N99B[? M';GJW^".AD]5V]KNEW:K>HZ1FXU5/WWE+-4<,8DZ*Z:XUIG6&E53-,Z3 ]/ M( E'JM6IN=,&%7SQY/&OU>WWDQ^E%R7>J59\KTJUU]F9\CIMZOF/- M[ZBGF?[7THS.JN#E]Z?^,MW+8UQ=OIA;8!QIT4 M M !YYZA8G%S\C&F*HFS=JM\5>,<3,=_S.!G>D/%]Q;_ -PXG9[, M6=3R*(B/1%VKCZ&"=TLU\.W35SQ#F%RG@U33S #(\ +(]3'([6G[FQ.?WN[ MCW(C^=%R/]*P2L74VRXHW5KN#SWWL&B[Q_,N1'^M9UR;:>C@9G<^.D]T+[DE M7"P5/PU\9 $ E0 &#UO:&U]9M56]3T+ R(JGFJ9LQ35/]:.)^EHNN= > MP]0JKN8MG+TZN8[HL7>:(^28_2E8;EC,,5A_97)CKGP:]W"6+OKT1/4KIK'5 MHK\=)W+3,S/ADV)B(C^KRU+5.K[OS&N]G$HPB_%'T5<2MP)>SM5F-OC MJBKIB/IHC[F18.OBB8Z)\]5(,[HJZ0,2OLU[8S[G\JU;[U8J[E^Q(6]M,3'KVZ9Z-8\VI5LW9_+7/=]GGO]S-2_Z#*GV6:OU' MW,U+_P OR_[FK]3T'JHHJ^^IIGVP^?)6O^71_99XVVJY;/\ [?9C_EJ/\G=] MWGW&EZE,\1@97/AQY*>7>Q=I;FRJIIQ]"U"Y,3$3Q8J\_@OR/$[:W>2U';]G MJ-FZ.6Y/8H[C]%^_[]413M74XY\]5F8CYV=PN@GI$R:8JG3,>S3,_P#B9-,3 M'CYOD^E<4:US;+&U>K33';YLU&SN&CCJF>SR5?T[JV[BNS15G:WIUBF9]]33 M%554=_LX;;HW5MV_8N17JFMYN93YZ+=$6_I[TYB.O;2YE=_N:=$1'W;=O)L' M1^37IF6@:)T.='VE44]G0Z,NY3/,7,FN:ZOHXCZ&ZZ?IFG:?3-.!@8N)$QQ/ MD;5-'/S0[0BKV*OW]]VN:NF9EOV[%JUZE,1T0 -=E !PYV7BX.+ M7E9F1:Q[%$7JGLV*9],3XU>:>[ MN;N"R_$XVK@V*)GPCIEK8C%V<-3K=JT3/G9>+@XM>5F9%K'L41S5IW;U'/- M-BB>S:H]E,?IY:XO&7;(6K6E>*GA3S1Q><]RLXS:"Y7K38C2.?E^S8=Y;TW) MNW+G(US4[V1'/--F)[-JCOYXBF.[SM>!<+=JBU3%%$:1')"OUUU5U<*J=9 ' MMX !WM&TC5-9S*,32L#(S+]<\4T6:)JF93!LSJ[[@U"FB_N+-M:39 MGO\ )41Y2[QQSX>$>R9Y:.,S+"X.-;U<1\.7LXVUA\'?Q,Z6Z=?#M0BV7:^P M]V;DKB-(T3+O43,1-VJB:;=//AS5/="V.T.B'8^W*::K6DT9V1$=][,_=)Y\ M_=/=QZN&]VZ*+=NFW;HIHHICBFFF.(B/1$*GC-LZ8W8:WK\:O*/-.X?9R9WW MJNJ//[*S[6ZM^K9$47=PZQ8PJ9CF;6/'E*XGT3/WOS2D_;G0=L'2:8F]I]S4 MKO=[[*N3,1,>>(CC]*2Q6<5G^88GUKDQ'-&[P35C*L)9XJ-9^.]TM+TC2]+H M[&FZ=B8<<<3Y&S31S[>([W='2U_+^Y^@ZAG\\>YL6Y>Y]'9IF?T(J.%O=K^=72>_[MI 4!:P 'Q?LV;]J;5^U;NVZO&BNF*HGY):KKW1KL?6N9 MS=NX45S3V8KM4>3FGV=GB/H;:,MJ_=LSPK=4Q/PG1XKM47(TKB)Z4';BZN&W MLGFO1-6S,&KL]U%Z(NTS/M[IB$9;FZ!=\Z3%=S$L8^JV:8Y[6-7[Z?5%,]\K M?"Z3T(U/3-.U.SY'4L'&S+??Q3>M17QSX\<^"+]W= 6S=7BN[I<7]&R*N M./(SV[<>A1 M7?P;-&L8M/X6+]_'MHGO^5%E5-5-4TU1,54SQ,3YI6K"XW#XNGA6:XJCX?7F M0=_#7;$\&Y3,/P!LL F_JGA8RB/WQ2L8 Y$OX M M "DW3_B>X^F'<5KL\17?IN^WMVZ:_\ 4T5+ MO6SPODP-JK_C'AHYSCZ.!B;D?&0!(M M, !W] UG4]!U.WJ6D9M[#RK?AB?3'='=*Q?1GU@\+-\EI^\K5.%D3 M[V,VU'[E5/IJC\'ZNY641N8Y3A]0,QV6Q>%UJM?CI^''V>6JU MX//,/?W7/PS\>+M\TVCK:9J&#J>+3E:?EV,JS5$3%=JN*H^AV59F)B=)3,3$ MQK ^/H ,/N7=&@;.](X'*<7CI_V:-8Y^*.UIXG'V M,-'^Y5OYN7L3YJNI:?I6)5EZEF6,2Q3$S-=VN*8^E"^_^L-I&!%W#VKBSJ61 M'-,9-SWMF)[XYB/&KS3Z%>-T[IU_IY&97SW4U5>\I]E,=T>+#+ME^ MR%BUI5B9X4\T;H\Y[E;Q>T%VO\-F.#'/R_9L.\=Z[EW9E57];U2]?IF>:;,3 MV;5'?SQ%,=S7@6ZU:HM4Q11$1$R(_"NS'9MT>VJ>Z/!8+H^ZO>C:;V,O=63]U,F._W/;YILT^V?&K MZ$3F&=X3 1I>)7S9^S-R;KRXQ]#TN]D?C79C MLVZ?7-4]T)WV)U=,#&BWE;LU"K+N=U4XN-[VB/">)J\9]$\?.G73\+$T_$HQ M,'&LXUBC[VW:HBFF/DASJ-F&U>+Q&M-G\%/PX^WR6?"9%8L[[GXI[NSS8[0= M"T?0<.G$T;3<;!LQ''9M41$S[9\9^5D05BJJJN9JJG64W33%,:1&X >7T : MCTSYGN'HIW+?YX[6GW+/]Y'8_P!3;D8=:',]R]#VH6>>)RLBQ9C^\BO_ $-[ M++?I<9:HYZH\6MC:^!A[E7PGP4[7)ZLF9[JZ'-*HF>:L:Y?LS_>U51]%4*;+ M3]3W,\KL#5,*:N9L:E-<1Z*:[='Z:9="VNM\/+^%S51/C'U5+9^O@XO3GB?/ MZ)L Y>F?YM,S^AY\53-54U M53,S,\S,^==[IRU#[F]$FX\CM=F:\.;$=_\ S9BW_J4@=#V*M:6;MSGF([(^ MZI;25ZW**.:->W_H 756@ !:7J=X?D]BZMG3'$W]1\G'KBBW1/UURJTN/U8\ M&TRY5'%65=O7YC_^R:8^BF%7VNN<#+^#SU1'C/T3>S]'"Q>O-$^7U28 MY>NX M "N/7,T_C)VYJE-/WU%_'KGV M3353]=2O2VG6UT[W7T86\VF/?8.?:N3/'X-4543'SU4_,J6ZMLK>])EM,?IF M8[]?JHN>6^!C*IY])^GT %B0X #,;9W/KVV\N,G1-4R,.N)[XHJ][5Z> M8\$S[-ZQ^=9BC'W1I5&3'/?D8L]BKQ\]/AW>I CL;E6$QL?[U$3//Q3VMS# M8[$8;V=6D<>2=P^T?)>HZX\I\UXQ6[;'63R[=--O<6AT7^(XF[BU]FJ9]/9GN27MSIJV M#K$13.K>X+O$>\RJ)H[Y\T3YU:Q.0YAAO7MS,<\;_#ZIFQFF$O>K7'7N\4C# MJ:=J>G:C1V\#.QLJ..?W*[%7U.VB9B8G26_$Q.^ !\?0 =# M5=:TC2[=5S4=2Q,6FB.9\K=BF>/9XH]W+T[;$TF*Z,7+O:I>ICF*<:B>S5_6 MGNAM8? XC$SI9HFKHA@O8FS9C_U-V_=MVK<>-5=44Q'RRK%N MCK':]E37:T#2\;3[/35LC;W;M49U6J95 M/,>2Q([7$Q/$Q-7A$H6WIU@-UZM-5G1*+>C8_A%5'O[L]_=/,^'R(>%JP6S& M!PN^:>'///EQ>*#Q.=8J]NB>#'P\^-V=1S\W4JW\W+V-S"X&_BITMQNY^1 M!NT]K:]NG/IPM#TZ]EW)F(JJICBBCOXYJJ\(CO6%Z.NKWI>!%O-W=D1J.1W5 M1BVIF+-/JJGQJ\\>A,VAZ/I>B8%&#I.#8PL:B.ZBU1QSYN9\\SZY=Y0[L\W7T[!P].P[>'@8MG%Q[<<46[5$4TQ M\D.P"KS,S.LIR(TW0 /@ (.ZXN9Y/9>CX$5<3?U";O'IBBW5'^N$XJU M=L;=T[G]YQ[UZ8_GU4T_P#MRG=FK?I,RM_#6>R)1F>N1JGE=Q:'HU-7=C8M>15$>FY5V M8Y_N_I0,ZQLO8]%EU$_JUGO\H4/.[OI,95\-( %@1( OCT8:?\ W''X@ENBFW;IH MHB*::8B(B/-$*+MK>_#:M=,_3S6C9JWON5]$/T!05J M M :ITOZ7]V.C#<.!%/:JJP:[E$>FJW[^F/GIA1=Z(W**+E MNJW58 =G!U#/P*^W@YN3C5>FU=FCG MYI;EH?2[O_2.Q%G7KU^W1'$6\B(N4M$&"]A;%^-+M$5=,1++;OW+7J53'1*; M]'ZR&YL>CLZCI.!FSW>_IF;<_-'G1,Q]F_;SG&4?GUZ8A<3 Z=^CW*JBFK/R<>9_P";CS$?.V#%Z3MA M9-44V=TZ=-4^$37QY^%&Q'7-C,'/J5U1V3]&Y1M%B(]:F)[?-?[&W+M[(M^4 MLZWIU=/'//NBF//QZ7:MZIIMWCR>H8E?,$TUS#5JV)I_+>_P#7[L].TM7+;[_L]"*,K&KJ[-&19JGT17$R^^W1 M^/3\[SZHU34[=7:HU',IJ],7ZHGZW)]V]9_\WU#_ !-?ZV*=B:N2]_Z_=DC: M6/\ 'W_9?SW9B?\ 56/[R'#;% M5M)=GU:(_?8N)G]._1[BS--.H9.1,>'DL>9B?E:QJ?63T*W%=.GZ%G7ZOP:J MZZ::9]L>*L0WK6R.7T>MK5TSY:-:O/\ %U<6D=$>>J;=9ZQ^Z,BGLZ;I>!@S MS]]/-R9CV3W-)USI7W[J_E*I:CLU\=6 MC=S'%7?6N3X>#GR\O+R[GE,O)O9%?XURN:I^EP D8B(C2&G,Z@#Z^ M Y<3&R,O(IQ\6SCOJ_Z]J]5O,W-_R/'-^ MJ/1Q^#X>?TM/&9AA\%1PK]<1XST0V=O"_.!CSQ5&):F)NUQW=U4^%/UIYV5L?;.T M,:+.AZ;:LUS'%=^KWUVOVU3^AL:BYEM=>NZT86.#'//'Y1WK/@L@MV_Q7YX4 M\W)]V'VKMC0ML8,8>AZ;8P[?$=J:*??5^NJKQEF 4^NNJY5-5@ !4?K8YONKI6]S\]V'@6;/'MFJO_ %K<*1=.^;[OZ7=Q MW^>>QE>0_NZ8M_Z5LV.M<+&U5>?-I+?\ J[YON+IBT&N9 MXINW+EFKU]NU73'TS#0&;V#F_<[?.A9\SQ&/J./*_ #B+I8 #H[@U*SH^@Y^K9'[UA8US M(KCTQ13-7'T/5-,U3%,<EO7+U%7$[?A;$8>S1:C\L1'8YG? MNS=N55SRS,@#.Q )"ZNFE_=3I>T:FJB:K>+57E5^KL43-,_VNRNBK5U-M)\ MIK.O:Y71W6,>WBVZI]-=7:JX_L4_.LJY=M;B/2X_@?IB(^OU7?(+7 PG"_5, MS]/H *PFP M !3OK/Z1]R^EK-OTT]F MUJ-BUE4<1W<\=BK_ #43/RKB(#ZXVB^5T31-P6Z8YQ[]>+=F([YBN.U3SZHF MBK^TL>RN)]#F%-,\543'UCOA#YY9])A)G]._Z?56@!U510 !RX==JWEV;E^U MY:S3.W3$]\<^;F'$/DQK&C[&Y-'2!T%:ABX=.N;+O5:OI=ZB+UNQ/ M[]315WT\?CQQ,>'>AJ_:NV+M5J];KMW*9XJIJCB8^1<;JU:]]V^BG M7*^U? MTVJK"N>RGB:/\E5,?(S'2!T:[6WG9JG4L&+6;QQ1F6([-R)[_'\:/:HV'VFN MX*_5AL;'"BF=.%''UQR_OC6>[DM&)M1>PTZ:QKIR*/"4^D7H1W3MFJ[E:?;G M6--IYF+MBG]THI[_ +ZCQCNCOF.Y%URBNW7-NY15173/$TU1Q,+CA<98Q='# MLU15'[X^97K^'NV*N#>WQMX;!7\3.ENG7X\G:@S!Q,K.R:,;#Q[N1>KGB MFBW3-4S\D)BZ/NK]N#5YHR]RW?N-B3W^2X[5^KQ\WA3X>?TK$;-V1MG:6-3: MT32[-FY$<57ZH[5VKNXGFJ>_OX\(XAL2DYAMA=N:T86G@QSSOGRCO63";/6Z M/Q7YUGFCB_?8UG9.P]K[/QXHT33+=N]QQ5DW/?WJO'QJGP\?-PV8%0NWKEZJ M:[DS,SRRL%NW3;IX-$:0 ,;V //W<^;]TMRZIJ///NK,O7^ M?3VJYJ_2O7O3/^Y>SM9U+GB<7 OWHGUTT53'U*!K[L3:W7KG1'C]E6VDK]G1 MTR/VF9IJBJF9B8GF)CS/P7M5GH/H>9&H:+@ZA$Q,9./;O1Q_*IB?TNXTWH/S M_NCT2[;R.USV<*FQS^2F;?\ H;DX=B;7HKU=OFF8[)=-L5^DMTU\\1( P,H M BKK2ZY]R>BR_A45\7M4R*,:GB>_L1,UUS[.*.S/\ .2JJMUNM M?]W[XP]"M5\VM+QNU7'HNW??3_EBCYY3FSF%_B*G\4]7WT1F;W_ $.$ MJGEG=V_9"H#KB@ .3%L7^\:W759T M;[F=%-C+KHFF[J63S/-O"Q;>/3/ MI[%,1S\O'+(.)8_$?Q.)N7OU3,]7)W.DX6SZ&S3;YH@ :C8 M M &H=,VA3N'HQUS3:*)KO>YIOV8B.^;EN>W3$>N>S MQ\K;R8B8F)CF)9;%ZJQ=IN4\=,Q/8QW;<7*)HGBF-'G8-DZ3]!G;/2!K.BQ1 MV+5C*JFQ'_I5>^H_RU0UMV^S=INVZ;E/%,:]KFERB;=4T5<<;@!D> $V]43 M.=MV]M5Q^%35',3\TN;;88/T M6)IOQQ5QWQ]M%RV>Q'#L3:GCI\)^[L-,WWT8[1W?17H8.9I^35C9V+>QKU$S%5%VB:9B8\?%Z%L3N3;.@;B MQIQ];TK%SJ)B(YN4>^CCT51WQ\ZV8#;&_;TIQ-/"CGC=/E/<@<5L]:KWV9X, M\T[X\_%0(6;WAU<=+R>W>VSJUS"N3/=9RH[=OQ_&B.8]G$H'LE;L'GV!Q>ZBO2>:=T_OH5_$97BL/ZU.L<\;V MCCZNV[EJN;=VBJBN/&FJ.)A\IA'@ _:8FJ8B(F9GP MB&S[7Z/]W[DJI^Y.AY5VW55V?+5T]BW3/KJGNABNWK=FGA7*HB/C.CW;MUW) MTHC6?@U=^TQ-4Q%,3,SX1"?]I=6[-NQ1>W+K-O'B8B9L8M/;J]=,U3W1[8Y2 M_M+HMV1MJFF<+1;-^_'_ (^7$7:Y[^?/''=ZH5W&;68&QK%O6N?AQ=L_35,8 M?(<3=WU_ACX\?8JILWHOWGNF:*]/TB[:QJI_[QD1Y.WX\3WSX\>B$V[(ZNNC M8%5.1N?/KU.[$\^0LKN3D*ECMJ<;B=8HG@1\./M\M$]ALCPUG M?5'"GX\78Q^A:)I.A85.'H^GX^%8IB([-JCCGCPYGQGY60!7:JIJG6J=93$1 M%,:0 /+Z C[K%:A]S^A[7*J:N*[]%O'I]?;N4Q/^7M* M6K1]NF?D5<=/V0L\# <+]54SX1]%)V M@N<+%<'FB/, 6E!K;]4W4/=?17.+-7,X.?=LQ'HB>S<^NN4N*Z=3/4O?[BT> MNKQBSDVZ?[5-<_F+%N0;06?19C=CGG7MWN@Y3<])@Z)^&G9N $,D0 M '%FY-G#P[^9DUQ;L6+=5RY7/A333$S,_-"@V[]:O;BW1J6N9',5YN37> M[,SSV*9GWM/R1Q'R+5=9_O\ ?> +HK8 D+J[:#.N]*^E4UT M=JQ@3.==]7D^^G_/-"/5E^IWH'D=%UCIQ+$S'X%$=JJ8]4S5$?U$ M/GV+_AWO(ZMI&Y[-'O,BW.)D3'X]/-5$SZYB:H_JH!7 M?Z;=M_LHZ--6T^W1V\JU;]TXT1',^4M^^B(].B=. MKCCRZE'SW#^BQ/#CBJW^?[^( LR% %LNJENC[L;"N:'D7.UE:/<\G3S/?-F MOFJB?DGM4^R(5-;]T![KC:?2/@Y-^[V,',_W3+F9[HHKF.*I_FU13//HY0NT M& _C<#53$?BC?'3'G"2RG%?PV)IJGBG=/6NJ Y"Z U_KU*ICO_?:\[:Z:J*IIKIFF8\TQP_%]M5V;M35*:J<[;VFWIJ^^J]ST MTU3_ %HB):CJW09T>9W'8TN_A<1$?[M?F.?[7*9L[9X:KVEN8Z-)\D?:FXM!J?5LV_>JYP->SL6.?"Y:IN?IAKVH]6G4J9G[G;CQ+D>;R]JJG MZHE(V]J,MKXZ].F)\FG7DF,I_+KUP@ 31D]7+>%OCR6HZ7>YGO[-=4Z ^D2BF)HP<2[//A3ET1Q\\PVZ<]RZKBO0P3EF+C^W*+!)T]!'21%,S]R,? MN_\ K+7Z*GS1T%=(]4S'W(L1QZ/_ ^S:_7Z MVSZ3T)]'>!3$5:+.95''%61>JF>[V<-*[M?@*/5BJ>KSEM4;/XJKUM(ZU,[= MNNY5V;=%5=7HICF6;T39VZ=9Y^Y>@ZAE1$\3-%BJ8CVKNZ7M3;.F4VXP-!TV MQ-ONIJIQZ>U']:8Y^EF8B(CB(XB$7?VUGBM6NV?I'FW;6SNZUE9D]GWUO'IBW$3ZJIYF8 M^1.PA,1M1F-[=%?!CX1]=\]Z2LY)A+?'3KT_O1JFV^CC96@41]S]OX?E(B(F MY>H\I5/'G]]SQ/LX;7$13$1$1$1W1$ @[MZY>JX5RJ9GXSJD[=NBW&E$:1\ M!C>P &$WSN3!VGM;-UW4*H\GC6YFBCGB;M<_>T1 MZYGN^E[MVZKM<441K,[H>:ZZ:*9JJG="MG6VUVG4>D'&T>U7VK>E8L4UQZ+M MSWU7^7R:&G%HL?IC MOY>]SC%W_P"(O57.>0!N-9)75JUZC0^E? IO7(MV-1HJPJYGPYKXFCYZZ:8^ M5B/?=WHGQCU2H&V6 JBNG%4QNXI^BV;.XJ.#58GCXX^K;0%&68 M !KG29N:UM'8^IZ[7-/E;%J:<>F?P[U7=1'LYF.?5$LEJU5>KBW1&^9 MTAXN5TVZ9KJXH5BZSFZ8W!TCW<#'N]O#T>GW+1Q/=-WGF[/MYXI_J(L?>1>N MY%^Y?OW*KEVY5-===4\S55,\S,OAVO!86G"8>BS3Q4QI^^ES?$7YOW:KE7+( M V6 !^T4U5UQ113-554\1$1WS*^/1KMZC:VQ=)T.FF*;F/CT^6X\]VKWUR? M[4RJ?U>-M_LCZ4-.INT=K%T^?=M_N[N*)CL1\MJF>U3_ %5WT'];C:WW0VKA M[HQK?-_3+GDLB8COFS7/$3/\VOC^W*R;+8[^&QL453NKW=?)Y=:&SS"^FPTU M1QT[^KE\^I5P!U11@ %U.@+=W[+NCK#OW[DUY^#_NF7,SS-55,1Q7/\ZF8 MGV\^AOZGG5LWC^QC?UO"RKO8T[5^SC7N9[J;G/[G7\\\>RJ?0N&Y'M#EW\%C M*HIC\-6^/K'5/=HO^48O^)P\3/'&Z0!!I, M F8B.9 '0R]:TC$IJJR=4PK,4QS/;OTQQ'SM9U7I6V M!IU%4WMR8=RJGQHLSVZOFAGM86]>]G1,]$3+%7>MV_7JB.F6ZB&]8ZQ.S,7_ M +ABZAJ$^JWY/\YH&Y^L;N'+HKLZ'IF+IU,S,1=N3Y2OCCT>$2EOCNFKZO-YVI;@UW5]?SJLW6=0R,V_/X M5VKGCV1X1\C'+QDNSEK+Y]+6ET9NBYM%RKL\W;%4\7;4^>*J?T^#8WGQH^J:CH^=1G:7FW\/ M)HGWMRU7-,^GY8]27-J=8?=&G6J+&LX>-JU%,13Y3][N<>F9CNF?F<_S#8^_ M15-6%GA1S3NGRGN6O";0VZHTOQI//'%YK5B%M&ZQFTLF8IU' U# GN[^S%R. M?D;?I/2[T?:C1%5O<6/8F?PA MCL'7M$S;=->)JV#>IJ^][-^GO^ED*:HJIBJF8F)\)B6A53-,Z3&C;B8F-8?H M#R^@ "L?6XW=[MUW$VAB7.;.!$9&7Q/C>JCWM/]6F>?Z_J6#WQN'$VMM34 M-?S.)MXEF:J:.>/*5SW441[:IB/E4/UC4,O5M5RM3SKLWJJ9F M?K7'9#+O2WYQ54;J=T=,^4>,*]M!B_1VHL4\=7'T?=U0'1U. 93:6BY.XM MS:?H>)$^6S;]-J)B.>S$S[ZKV1',_(\UUTT4S55.D0]4TS5,4QQRLQU3-L3I M>R,C<&1;B,C5[O[GS'?%FW,TT_/5VY]<=E,[JZ/I^+I6DXFF85N+>-B6:;-J MF/-33'$.TXKF&+G&8FN_/+/=R=SI&$P\8>S3:CDC_L :;8 M M '3UO3<76-'S-*SJ.WC9=FJS=I]--43$_+WNX M/M-4TS$QQP^3$3&DO/\ W3HV7M[<>?HF=3--_#OU6JN8X[41/=5'JF.)CU2Q MBPO6[V?-&1A;SP[7O;D1B9W9C\*.?)US[8YIF?53"O3L^58Z,=A:+T<<\?3R MN=8["SA;]5ODY.CD $@TP ")F)B8GB8\)72Z ]YQO'86/]JME;XL9-^Y,:9F<8^=3YHHF>ZOVTSW^SGTH': M'+/X_"3P8_'3OCZQU^.B4RC&_P +?CA>K.Z?-=Q--?,>'AW0JOJ.]MWYU,W&L_S[M-/URPVI;XVAIT\9NX MM.LSZ[T3]2BN3G9N3/.3F9%Z?3%,Q.N4Y''_ $]N:VNZGUBMFX\S&%B:CF^B8MQ1^N/I#5KVAQ57%$1U?=8O4^LO3S/W-VS,QYO=%_C\UK>I]8S>%^OG!P=-P MZ>?":)N?7,(8&_;V;XROCK\(2%J?31TB9M7:^[M6-ZL> MW%,?I:UJ.\=U:A*OW/6KF> MN7W>O7KU4UWKM=RJ?/75,S]+X!MM< !]6KERU7%=JY515'?$ MTSQ++Z?NO*[=%R-*XUZ7JFNJF=:9T;_IW3 M)TB8=<5?LANY$1Q[V_135#9--ZQ.]+%4>[,;3LRF/-Y.:)^>$.#0N9-@+GK6 M:>S3P;=&8XJCBN3VK#Z;UE[G:C[H[9IBGTX]_O\ I;)IO6-VAD5<9FGZEAQZ M9IBOZE5!'W-ELMKXJ)CHF?KJVJ,\QE/'5KTQ"YNG]-O1WF5]F-:JL>N_9JHC MZ6Q:=OW9NH5]C#W+IMZKT1>B/K40&AM3$]L>:< M^M9OFWJNK8VU-,R8N8>%Q?RJ[=7--R[5'O8YCQBFF?GJ]2# 67+\%1@IXVG85J;N3E7:;-FB/&JJJ>(CYY7OV)MW&VKM'3M!Q>S-.)9 MBFNN(X\I*GQY/-FP M',5U M 8C>6@XNYMK:AH. M;^\YEF;?:X^\J\::H]<51$_(HAKNEYFBZSEZ3J%J;65B7:K5VF?3$\=WJGQB M?1+T&5QZW&RYHOXV]L&U[VYV<;/BF/PHY\G@OSAJY_# M7Q=/W\E?S_!^EM1>IXZ>/H^WFKT Z2IH "U?5;WY]W-N5;6U&]SJ.ET1Y" MJJ>^[C^$?+1W1[)I]::% =HZ_G[8W'A:YIM?9R,6Y%<1/A7'X5,^J8YCY5Y] MF[AP-T[:PM=TVOM6,JWVNS,]]%7A51/KB>8M&K0S>KQL6]%W5A[HOTS^#3TSVZ:I_R\?2M&-^WM/F5']S7IB/)JUY)@ZOR MZ=BF>V/JU*]G?AQ^+=HIN_3W)*UM?@*_6X5/3'E,M.YL_BZ>+2>OS5>$Y: MQU;MQ6(N5Z9K.!ETQ]Y17%5%=7T<1\[0=T=%N^-NVJ[VH:%?JL44]JN]8XNT M4QZYIYX2N'SG XB=+=V->SQT:%W+L5:WUT3X^#2Q^U4U4U335$TU1/$Q,=\/ MQ)M( "(YGB&U[5Z.=Y;EBFO2M#R:[-4S$7KE/D[?/\ .GN8KU^W9IX5 MRJ*8^,Z,ENU7SB.)^=N.E M=6O0K57:U'7\W*C\6U:BW]/,_4AKVTN6VMWI->B)G[)&WDV,K_)ITS"L1'?X M+CZ3T%]'F!$^4TW(SN[CG)OS/YO9;/IFP-EZ=;\GB[9TR*?_ %+$7/SN4;=V MSPM/J453V1]9;E&SE^?6JB.V?)1FQ@YM_CR.)?NKCY^%YL3#Q,.CL8F+8QZ/Q;5N*8^ASHZ[MK=GV=J(Z9U\FY1L MW1'KW)ZH_P"U-L#H.Z1>K:HR#"4\>L]?DKWA=6C&BB*L[=-R)C[Z+6 M-$QQW^>:H09OK%T/!W1F8.W2HR+DQS=JCNJJCC\'GP]4<^=9CK, M=($;;VW^Q[3;_9U;4Z)IKFFKWUBQ/,55>J:N^(^6?,J6M>SES'8JW.)Q5/;7ZEG&%V+MW$VIM3 T'#B.QBVHIKKB./*5SWU5S[9YEFG',XS"MT/+L)&%L1;Y>.>D 1;> M M '0W'I&%KVA9NC:C;\IBYEJ;5R//$3YX]<3Q,>N'?'JFJ:*HJIG2 M8?*J8JC2>)03>>WLW:VY\[0=0I_=\2[-/:B.(N4^--<>J8XGY6'6FZU&Q/NQ MH%.[=.L=K/TVCLY44QWW,?OGGVT3//LF?0JR[#DV94YAA:;OYN*>G[\;GF8X M.<)?FCDY.@ 2K1 $L]6_I$_8GN/[C:I?[&BZE7$555>%B]X4U^J)[HGY)\R M)AJXS"6\99JLW(W3^]6?#8BO#W(N4<8$*=67I(^[VE1M36[?MXU M&F:K,G\&YQ][,_BU<<3\D^9:,AV@NX M.Y%J].MN>?D^,?#X(3-,IHQ%$W+<:5^*D0^[]JY8O5V;U%5NY;JFFNBJ.)IF M)XF)CTOAU!20 ?!D]L:#JFY-;Q]'T?%JR$1YZJI\T1YY8Q<7J\; MM;0VE;U#,L\:SJ=NFYD35'?:HGOIM1Z.[B9]?LA$9UFM.6X?A\=4[HCX^4)# M+<#.,N\'DCC<71?T*[8')\5C+V+N3'HX%N-( &LS #"[WW+I^T] ML9FNZE7Q9QZ/>T1/OKM<_>T1ZYG];,7*Z+=NJYKVRF+]_!I.[MP:AN?<69KFJ7>WDY5?:F/-13^#3'JB.(8D'7:**;= M,44QI$*!55-4S5/'( ]/( L7U2MCS'EM\:A9\8JQ].BJ/DN7(^FF/ZR%^C? M:F9O/=^'H6)S33=J[61=X[K5J/OJOF[H],S$+S:/I^)I.E8NF8%J+.+BVJ;5 MJB/-33'$*?M9FGH+/\+1/XJN/X1]_#58;V#7/FIY]];]M,SQ[)B?.NJU'I9V5 MB[XV?D:3<[%&71^ZX5Z8_>[L1/']6?"?5/JA.Y!FLY?B=:I_!5NGSZO#5&9K M@?XNSN]:.+RZU&AV-2PLK3=0R-/SK%=C*Q[E5J[;KCB::HGB8^AUW6HF)C6% M!F)B=) 'U\ =K2-1S=)U3&U/3LBO'R\:Y%RU MUZ,VW-%K4;$1;S[]3V5N6QK.FU=J*9[-^Q5/ M%%^WYZ9_1/FE!9[D].8V?P^O3Q3].ON2F5YC.#N;_5GC\U\1A]F[CTS=6WL; M6])O>4Q[]/?$_?6ZO/35Z)AF')ZZ*K=4T5QI,+Y35%=,54SK$@#P] M #0^L'F^X>AW<%V)XJN6:+,>OMW*:)^B M9;XA_K;YWN;HOLXL5=^7J-JW,>FFFFNOZZ:?G2.46O2XZS3_ ,H[IU:>85\# M"W)^$HJZI>;&-TIUX\U<1EZ==M1'IF*J*_JHE;52;H!SO<'2_MZ],\17D56) M]?E**J(^FJ%V4UMA:X..BKGICQF$;L]7PL--/-( JB> 4]ZSNW:=#Z4,C M*L413CZK:IS*8B.(BN9FFN/;-5,U?UD7+,=-1/Y2J:J MOLZ?G66HJU[,HGL<=\XU$_\ B3'I_%Y]OF;.#PEW&7HLVHUF?WJPXC$48>W- MRN=T-,ZSW2;$47MCZ%?GM3W:G?HJ\(_Y,?ZOF]*NCZNW+EZ[7=NUU7+E=4U5 MUU3S-4SXS,^>7R[!EN76\OL19M]<\\\[GV,Q=>+NSSN/<$;EU.S,Z5IEV)MTU4]U^_'$Q3ZXI[IGY(]+4QV,MX.Q5>N<4=_P M;&&P]>)NQ;HXY3!U=-@_L0VE&?J%GLZQJ=--R_%4=]FWXT6_5/GGUSQYDH@X MWB\5F/9+H6RF<^DI_@[L[X]7XQS=7)\.A4L]R[@3_$6XW3 MQ^:-0%V5H !OG0STC9VPM?[J?_$H M_33Y_-W^-3VBR#^,I_B+$?[D<1C7Z(KM7;=7:IKIGPF),W[]<<^CLTT_74L.J/UKM6IU#I2G M"MU\TZ=AV[%4<]T5UW.!@ZHYYB/K]$ M;;4SON7NC2M2FKL^Y,VS?Y]'8KBK]#T!>=B^O1WJU&N;%T35:;G;G(PK55<\ M_AQ3$5Q\E43":VUL[K5V/C'UCZHW9JYON4=$L\ H2U (UZS6GQG=#VJ7( MI[5>),1Y*=M';TOTU\\>$@"X*\M=U0]/]S='&9G51[_,U&N8G^11113' MT]I,K1>@# ^Y_0_M^S,<3[%MT_" !'-P !J/2EOS2]B;>KU#,F+V77$TXF)%7%5ZO]%,>>?TLMBS)XN7*;5$UUSI$.ITQ=(6!L/;M5^:J+VJ9$33A8W/?-7'W]4?BQY_F4 MQUO5,[6=6R=4U+(KR,O)N399C5C+F[=3'%'U $VC M ')C6+V3DV\;'M5W;UVN*+=%$*KM7:O79CWMFW'WU<^SZ9XA>+:VAZ?MO0,31-+L^2Q<6W%%$>>J?/5/IF9 MYF?:T_H,Z/+.Q=L1[IHMUZSFQ%>9=CO['HM1/HI^F>?4D)RO:/./X^]Z.W/^ MW3Q?&>?R^Z\Y/EW\+;X=F[KVWE:'JEJ*[&13W51'OK=UT^B8 MG]7G9@>[=RJW5%=$Z3#S53%=,TU1K$J%;\VKJ>SMRY.B:I1^Z6IYMW:8][>M MS][73ZI^B>88%=CIFZ/Y-N[;KCB::H\8=9R+.*7U8.YN]6> M+R=8!.(P !*O05TL9.R\RG2-7KN9&W[]??'WU6+5,]]=$?B^FGY8[_ !MM MIN;B:E@6<_ R+>3BWZ(KM7;=7--=,^$Q+ST29T*=*VH;&S*=/S9KRM!O5\W+ M/C58F?&NC],>?V^-1V@V=C%:XC#Q^/ECG^_BL&4YO-C2U>G\/)/-]EQQT=!U M?3MC;8TVG4='C57(M4UU_A5S$S$1Z^*9G MY&A9W3WT?8\5>2S,O(JCPBWC5<3\LMO#Y?BL1&MJW-4<\1.G:U[N+L69TN5Q M$]*4Q!6=UE- HBJ,/0=0NU>::ZZ:8GZ6M:AUE=9N433@[>P[,^:JY>JJX^3A M)6MFLRN?V].F8CZZM.O.<%1^?7HB5FA3_4^GKI S*9IMY>'B1/A-FQ$3'RS, MM4UCI"WKJT<9VY-0N1QQQ3<[$$C9V-QE7KUTQVS]/JT[FT6'CU:9GN6N MZ4>E'0-E:7=GW1:S=5JHGW/AVJXF9J\(FJ8^]I]/L4SUC4,O5M5RM3S[LWLK M*NU7KM<^>JJ>9^MUJZZJZYKKJFJJJ>9F9YF9?BXY/DMG+*)BF=:IXY\N:%>S M#,KF-JCA1I$<4";NKETK8VVJ)VON&]Y/2[ER:\;)J\,>JKQIJ]%$SW\^:9GT MH1&[C\#:QUF;-V-T]T\\-?"XJYA;D7+?&]#<++QKR:8CCL MY%NFJ/T*/?V+Q$3_ +5R)CXZQYK-:VCM3'^Y1,=&_P ETA573.L;NZQ5_O\ MIVFYD>BFF;?U3+9=+ZR]B9_[3VS=ICTX]^*OSN$9=V6S*CBHUZ)CZZ-VC/,' M5QU:=,2L*(=TSK$;)R)B,RQJ.%_.M=O\UM>V.E;8^X=0L:?INL1.5?J[%JU= MMS1555Z(Y1U[*<=9B9KM51$?#/PUR=*;D=K=JZ*:Z*J*XYIJCB8],//? M5\.K3]6S,"OGM8U^NS//IIJF/T/0E1KIFP8T_I5W)C13V8G/N78CT1YB+D6K4:U2QW;M%FB:ZYTB':Z3M^:/L70ZLW4+D7,NY$QBXM,^_O51 M]41W:''N_:9_!]7?YX:7 MU=NB^=UZE&X-:LS]Q,2Y[RW/=[JN1W]G^;'G]/AZ>+94TTTTQ33$4TQ'$1$= MT0HVU&><&)P=B=_YI^GGV+/D>6:S&(NQNY(^OD_0% 6L M M 1%UA.BVG=NG5:]HMB(UW%H M]]13''NJW'X,_P J/-\WH2Z-K!8R[@[T7K4Z3'?\)8,3AZ,1;FW7&Z7G=1N_;>/3&=13-S/QJ(_?XCOFY M3'X\>>//[?&LDQ,3Q,<3#KN5YG:S&S%VWQ\LUCU59.EWJH]U8=57O:OY5/XM7'G\_A/FXM_LC=FC;PT2 MWJNC95-VW/=T-8IU/1,N;-SNBY;GOMW:?Q: MJ?/"MYWL];S")N6_PW.Z>GS3.69M7A)X%>^CPZ/)?8:#T4=*.A[[PXM6ZJ<+ M5J*.;V%77W^N:)_"I_7'+?G,L1AKN&N3;NTZ3"Z6;U%ZB*[>* MI^=I&I]!G1WF4\6]+OX?=QSCY%7/^;E)8VK&-Q.'C2U-R*;O_P 6MZIU:,ZF/^S-RXUV>/\ ^19JM^G\ M7M>I9(2-K:/,K?%=UZ8B?HTZ\GP=?Y.S6%1]6ZOF_,2J8Q*<#4(]-K(BC\_A MJ>L=&6^]*FOW5MK4)HHY[5RU:FY1''\JGN7D$C9VQQM'KTTU=4Q]?HU+FSV& MJ]69AYWWK5RSB5RR;.[69T M3I'!JCCCZPKN8Y;7@JHUG6)XI=($[=6OHLPM?QZMV;CQ_+X-%R:,+&J^]NU4 MS[ZNKTTQ/=$>>8GGP[]W,,?:P%B;UWBCOGF:V$PM>*NQ;HXT0:'MC<6MS,:1 MHN?F\1S,V;%57>_?HHF/;$SRN-BX]C%QZ,?&LV[ M%FW'9HMVZ8IIICT1$=T.11;^V>)JG_:HB(^.L^2SVMG+,>O5,]WFJ[IW5MW- M=FFK-UG3,>F?&*9KJJC_ "\?2V7 ZM&F4335F[FR;L<=]-O&BGO]O:GZD^B- MN[3YE<_N:=$1Y-VC)<'1^37IF42X/5\V%CU15=^Z>3,>,7,B.S/S4\_2VK0. MC'8VAZA8U#3- LV M^FB(ZA3_ *TV%[EZ7LR_Q_WO%L7OFH\G_H7 5BZY&%V-U:'J''[_ (-=GG^9 M.@7"]W]+^W;''/8R9O?W M=%5?^EHZ6^J=A>Z>E?R_'/N3 O7N?1S--'^MT+-KGHL#=J_XSX*E@*.'B;=/ MQA;@!Q=T<'Y75311-==44TTQS,S/$1"O_3/TZV\?RVA;*O1R_+K^/N^CLQTSR1TM7%XRUA:.'IU;]V[ M?O5W[]RN[=N5357775,U53/C,S/C+X=3RG)K&6V]*-]4\<_OBCX*/C\QNXRK M6K=')'[Y0!+H\ 2!T*]'&7OS7OW;REC1L6J)S+\=TSZ**?Y4_1'>Z'11L M#5-^;@IP\6FJS@6:HJS,N8][:H]$>FJ?-'Z%S]JZ!I>V="Q]&T?&BQB6*>*8 M\9JGSU53YZI\\JOM#GT8&CT-F?\ ;M3F497.)J])R[,+V O1=M3TQR3'-+5Q>$MXJW-NO\ Z>=D MQ,3Q,<3 L=U@>ASROE]U;2Q?W3OKS<&W3X^FY1'UQ\L*Y51--4TU1,3$\3$^ M9UK+=^ )!J .;!R\G!R[67AW[F/D6 MJNU;N6ZIIJIGTQ*R'1!T\V,R+6C[VN46,GB*;>H1'%NY^4C\&?7X>Q6D1V8Y M7A\PM\"]&_DGEAN8/'7<)7PK<],J7TIG MT4]+FO[)N48=VJK4M'[4=K%N5=]N/3;J\WL\.[S+3[#WQMW>>G>ZM%S::ZZ8 MCRN/7[V[:F?--/S]_AW.9YKD6)RZ=:HX5'/'UYETP.:6<7&D;JN;RYVR@(1) M "I/6PTFC Z4(S;=$4TZCA6[U4Q'C73-5 MN?HHI^=;97GKF8/-C;>ITQ][5?L5S[>Q53]52Q;*WO1YC3'ZHF.[7Z(C/+?# MP=4\VD_3ZJY+[[ TFG0]D:+I--$4SC85JBOB/&OLQ-4_+5S/RJ.;0P(U3=FD M:9,W6K4?&?I'U1NS5OVE?1 H2T@ "!>N5A M]O;NW]0X_>M;CS^/WG'LV>?Y]54_^V@%:#J%N M4_"58NK]A3G],&W[7',6[]5^?5Y.W57'TTPNPJ7U2HX.%F>>0!5$Z -(Z>,/W;T0;CL\<] MG%B]_=UTU_Z6R[AU[1]OX%6=K.HX^%8I_"NUQ'/JB//*O'2UT]4:OIN=H&V, M+C#RK5S'O9>13WUVZHFF>Q3YN8GQGOCT)G)LOQ6)Q%%RS3NIF)UY-T\Z.S'% MV+-FJBY5OF)C3E0*VG W[N+3=F?L5TO+G!P:[M=V_59[KEV:N.Z:O-'$1X<> M#5AUN[9MW8B*XUTG7?SJ#1 !OW1#T9:OOS48KIBK$TB MS7$9&753W3Z::/35Q\WG9WH5Z&\_=]5O6-;B[@Z'$\T3QQ)[XIY\*?'WW MS64!S>N MNJNJ:JIUF5QIIBF(IIC2( 'EZ M M &F=*/1SH>_--BUG41CY]JF8Q\VW3';H M]4_C4\^;YN&YC-8OW,/>W$BN(\8_E1]#I&2[36L9I:O_AK[I\I^'8I MV8Y+7A]:[6^GOA% "U(( ;CL/I*W9LZY33IFHU7<./'$R.:[4QZH_!^ M1IPQ7K%N_1-%VF)CFEDMW:[57"HG25L=A]/VV-:FWC:[;G1,NKN[5=7:L3_7 M\WR\)G(Q+]J_9KCFFNW5%43\L//)GMI[QW+M>_%S1-6R<6F)YFUV MN;=7IYIGN5#'['6KFM6%JX,\T[X[>..]8,)M#-\=L?58<-F&'Q/LZM_-Q2V(!&MT 8?? M.%]T=E:YI_9[4Y.GW[41QYZK=40S#\JIIJIFFJ(FF8XF)\\/=NN:*XJCD>:J M>%3-,\JM_4RP^UJ6Y-0F/WNS8LQ/'CVJJYG\R%D4<]!71[F[ TO5,7/RL7(N M9F3%RBJQ-4Q%%-/$1/,1W]\I&2F>XNC%X^N[;G6F=-.J(:.5V*K&%IHKC2=_ MC(#YNW+=JB:[E=-%,>-54\0B$@^A'N\NF/8^V^W:KU+[HY5,3^X8?OYY]$SX M1/ME"6]NL%NC5HN8^A6;6C8T]T7(]_>F.?3/='=YN)]J:P.S^.QF^FC@QSSN M^\]4(W$YMA:-ZRVZ=U;?VSASE:WJF/AT>:FNKWU4\<\13XS*"]_=8 MNY7Y3$V?I_8B8X]V94=_MIH_7\R =1SLW4R.SEZ^Q7,5GU^[NM_ACO9'<&NZQK^?5G:UJ.1G9$\^^NU<\ M>J(\*8]4<,<"TTT4T1%-,:1"$JJFJ=9G> /3R S6S]K:WNO5J--T/!N9 M-V?OZHCBBW'XU57A$>UXN7*+=,UUSI$;YM6Z+5JFU:HIHMT1%---,<13$>$1'FA] I:R M M M #\JB*J9IJB)B8XF)\[] 0CTM]!&GZUY;5MI1:T_49[5=S$GNLWI\?>_B3X M^KO\W"M&NZ/J>AZE=T[5L*]AY5J>*K=VGB?;'ICUO05KV^-E[>WEI_N/7<&F M]-/[U?H][=M?S:OT3S'J6S*-J+V%TMXC\5'/RQYH',,CMW]:[/X:NZ?)0T2C MTH="VXMH^4SL"*M7TF._RUJC]TM1_+I\WMCF$73W3Q+H>%QEG%V_26:M8_?' MS*C?P]RQ5P+D:2 -EA 'W9NW;%VF[9N5VKE,\TUT53$Q/JF'P#ZD+:? M3)OK;_8MTZK.H8]/=Y+,CRG=_.\>?;,I:VKUD-&R>S:W%I&1@USQS=QY\K1' MKF/OOH5C$/B\@P&*WUVXB>>-WAN[4AA\UQ5C=37K'-.]>W;6_P#9^X::?N5K MV'=KF.?)55Q17'MIGOALM-5-5,54S%43X3$O.V.[P;+M_?V\="JB=-W#GVZ8 MCCL5W)N4\>CBKF(^16\3L5RX>[U51]8\DQ9VDY+M'9Y3YKW"J>@=8K=N'V:- M4P,#4J*8XYB)M53ZYF.8^AOFB=9#;61%NC5=)S\*N?OZZ.+E$>SB>?H05_9G M,;/Y.%'PF)[N/N2EK.L'<_-IT_O1. T31^E_H]U/]ZW%CV)YXB,F)M3/]IM> M!KFC9]NFYAZIA7Z:O":+U,\_2B+V$OV?:433TQ,)"W?M7?4JB>B60'Y3535' M--451Z8E^M=E ?%V]9LQS=NV[<>FJJ(!]C!ZKO#:VE_\0U_3L;^? M?I_6T[6.G3H^T_MTV]2NYMRGPIQ[-543[*O!MVB):]S%V+7KUQ M'6DT5\UOK+8U,S3HVV[MS^5E7HH^7BGEH&O].^_M2YIQ\S'TVCGN]S6H[7RS M5RF,/LKF-WUJ8IZ9\M4?=SW"6^*9GHCST6]RLK&Q;Y>F38.B1535K-&=>CGBWB1-R>?1,QW1\JGVL:[K.L5S7JFJ9F9,SSQ>O35$ M3ZHGNACD_A=B[5.^_GW=/61U&]V[6W-%M8U// MO;V75VZN/YL=WTHEW3OG=>YJI^[.MY61;GF/)15V+?'H[,<1/R\M<%DPF48+ M![[5N(GGXY[90V(S#$XCVE=$9GG6%RZG_[)M:EJ\7-*T:9 MY[==/%V]'\BF?-/XT]WCX\<+2;1VSHNU=(HTS0\&WBV*8CM3$/PJ(\/-WQZ^Z4K#9PN,OX2OT MEFK2?WQ\[#?P]K$4\"Y&L**;ZV#N;9N7-K6=.N46)JFFWE6X[5JY[*H]7?Q/ M>U=Z&YN+C9N+KWI6HS7F[1R(TS(GOG M%O3-5FKV3WS3Y_3X^9>\LVOM7-*,7'!GGCB\X[U7QFS]=&M5B=8YN7[JOC.[ MNVAN+:F9.+KNEW\2K\&N8YMU^NFJ.Z?D8)<;=VB[3%=$ZQ/+"O5T545<&J-) M 'MX 'U:N7+5<5VKE5%4=\33/$P^0&:P=V;GP9IG$W!J=KL^$1D MU\?-,\>9G\+IYLJJF/"+E-%7UPT8:US!8:YZ]NF>F(EGHQ-ZCU: MYCKE*>'T^=(6/$15E8-_\KC<_5,,A8ZQ6]J>/*XFE7._OXLU4\QZ/OD.#4JR M3+ZN.S3V,].98NGBN3VIQM=9+Y/%?66UN:*HIVW@TU3'=/EZIXGYG4N]9#=55 MN8MZ3IM%?FJGM3Q\B$@C9[+8_M1W^;Y.;8R?[D]R7[_6'WW7SY.UI5OF./\ MN\SQ_F8K.ZA@,[6]9SJ9IS=6S\FF>[B[D5U1],L>-RWA MK-KU*(CHB(:]=ZY7ZU4STR ,[$ #DQ[%[(O4V<>U7=N53Q331 M3,S,^Q,/1UT [AUJ:,S M,]$-C#X6]B:N#:IU1#@8>7GY=O$P<:[DY%R8IHMVJ)JJJGT1$)UZ-.KWFYG46[LQQ7DW/?W MJ_;5Z.Z.Z.([O!LJB9GM==O:T86.#'/R_;Q6C!9!;M_BOSPIYN3[L?M[0])V M_IU.G:+I]C!Q:>_L6J>.9],SXS/KGO9 %0JJJKF:JIUF5AIIBF-(X@!Y?0 M M M '6U/ P=3PZ\/4<2QEXUS[ZU>HBNF?DE#6_.KSH6I> M4RMKY:[$S[?OJ?I3<-W!YAB<%5PK%$][5'HC2NXK9VJ-]BK7X3YJ;B6]Y] 6\=&\I?TJ+6MXM/,_N'O;L1SWSC0%_"WK$Z7*9AU M@&VUP "(F9XB.9 &W;0Z-MY;I[->E:+D3 MCU3Q[HNQY.UZ_?5<1/'HA-6R^KCIV--&1NK5:\VY$\SC8L=BWX^>N>^8^2/: MB<;GF"P>L7*]9YHWS]NO1OX;+,3B=]%.[GG="N6E:9J&JYE&'IF%?S,BY/%% MNS1-54S[(3)L/J\Z[J/DLK<^51I6-/%4V*.*[U4>/'HI^6>8]"R&W-NZ'MW$ MC%T32\7!M<<3Y*CBJK^=5XU?+,LHIN/VPQ%W6G#4\".?CGRCO6+"[/VK>^]/ M"GFY&L;'V%M?9V/%O1=-MT7N.*LJ[[^]7[:O-[(XALX*G=O7+U4UW*IF9Y93 MUNW3;IX-$:0 ,;V M M ,9N#;^B:_BSC:SI M>)G6YCLQY6W$U4QZJO&GY)ADQZIKJHGA4SI+Y53%4:3&Y"^[.KOM;4)KO:'F MY6D79F9BW/[K:\.Z(B>*H]O,HEW3T$[[T:FN[C8EG5[%,*IG MV0N$)[";39AAMTU<*/\ EO[^/O15_)<)>WQ3P9^'EQ//?4],U'3,BO'U'!R< M2]1/%5%ZW-,Q/RNH]"=3TW3M3L>0U+ Q]LYGRF/??0GVLS;G VWJ-=NY][=KLS1;_M3W,5V_:LQKWUSY1YI6QLW''=K[/.?)6 MW:?5MS+G8O;FUJUCT]TS8Q*>W5,>B:IXB)]G*7-I]%6Q]MQ17AZ+:R,BF/W_ M "_W6N?7Q/O8GUQ$-V%9Q>=X[%[KER=.:-T=WU36'RW#8?U*-_/.\B(B.([H M 13> M M ?-VW;O6ZK=VW M3*[=%<:51JB[5.@7H\S?WK"S<#^CY,_P"N*FLZEU:M$NU9A:]6]/7O\=6G7EF$KX[<>'@K/J/5IUBGG[G;CP+OH\O;KM_5 M%7K87-ZN^^;$3Y&]I>5,1_X=^8Y_M1"V0WJ-J\RIXZHGIB/IHUJLBP<\43'6 MIO?Z"^DFU55QHMJY3'X5.9:[_D[7/T.C>Z'>D6U7515MO(JF//1735'SQ*ZP MV:=LL=''33/5/FPSL[AIXJI[O)1W_9?T@?Q4U3^XEP7NCC?EJOL5;0UN9]-. M%75'SQ"](RQMIBO\=/?YO'\N6/USW>2C5GHRW]=HBNG:6KQ$^:K&JIGYIAS6 M.BGI!O5S33M;4*9B.>:[?9CYY7?'R=L\7_CI[_,C9RQ^J>[R4NQ^A;I'OT]J MG;U=/?QQ7?MTS],LAA] ?2+>F(O:?BXT3,]]S+MSQ_9F5P1BJVQQ\\5-,=4^ M;)3L]A8XYF>N/)5C%ZMV[KG9F_J^CV8G[Z.WN4,Z=U<]F6::9S,_5L MJN/'LW***9^3LS/TMJTKH?Z/-.JIKM;=LWKE/X5^Y77S\DSV?H;X(^[F^.N^ MO=J[=/!M6\OPMOU;<=C'Z5H>BZ5_PS2<#"]>/CT6YGYH9 $?55-4ZS+;B(B- M( 'Q] M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M 8 ?_9 end